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This multi-modal investigation aimed to refine analytic tools including proton 
magnetic resonance spectroscopy (1H-MRS) and fatty acid gas chromatography-mass 
spectrometry (GC-MS) analysis, for use with adult and paediatric populations, to 
investigate potential biochemical underpinnings of cognition (Chapter 1). Essential 
fatty acids (EFAs) are vital for the normal development and function of neural cells. 
There is increasing evidence of behavioural impairments arising from dietary 
deprivation of EFAs and their long-chain fatty acid metabolites (Chapter 2). 
Paediatric liver disease was used as a deficiency model to examine the relationships 
between EFA status and cognitive outcomes. Age-appropriate Wechsler assessments 
measured Full-scale IQ (FSIQ) and Information Processing Speed (IPS) in clinical and 
healthy cohorts; GC-MS quantified surrogate markers of EFA status in erythrocyte 
membranes; and 1H-MRS quantified neurometabolite markers of neuronal viability 
and function in cortical tissue (Chapter 3). Post-transplant children with early-onset 
liver disease demonstrated specific deficits in IPS compared to age-matched acute 
liver failure transplant patients and sibling controls, suggesting that the time-course 
of the illness is a key factor (Chapter 4). No signs of EFA deficiency were observed in 
the clinical cohort, suggesting that EFA metabolism was not significantly impacted by 
liver disease. A strong, negative correlation was observed between omega-6 fatty 
acids and FSIQ, independent of disease diagnosis (Chapter 5). In a study of healthy 
adults, effect sizes for the relationship between 1H-MRS- detectable neurometabolites 
and cognition fell within the range of previous work, but were not statistically 
significant. Based on these findings, recommendations are made emphasising the 
need for hypothesis-driven enquiry and greater subtlety of data analysis (Chapter 6). 
Consistency of metabolite values between paediatric clinical cohorts and controls 
indicate normal neurodevelopment, but the lack of normative, age-matched data 
makes it difficult to assess the true strength of liver disease-associated metabolite 
changes (Chapter 7). Converging methods offer a challenging but promising and 
novel approach to exploring brain-behaviour relationships from micro- to 
macroscopic levels of analysis (Chapter 8). 
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1 Exploring the biological basis of individual 
variation in cognitive ability 
 
1.1 Approaches to studying human intelligence differences 
 
This chapter provides a brief introduction to some of the approaches to studying the 
individual variation in cognitive ability and outlines the aims of this thesis. 
 
The wide ranging variability in cognitive ability found in human beings results from 
differences in brain functioning, differences in the exploitation of learning opportunities 
provided by the environment, and from interactions between the brain and the 
environment (Angoff, 1988; Ceci and Williams, 1999; Sternberg, Lautrey et al., 2003). 
Individual differences in intelligence are typically measured using psychometric tests, 
which cover cognitive domains such as reasoning, processing speed, executive function, 
memory and spatial ability. The term ‘general intelligence’ or ‘g’ (interchangeable with 
IQ) (Spearman, 1927), recognises that people who perform well in one domain of 
psychometric assessment also tend to perform well in the others (Chabris, 2006; Deary, 
2001; Deary, Penke et al., 2010; Neisser, Boodoo et al., 1996). Figure 1-1, adapted from 
Deary, Penke et al. (2010) illustrates the high associations between g and five principal 
cognitive domains putatively assessed with psychometric measures. 
 
 
Figure 1-1 The hierarchy of intelligence differences, adapted from Deary, Penke et al. (2010) 
The diagram shows the high inter-relatedness of different cognitive domains putatively assessed with 
psychometric measures. Data is based on 33 studies conducted by (Salthouse, 2004) comprising 7,000 
participants from age 18–95.  
 
Maclullich, Seckl et al. (2003) suggested that validating the construct of intelligence and 
cognitive abilities involves, in part, discovering associations between more basic 
cognitive constructs and individual differences in psychometric test scores. This type of 
reductionism is realised in two broad approaches: (1) the relationships between tests of 
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psychometric intelligence and basic information processing tests, such as reaction times 
and inspection time, which are used to discover the extent to which putatively 
fundamental cognitive components account for variance in broader IQ-type measures 
(Vernon, 1983); and (2), more biological approaches, such as the relationships between 
tests of psychometric intelligence and measures of brain structure and function 
(Garlick, 2002; Gray and Thompson, 2004; McDaniel, 2005; Thompson, Cannon et al., 
2001; Toga and Thompson, 2005). 
 
Investigations into the bases of human intelligence differences can thus be separated 
into two broad groups: cognitive correlates and biological bases (Figure 1-2, page 19, 
adapted from Deary and Caryl (1997)). ‘Differential psychology’ is the general term for 
research that seeks to accurately describe cognitive and personality traits and discover 
the real-life impact of trait differences, whilst ‘differential neuroscience’ is the term 
more specifically concerned with research investigating the biological bases of 
quantitative intelligence differences (Deary, Penke et al., 2010). 
 
These two approaches can be considered as looking at intelligence on different levels. 
The cognitive (differential psychology) approach is a factor-driven strategy, which 
identifies the cognitive components that give rise to differences in human abilities and 
how these are related to one another, without necessarily revealing the causes or 
consequences of these differences. The biological (differential neuroscience) approach 
uses more of a constructivist account by understanding the underlying differences in 
brain structure and function that provide a scaffold for variation in cognitive skills 
across the population. In Figure 1-2 the asterisks indicate the normally assumed 
(reductionistic) direction of causation of intelligence differences, but Deary and Caryl 
(1997) stressed that these relationships are not unidirectional; the direction of 
causation could be reversed, or individual differences in both variables might be caused 
by a third variable. 
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Figure 1-2 Research on human intelligence differences, adapted from Deary and Caryl (1997). 
Approaches to investigations of intelligence can be divided into those seeking cognitive correlates and 
those seeking the biological bases of variation in cognitive abilities. The asterisks indicates the normally 
assumed (reductionistic) direction of causation of intelligence differences. 
 
Cognitive and biological approaches can be used together in a mutually informative 
way. Developments in the accuracy, resolution, versatility and accessibility of 
psychological assessment methods and neuroimaging technologies are advancing the 
study of the neurophysiological basis of individual variation in cognitive ability in 
normal individuals, with increasing precision (Deary, 2001; Deary, Penke et al., 2010; 
Haier, 2009; Jung and Haier, 2007; Matarazzo, 1992).  
 
The challenge, however, is to specify the appropriate functional outcome to be 
measured. In the interests of hypothesis-driven inquiry, the most productive approach 
is to measure an outcome known to be associated with a particular biochemical 
pathway or mechanism. The investigation of information processing speed (IPS) has, for 
example, been integral to the study of individual differences in cognitive ability and goes 
back to early notions by Galton (1883) (in Sternberg, Lautrey et al., 2003), who 
attempted to measure reaction time and diverse sensory and motor variables in relation 
to independent indicators of accomplishment or intelligence. 
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Salthouse (1996) suggested that a basic parameter such as speed is directly related to 
biological factors and is essential for higher order cognitive processing. Vernon (1983) 
asserted that a large part of the variance in g is attributable to variance in speed and 
efficiency of execution of a small number of basic cognitive processes. The existence of a 
unitary intelligence factor is in itself, however, a matter of some debate (Kranzler and 
Jensen, 1997). The strength of the relationship between processing speed and 
intelligence is also debateable (Neisser, Boodoo et al., 1996); processing speed cannot 
substitute psychometric intelligence or g as it is not identical with intelligence (Chabris, 
2006; Deary and Caryl, 1997). Reed and Jensen (1992) suggest that in theory, inter-
individual differences in speed of information processing could be due to differences in 
brain (cerebral cortex) structure, average cortical nerve conduction velocity (NCV), 
average cortical speed of synaptic transmission, or most likely, to differences in all of 
these.  
 
Whilst the functional organisation of neurons is vital to the study of cognitive function 
(van den Heuvel, Stam et al., 2009), an investigation of inter-individual variation in the 
biological properties of neurons and the physiology of neuronal cell membranes is likely 
to provide information about the mechanisms of information processing in the brain, 
and provide some suggestions as to the cause of individual differences in the ability to 
process this information. 
 
1.2 Applying an integrative multi-modal approach 
 
The process of effectively describing complex phenomena such as cognitive ability and 
putative biological bases poses a considerable challenge. A multitude of terms have 
been used to describe combinatorial approaches, including integration, synthesis, multi-
method and mixed-methods, but these can be generally described as the integration of 
more than one method or data source to investigate a phenomenon (Creswell, 2003). 
Combinations of methods can provide advantages at different levels of analysis in the 
spectrum from molecule to man, and triangulation can be used as means to gain 
multiple perspectives on complex phenomena and produce a more complete picture. 
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1.3 Aims 
 
1.3.1 General aims 
 
Using a multi-modal approach, the present set of studies aimed to develop and refine 
analytic tools for biochemical assays, for use with both adult and paediatric populations. 
The main aim was to investigate some of the potential biochemical underpinnings of 
cognition, relating neural, systemic and behavioural levels of analysis. 
 
At the systemic level, quantification of fatty acid biomarkers in erythrocyte membranes 
with gas chromatography-mass spectrometry (GC-MS) provides surrogate markers for 
cortical fatty acid levels, allowing the study of the cognitive effects of variation in 
phospholipid cell membrane composition. At the neural level, proton magnetic 
resonance spectroscopy (1H-MRS) enables non-invasive, in vivo analysis of brain 
metabolism and offers a way of investigating the strength of relationships between 
biochemical markers of neuronal viability and cognitive ability. Figure 1-3, page 22 
provides an overview of the converging methods approach of the current work 
investigating potential biochemical correlates of cognition. 
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Figure 1-3 The converging methods approach used in the present study 
Quantification of fatty acid biomarkers and 1H-MRS-detectable neurometabolites enables the 
investigation of specific biochemical properties of neuronal function which may underlie variability in 
performance of psychometric measures of intelligence and processing speed. 
 
1.3.2 Specific aims  
 
A deficiency of essential fatty acids (EFAs), which are crucial for normal neural function 
and development, is common in children with liver disease. Liver disease and 
subsequent liver transplantation provide models to answer questions of whether: 
 
1. Sub-optimal concentrations of essential fatty acids, as a result of fat 
malabsorption or dependence on inadequate dietary sources, is associated with 
deficits in cognitive ability. 
2. 1H-MRS-detectable metabolites can provide surrogate markers of sub-clinical 
changes in neuronal viability. 
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To answer these questions, the aims were to: 
 
1. Measure and evaluate the range of fatty acid concentrations in cross-sectional 
cohorts of children with a variable onset of liver disease, pre- and post-liver 
transplant. 
2. Provide a set of convergent measures for assessing the impact of potential EFA 
deficiency in paediatric liver disease. 
3. Determine if/how cognitive function is related to fatty acid status. 
4. Characterise surrogate measures of neural viability and health using 1H-MRS and 
assess the relationships between 1H-MRS-detectable metabolites and cognitive 
ability in both a healthy and clinical population. 
 
1.4 Summary of chapters 
 
Chapter 1 introduced the framework for investigating the biological bases of cognitive 
ability and outlined the approach and aims of the present study. 
 
Chapter 2 provides an overview of the physiological importance of EFAs and the 
potential mechanisms that may impact cognitive function. 
 
Chapter 3 provides descriptive data for the clinical patient population and outlines the 
three converging analytical methods used: psychometric assessments, GC-MS for 
assessment of fatty acid status, and 1H-MRS for analysis of in vivo brain biochemistry. 
 
Chapter 4 investigates the impact of the time-course of liver disease and subsequent 
liver transplantation on cognitive ability. 
 
Chapter 5 investigates the effect of paediatric liver disease on EFA status and the 
relationships between levels of omega-6 and omega-3 fatty acids and cognitive ability. 
 
Chapter 6 examines the use of 1H-MRS as a tool for assessing brain tissue composition in 
vivo and the relationships between 1H-MRS-detectable neurometabolites and cognitive 
ability in a healthy adult cohort. 
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Chapter 7 explores the ability of 1H-MRS-detectable metabolites to provide surrogate 
markers of subclinical changes in neuronal viability in paediatric liver disease, and 
whether levels of these markers can be related to cognitive function.  
 
Chapter 8 summarises the main findings and their implications, offers suggestions of 
future directions of work motivated by this study, and concluding remarks. 
25 
 
2 Essential fatty acids and the brain 
 
The adult brain contains approximately 50–60% of its dry weight as lipid and is 
exceeded only by adipose tissue in its concentration of fatty acids (Yehuda, Rabinovitz 
et al., 1999). High levels of fatty acids are found in cellular membranes and the myelin 
sheath of the cortex, which are composed of 50% and 70% of fatty acids respectively 
(Yehuda, Rabinovitz et al., 2005) and they appear to be vital to the structure and 
function of neural tissue. The nature of essential fatty acid (EFA) metabolites, and their 
importance and function in the brain, are described in this chapter. 
 
2.1 Common fatty acids and nomenclature 
 
Fatty acids are major components of brain lipids. They consist of hydrocarbon chains of 
different lengths, terminating in a methyl group at one end and a carboxyl group at the 
other (see Figure 2-1). Most naturally occurring fatty acids consist of an even number of 
carbon atoms. The number of intermediate carbon atoms vary and as such, fatty acids 
chains can be classified as short (2–4 carbon atoms), medium (4–6) or long (6–10 and 
greater). 
 
 
 
Figure 2-1 The basic structure of a fatty acid 
 
The term ‘saturation’ refers to a chemical structure in which each carbon atom in the 
fatty acyl chain is bound to (‘saturated with’) four other atoms. Saturated fatty acids 
have no double bonds, mono-unsaturated fatty acids have one double bond and 
polyunsaturated fatty acids have two or more (see Figure 2-2, page 26). For example, 
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oleic acid (18:1) has 18 carbon atoms and one double bond. The location of the first 
carbon atom, where the first double bond appears when counting from the methyl end 
of the molecule, is designated by the omega or n number. The main types of 
polyunsaturated fatty acyl chains found in mammalian membrane lipids can be 
categorised into three main families based on the location of the first double bond, 
namely n-3, n-6 and n-9 (see Figure 2-2). 
  
 
 
Figure 2-2 Examples of structural formulas for omega-9, -6 and -3 fatty acids 
 
2.2 Fatty acid biosynthesis 
 
The availability of EFA precursors and the action of metabolic enzymes are crucial to 
the synthesis of highly polyunsaturated fatty acids (PUFAs). The mechanisms of fatty 
acid metabolism have been reviewed in depth by Sprecher (2000) and will be briefly 
summarised here.   
 
Higher animals are unable to synthesise de novo neither omega-6 or omega-3 long-chain 
PUFAs as they lack the capacity to introduce double bonds at the n-6 and n-3 positions 
from the carbonyl end of oleic acid (Calvani and Benatti, 2003). As such, they are 
dependent on dietary sources of EFA precursors, such as linoleic acid (LA, 18:2n-6) and 
α-linolenic acid (ALA, 18:3n-3), to meet their physiological needs for these families of 
fatty acid (Simopoulos, 2000; Sprecher, 2000). Figure 2-3, page 27, adapted from de 
Groot (2003), is a schematic representation of the major pathways of fatty acid 
metabolism and illustrates the synthesis of long-chain PUFAs. Table 2-1, page 28, lists 
the principal fatty acids with their common, chemical and abbreviated designations. 
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Figure 2-3 Schematic representation of the major pathways of fatty acid metabolism, adapted 
from de Groot (2003) 
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Table 2-1 Fatty acids with their common, chemical and abbreviated designations 
Common name Abbreviation Systematic name 
Omega-
reference 
Omega-9 
 Mead 
 
all-cis -5,8,11-eicosatrienoic 20:3n-9 
 Omega-6 
Linoleic LA cis,cis-9,12-octadecadienoic 18:2n-6 
γ-linolenic GLA all-cis-6,9,12-octadecatrienoic 18:3n-6 
dihomo-γ-linolenic DGLA cis,cis,cis--8,11,14-eicosatrienoic 20:3n-6 
arachidonic AA all-cis-5,8,11,14-eicosatetraenoic 20:4n-6 
Osbond 
 
all-cis-4,7,10,13,16-
docosapentaenoic acid 
22:5n-6 
Omega-3 
α-linolenic ALA all-cis-9,12,15-octadecatrienoic 18:3n-3 
eicosapentaenoic EPA 
all-cis-5,8,11,14,17-
eicosapentaenoic 
20:5n-3 
clupanodonic DPA 
all-cis-7,10,13,16,19-
dicosapentaenoic 
22:5 n-3 
docosahexaenoic DHA 
all-cis-4,7,10,13,16,19-
docosahexaenoic 
22:6n-3 
 
Saturated fatty acids can be synthesised de novo from Acetyl coenzyme A. The liver is 
the most important organ for such synthesis, which takes place both in mitochondria 
and in the endoplasmic reticulum. Reactions are catalysed by several enzymes that form 
a multi-enzyme complex known as fatty acid synthetase. The end product of these 
reactions would normally be palmitic acid (16:0). Double bonds are formed in 
desaturation reactions catalysed by a site-specific enzyme, represented by Δ. The 
numbering for the site of action of these enzymes is taken from the position of the 
double bond in relation to the carboxyl end of the molecule. 
 
LA and oleic acid compete for the same Δ6-desaturase in the metabolic cascade. The 
desaturase enzymes show a preference for the different fatty acid series, in descending 
order from n-3 to n-6 to n-9. Oleic acid is not an EFA, as in animals, including humans, 
there is the capacity to introduce a double bond, or desaturate at the Δ9 position in 
saturated stearic acid. There is little requirement for saturated fatty acid synthesis in 
humans because the dietary supply is usually adequate. 
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Omega-6 and omega-3 fatty acids share metabolic pathways (see Figure 2-3, page 27) 
and thus interact with each other through a complex system involving several factors: 
dietary substrate availability, competition for the same metabolic enzymes for synthesis 
and membrane incorporation, and negative feedback of the end products.  
 
2.2.1 Omega-6 fatty acid synthesis 
 
In the omega-6 pathway, LA is converted to γ-linolenic acid (GLA, 18:3n-6), a positional 
isomer of ALA. GLA, in turn, can be converted to the longer chain arachidonic acid (AA, 
20:4n-6). The activity of the desaturation/elongation pathway in the liver is the most 
important in terms of supply of long-chain omega-3 PUFAs to other tissues. The initial 
conversion of ALA to stearidonic acid by the action of Δ6 desaturase is the rate-limiting 
reaction of the n-3 pathway. The activity of the Δ6-desaturase is slow and can be further 
compromised by nutritional deficiencies and inflammatory conditions. Therefore, the 
maximal capacity for synthesis of AA occurs with GLA, the product of the Δ6-desaturase. 
GLA is converted to dihomo-γ-linolenic acid (DGLA) and then to AA. Like the Δ6-
desaturase, the activity of the Δ5-desaturase is limiting in AA synthesis and its activity is 
also influenced by diet and genetic factors (Simopoulos, 2010). The metabolic pathway 
of omega-6 fatty acid synthesis is illustrated in Figure 2-4. 
 
 
Figure 2-4 The metabolic pathway of omega-6 fatty acid synthesis.  
FADS: Fatty acid desaturase enzymes (1 and 2) which are responsible for catalysing the conversion of 
fatty acids. 
FADS2 
FADS1 
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2.2.2 Omega-3 fatty acid synthesis 
 
The introduction of a double bond at the Δ6 position is followed by the addition of two 
carbons by elongation and then by desaturation at the Δ5 position by Δ5 desaturase to 
form EPA. DPA (22:5n-3) is synthesised from EPA by the further addition of two 
carbons, and is then converted into DHA (22:6n-3) by further chain elongation, Δ6-
desaturation and peroxisomal β-oxidation. The metabolic pathway of omega-3 fatty acid 
synthesis is illustrated in Figure 2-5. All reactions occur in the endoplasmic reticulum, 
with the exception of the final reaction, which results in the formation of DHA. Although 
ALA can serve as the precursor for EPA and DHA synthesis in humans, the rate of 
conversion of dietary ALA to DHA in the body is very low (Pawlosky, Hibbeln et al., 
2001), and varies between individuals. Therefore, direct dietary intake of omega-3 fats 
rich in EPA and DHA is of the most benefit to compensate for the potentially suboptimal 
levels derived solely from endogenous metabolism of ALA precursors. 
 
 
 
Figure 2-5 The metabolic pathway of omega-3 fatty acid synthesis.  
FADS: Fatty acid desaturase enzymes (1 and 2) which are responsible for catalysing the conversion of 
fatty acids. 
 
FADS2 
FADS1 
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2.2.3 Recommended and actual dietary intake of essential fatty acids 
 
It is now accepted that it is important to consider the functions of the different types of 
fatty acids (omega-3, -6, and -9) rather than simply the amount of total fat or 
polyunsaturated fat. Fatty acids other than the EFAs can be synthesised endogenously, 
however, the major source is from dietary fat, which accounts for 25–50% of the energy 
content of most diets (Heird and Lapillonne, 2005). 
 
Healthy adults have approximately 1kg of LA stored in adipose tissue, yet adipocytes 
contain hardly any ALA or long-chain PUFAs (LCPUFA). Recommendations regarding 
adequate dietary intake of EFA and LCPUFA (generally expressed as g/day–1 or as a 
percentage of total energy intake), are highly variable between countries, and vary with 
age (i.e. with adipose tissue stores and growth rate). The International Society for the 
Study of Fatty Acids and Lipids (ISSFAL) has produced a number of statements which 
deal with recommendations for dietary intake of PUFAs throughout life, which are 
summarised in Figure 2-6, adapted from Alessandri, Guesnet et al. (2004).  
 
 
 
Figure 2-6 Recommended dietary intakes for omega-3 fatty acids (g/day), adapted from 
Alessandri, Guesnet et al. (2004). 
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The estimated daily intake of omega-3 PUFA in western countries varies greatly, 
ranging between an intake of 15/1 to 16.7/1 omega-6 to omega-3, compared to a ratio 
of closer to one based the diets humans evolved eating (Simopoulos, 2000). DHA intakes 
largely depend on fish consumption, which can differ greatly between countries (Welch, 
Lund et al., 2002), and has been related to the quality and length of education and 
degree of attention paid to maintenance of a healthy diet (Johansson, Solvoll et al., 
1998).  
 
The nutritional demands for DHA in healthy adults are likely to be modest, as they 
reflect principally the need to supply DHA to support turnover and re-synthesis of cell 
membranes. The actual intake is often under the recommended amount, for example, 
the mean intake of ALA rarely reaches that which is recommended (Johansson, Solvoll 
et al., 1998). Table 2-2 summarises the various international recommendations on 
dietary PUFA intake (ISSFAL, 2010), which include an intake of 2% of total energy 
intake for LA and 0.7% for ALA for adults. 
 
Difficulty in estimating recommended intakes, particularly for infants, arises from three 
principal issues identified by Gibson and Makrides (2000). Firstly, LCPUFAs can be 
synthesised from precursor fatty acids; secondly, plasma omega-3 LCPUFA 
concentrations representing deficiency and sufficiency are not clearly defined; thirdly, 
there are currently no recognised clinical tests for omega-3 LCPUFA deficiency and 
sufficiency. 
 
The importance of breast milk as the sole natural source of omega-3 fatty acids, as well 
as the omega-6 fatty acids to support the growth and development of the breastfed 
infant, is well documented (Innis, 2000; Innis, 2004; Innis, 2007; Koletzko, Agostoni et 
al., 2001; Koletzko, Lien et al., 2008). Breast milk from women following western diets 
generally contains 10% to 17% LA, 0.8% to 1.4% ALA, 0.3% to 0.7% AA, and 0.1% to 
0.5% DHA (Innis, 2003). Concentrations are largely dependent on maternal dietary 
intake (Innis, 2004) and varies with dietary habits and geographic region (Yuhas, 
Pramuk et al., 2006). For example, DHA can be up to 1% of total milk lipids in cases 
where fish is a major food source. 
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The IFFSAL report summarises the general consensus that the total fat content of infant 
formulas falls within a range of 4.4–6.0 g/100 kcal (equivalent to about 40–54% of 
energy content), which is a value consistent with that typically found in breast milk, and 
which is taken as the gold standard. A summary of recommendations for EFA intake for 
full-term infants is found in Table 2-2, page 34, adapted from (ISSFAL, 2008). For LA, 
the level accepted in formulas ranges from around 6% to as much as 25–30% of total 
fatty acids. In general, the minimum acceptable level of LA is around 3% of total energy. 
The low level of ALA in breast milk (usually less than 0.2% of total fat) has prompted 
agencies to make recommendations for minimum requirements.  
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Table 2-2 Summary of the international recommendations on dietary polyunsaturate intake, 
adapted from ISSFAL (2010) 
Source Date 
n-6:n-3 
ratio 
Other specific 
recommendations (%en = 
percentage of daily energy 
intake) 
National Nutrition Council 
of Norway 
1989 none 
0.5%en n-3 LCPUFA (1-2g 
/day) 
NATO workshop of -3/-6 1989 none 
0.8g/day EPA/DHA 
(0.27%en) 
Scientific Review 
Committee of Canada 
1990 5:1-6:1 n-3 at least 0.5%en 
British Nutrition 
Foundation Task-force 
1992 6:1 EPA 0.2-0.5%en; DHA 0.5%en 
FAO/WHO Expert 
Committee on Fats and Oils 
in Human Nutrition 
1994 5:1-10:1 
Consider pre-formed DHA in 
pregnancy 
UK Committee on Medical 
Aspects of Food Policy 
(COMA) 
1994 none 
Minimum intake EPA/DHA 
200mg/day 
Ad Hoc Expert Workshop 2000 none 
EPA+DHA -.03%en; 
0.65g/day minimum 
France: AFFSA, CNERNA & 
CNRS 
2001 5:1 
500mg n-3 LCPUFA/day; DHA 
120mg minimum 
US National Academy of 
Science/ Institute of 
Medicine 
2002 none 130-260mg EPA+DHA/day 
American Heart Association 2002 none 
If no coronary heart disease, 
eat oily fish twice a week 
UK Scientific Advisory 
Committee on Nutrition 
(SACN) 
2004 none 
Minimum intake EPA/DHA 
450mg/day 
ISSFAL 2004 none 500mg n-3 LCPUFA/day 
Australia and New Zealand 
Government 
Recommendations 
2005 none 
LC n-3 for men: 160mg/day; 
for women: 90/mg/day 
Superior Health Council of 
Belgium 
2006 none 
Minimum 0.3%en EPA+DHA 
for adults 
Health Council of the 
Netherlands 
2006 none 450mg n-3/day 
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2.3 Physiological functions of EFAs 
 
The cell membrane provides structure for cells and organelles.  For neuronal cells, it 
maintains the internal and external physiochemical properties fundamental to the 
propagation of action potentials and the general functioning of the cell (Alberts, 2002). 
Mammalian cell membranes consist of a bilayer composed primarily of lipids 
(phospholipids and cholesterol) embedded with protein receptors, transporters, and 
enzymes. Figure 2-7, adapted from Sum (2005), provides a schematic representation of 
the phospholipid membrane that encapsulates all mammalian neurons. 
 
 
 
Figure 2-7 Schematic representation of a phospholipid cell membrane, adapted from Sum (2005) 
 
Phospholipids are one of the principal lipid components of the membrane. Each 
phospholipid has a glycerol 3-carbon backbone with a phosphorous attached at the 3 
position, to which one of five possible ‘head’ groups are attached (choline, 
ethanolamine, inositol, glycerol and serine). These five types of phospholipid make up 
over 80% of total phospholipids (Reddy, Keshavan et al., 2004). A more detailed 
account of the structure of the various phospholipid species is provided by Christie 
(1982). Each phospholipid type consists of a large number of fatty acid chains, attached 
to the 1- and 2-carbon atoms in the glycerol backbone, which governs the functional 
properties of the phospholipid, such as its conformational shape (see Figure 2-8). 
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Figure 2-8 Schematic illustrating phospholipid membrane fluidity conferred by LCPUFAs, adapted 
from Nelson and Cox (2000) 
Red squares signify double bonds which result in a ‘kinked’ structure 
 
As an integral component of cell membranes, fatty acids exert a multitude of effects not 
only on phospholipid membrane structure and function, but also on enzymes and 
receptors embedded in the membrane and through localised action as precursors for 
localised hormone-like factors. Some of these effects are briefly described below. 
 
2.3.1 Membrane fluidity 
 
Both the chain length and the number of double bonds of the fatty acyl chains that 
constitute membrane phospholipids have substantial and significant effects on the 
dynamic properties of the membrane, such as its fluidity, permeability and rigidity 
(Hac-Wydro and Wydro, 2007). Saturated fatty acids, for example stearic acid (18:0), 
have straight carbon chains that cause relatively solid regions in the membrane. In 
contrast, PUFAs, such as oleic acid (18:1n-6), LA (18:2n-6) and ALA (18:3n-3), have a cis 
configuration at each double bond that produces ‘coiling’ of the hydrocarbon backbone 
resulting in a reduction in fatty acid length and a more curved, or ‘kinked' structure that 
increases the fluid properties of the membrane (Figure 2-8, adapted from Nelson and 
Cox (2000)). DHA (six double bonds) and EPA (five double bonds) confer the greatest 
level of fluidity from the major membrane fatty acids (Feller, Gawrisch et al., 2002; 
Gawrisch, Eldho et al., 2003). As a rule, the more fluid a membrane, the more efficient its 
biochemical performance (Else and Hulbert, 2003).  
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Alterations in the fluid properties of the lipid membrane can affect the conformation of 
integral membrane proteins which in turn modulates their function. The most detailed 
characterisation of direct PUFA–protein interactions comes from studies on rhodopsin 
(Grossfield, Feller et al., 2006), which show that DHA acyl chains specifically bind to the 
protein and directly modifies its conformational state. 
 
2.3.2 Myelination 
 
The myelin sheaths surrounding axons of the central and peripheral nervous systems 
are specialised extensions of glial cells, with unique morphological and biochemical 
properties related to axon protection and impulse conduction. The integrity of the 
myelin is of the utmost importance for the proper functions of axons in the nervous 
system. Myelination improves the connectivity of the brain, facilitating the synchronous 
integration of information across the many spatially segregated associative neocortical 
regions involved in higher cognitive functions (Nicholls, Martin et al., 2001). 
 
Lipids constitute around 70% of the myelin sheath, and dietary fatty acids are positively 
involved in the control of myelinogenesis (Di Biase and Salvati, 1997). During 
maturation, a shift from short chain saturated fatty acids to the long chain unsaturated 
forms has been observed (O'Brien and Sampson, 1965; Svennerholm, Vanter et al., 
1978). In rats fed with diets rich in polyunsaturated omega-3 fatty acids, decreases in 
the relative amount of myelin basic protein (MBP) and a CNPase activity indicate a delay 
in myelin deposition and/or an instability of its structure (Di Biase and Salvati, 1997), 
whilst acceleration of myelinogenesis can also be induced by dietary lipids (Salvati, 
Sanchez et al., 1996). 
 
2.3.3 Ion Channels 
 
Fatty acids are important direct modulators of ion function, both through modulation of 
membrane parameters such as fluidity (Leaf, Xiao et al., 2002), but also through direct 
action on channel proteins (Ordway, Singer et al., 1991; Tillman and Cascio, 2003). It is 
not only the presence of specific lipids, but the particular combination of lipids which 
38 
 
are necessary for ion channels to exhibit native properties (le Maire, Champeil et al., 
2000).  
 
For example, Ehringer, Belcher et al. (1990) have shown that DHA has a more 
pronounced effect on membrane ion permeability than LA, despite largely similar 
effects of both fatty acids on membrane fluidity. In terms of direct action on ion 
channels, DHA has been shown to have a facilitatory effect on NMDA-glutamate 
receptors in rat pyramidal neurons (Nishikawa, Kimura et al., 1994), whilst in CA1 
neurons isolated from the rat hippocampus, both EPA and DHA had an inhibitory effect 
on sodium and calcium currents by inducing a shift in the inactivation response 
observed in more negative potential membranes (Verlengia, Gorjao et al., 2004). AA has 
been shown to modulate secretory chloride channels (Hwang, Guggino et al., 1990) and 
specific classes of K+ channels have also been shown to be reversibly opened by AA, with 
a dependence on PUFA carbonyl chain length (Fink, Lesage et al., 1998). 
 
Whilst there is a wealth of evidence suggesting the modulatory role of PUFAs in ion 
channel function, Tillman and Cascio (2003) stress the difficulty of assigning the causes 
of the observed effects of fatty acids due to the multiple, inter-dependant and complex 
factors which govern the interaction ion channels and their lipid environment. 
 
2.3.4 Neurotransmitter function 
 
The decreased DHA in the brain of animals fed an ALA-deficient diet during 
development is accompanied by altered metabolism of several neurotransmitters, 
including dopamine and serotonin, and membrane-associated enzyme and receptor 
activities (Innis, 2007). Chalon recently summarised investigations of chronic omega-3 
fatty acid deficiency and neurotransmission in rodent models (Chalon, 2006) (where 
the these effects best described), and report complex, multi-factorial modulations, 
including synthesis, storage, release, and receptor-mediated uptake, with effects also 
differing between regions of the cortex. 
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2.3.5 Eicosanoids and immune function 
 
Whilst PUFAs are widely understood for their role in cell membrane structure and 
function as described above, they have an important secondary role as eicosonoid 
precursors. Eicosanoids are hormone-like autocrine or paracrine factors such as 
leukotrienes, prostaglandins, and thromboxanes that exert local effects by mediating 
processes such as constriction or relaxation of endothelial cells, platelet aggregation, 
leukocyte activation and chemotaxis, and consequently modulate the immune response 
(Shaikh and Edidin, 2008). 
 
AA is the precursor of 2-series prostaglandins and 4-series leukotrienes, which are 
highly-active mediators of inflammation and generally pro-inflammatory and pro-
aggretory. Factors derived from EPA, however, perform competitive functions that 
decreases the production of several substances, including cytokines, interleukin 1β (IL-
1β) and tumour necrosis factor α (TNF-α), leading to a predominantly anti-
inflammatory state (Calder, 2002; Calder, 2006; Simopoulos, 2002b). EFA-derived 
eicosonoid precursors are also involved in the brain in oxidative stress, memory and 
learning, and potentially in neuropsychiatric disorders such as depression (Tassoni, 
Kaur et al., 2008). Figure 2-9 summarises some of the physiological effects of essential 
fatty acids. 
  
 
 
 
 
 
 
 
 
Figure 2-9 Summary of physiological functions modulated by EFAs, adapted from Horrocks (2003) 
 
In summary, the effects of EFAs are multifactoral and are also specific to individual 
classes of fatty acid. EFAs and their PUFA metabolites have important roles not only at 
the membrane level, but also through their involvement in inflammatory processes, 
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both of which may be important in understanding the modulatory role of fatty acids on 
cognition in health and in disease. 
 
2.4 Essential fatty acids and cognitive ability 
 
2.4.1 Essential fatty acids and brain composition 
 
Within the brain, four EFAs are particularly important: DHGLA (23:3n-6) and AA of the 
omega-6 series, and EPA (20:5n-3) and DHA (22:6n-3) of the omega-3 series (Sprecher, 
2000). Between them, these four fatty acids make up 15–30% of the dry weight of 
neuronal tissue, with AA and DHA amounting to approximately 80–90% of that total 
(Horrobin, 1998). Figure 2-10 illustrates the routes whereby the EFAs required for 
normal brain function reach brain phospholipids. 
 
 
Figure 2-10 The routes whereby the EFAs required for normal brain function reach brain 
phospholipids, adapted from Horrobin (1998) 
 
Individually, DHA constitutes 10–20% of total fatty acid composition, compared ALA, EPA 
and DPA, which comprise <1% (McNamara and Carlson, 2006). DHA has also been reported 
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to constitute as much as 15–25 mol% of the lipids of the grey matter of the human brain 
(Huber, Rajamoorthi et al., 2002). The presence of DHA chains in mixed-chain 
phospholipids leads to a marked increase in the fluidity of the saturated chain (see section 
2.3.1), with the ‘kinked’ structure of the fatty acid chains able to influence permeability 
properties of the bilayer (Huber, Rajamoorthi et al., 2002), 
 
DHA accumulates specifically in phosphatidylserine in brain cortex and hippocampus and 
plays a regulatory role in membrane phospholipid homeostasis (Kim, 2007). This relatively 
specific tissue distribution of DHA gives some indication of a possible important role in the 
membranes of these tissues. Figure 2-11, adapted from Stillwell and Wassall (2003), 
illustrates the incorporation of DHA into the phospholipid membrane and its association 
with cholesterol and trans-membrane proteins. 
 
 
 
Figure 2-11 The incorporation of DHA (22:6n-3) into the membrane phospholipid bilayer, adapted 
from Stillwell and Wassall (2003) 
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2.4.2 The impact of EFA deficiency on cognitive ability 
 
The plasma membrane is a primary interface between exogenous influences (for 
example, diet) and endogenous control over the biosynthesis or utilisation of varied 
substrates. The physical properties of the individual lipid components in the membrane 
are integral to the characteristics of the lipid matrix. The specific organisation and lipid 
composition of membranes affect their physicochemical properties and determine their 
proper functioning. It is therefore of interest to consider whether dietary fatty acid 
balance modulates the lipid composition of the plasma membrane, thereby having 
potential to modify control functions at this cellular interface, which have identifiable 
cognitive outcomes. 
 
One of the best ways of identifying the importance and functions of EFAs is to study the 
consequences of EFA intervention. There are three principal methods typically 
employed: (1) animal studies, which involve controlled dietary deprivation of EFAs with 
comparison to untreated offspring; (2) observational breast feeding studies comparing 
breastfed vs non-breastfed children (EFA-deficient formula milks); and (3) randomised 
controlled trials comparing children fed formulas either supplemented or 
unsupplemented with EFAs such as DHA.  
 
EFAs and their LCPUFA metabolites, omega-6 fatty acids (n-6) and the omega-3 fatty 
acids (n-3), are crucial for the normal function and development of human and animal 
cells. The functional importance and mechanisms of action of omega-3 fatty acids on 
brain function have been extensively reviewed (Alessandri, Guesnet et al., 2004; Benatti, 
Peluso et al., 2004; Salem, Litman et al., 2001; Simopoulos, 2000; Sinclair and Wesinger, 
2004; Wainwright, 2002; Wurtman, 2008; Yehuda, Rabinovitz et al., 1999; Yehuda, 
Rabinovitz et al., 2005). A summary of findings relating the importance of EFAs to 
cognitive outcomes, using the three methods outlined above, will be briefly described 
here. 
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2.4.2.1 Animal models of essential fatty acid deficiency 
 
A main advantage of animal studies is that they afford the opportunity for more 
flexibility in design and in the ability to control experimental variables than can be 
achieved in human studies. Animal studies with different proportions of PUFAs in the 
diet have proved fruitful in identifying broad dietary requirements for maintaining 
optimal brain function (discussed in section 2.2.3, page 31) and have demonstrated that 
metabolic and behavioural defects arise from severe long-term omega-3 PUFA dietary 
deprivation. This allows the physiological effects of these fatty acids to be magniﬁed and 
the behavioural consequences to be more easily identified. Feeding the newborn animal 
with milk formulas low in ALA reduces DHA and increases AA and osbond acid (DPA; 
22:5n-6) in the brain, brain synaptic membranes and retina (Ward, Huang et al., 1998). 
 
Levels of DHA and EFA precursors seem to be crucial for normal cognitive function as 
deviation from its physiological level is associated with cognitive impairment, including 
impaired visual evoked potential and disturbances of cognition, including deficits in 
frontal cortex-dependent working memory, hippocampus-dependent spatial learning 
and elevated indices of anxiety and depression (reviewed by McNamara (2006)). 
 
The latest work in rat models of omega-3 deficiency have found deficits in spatial 
reversal learning that may be related to changes in dopamine transmission in critical 
brain circuits such as frontal cortex and hypothalamus (Fedorova, Hussein et al., 2009) 
and delay in the development of parameters related to glutamate transmission, which 
manifests as increases in memory impairment and anxious behaviour in adulthood 
(Moreira, Knorr et al., 2010). 
 
Compared to a DHA and EPA diet, omega-3 deficient and low LA diets also caused a 
substantial deficit in prepulse inhibition (PPI) in rats, whereas the high LA diet induced 
a less pronounced, but significant reduction of PPI (Fedorova, Alvheim et al., 
2009). Deficits of PPI manifest in the inability to filter out the unnecessary 
environmental information and have been linked to abnormalities of sensorimotor 
gating. 
 
44 
 
Regionally specific effects of DHA have also been observed with relation to learning 
performance in rats. Hippocampal DHA levels were observed to increase from 12 to 
15% in supplemented rats, accompanied by improved water-maze learning memory 
performance (Chung, Chen et al., 2008), whilst others have observed that chronic 
administration of DHA may be conducive to the improvement of reference memory-
related learning ability, which may be related to the ratio of DHA to AA in hippocampal 
tissues (Gamoh, Hashimoto et al., 1999).  
 
Whilst there is an abundance of research with rodent models, there have been few 
investigations of non-human primate models of omega-3 deficiency and behaviour. In 
rhesus monkeys, chronic dietary deficiency in omega-3 fatty acids has been associated 
with deficits in visual acuity and electroretinogram abnormalities, which represent 
defects in photoreceptor function in rod and cone cells (Anderson, Neuringer et al., 
2005), as well as deficits in visual attention processes, related to attention to novel 
stimuli (Reisbick, Neuringer et al., 1997), and increased stereotype behaviour (Reisbick, 
Neuringer et al., 1994). The extrapolation of animal models, particularly from rats to 
human infants, should be done with caution as omega-3 fatty acid depletion is typically 
more severe and the animals have often been depleted for more than one generation. 
 
2.4.2.2 Human infant models of essential fatty acid deficiency 
 
Results of intervention trials assessing the cognitive effects of omega-3 deficiency in 
humans have been variable, and the experimental protocols less rigorous, because of 
ethical considerations such as the potential of long-term dietary restriction, and indeed 
supplementation, for inducing long-term irreversible damage.  
 
Much of the support for the importance of EFA intake in early life comes from 
observational studies of breastfeeding data. The importance of EFAs in infant nutrition 
is confirmed by the rapid accumulation of these fatty acids in the brain during the first 
postnatal year (Martinez, 1992) and last intrauterine trimester. After birth, infants are 
reliant on maternal breast milk (or formula) as the sole source of DHA, with substantial 
accumulations of DHA and AA in the human brain during the first postnatal months 
(Heird and Lapillonne, 2005). 
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Although infants are able to synthesise DHA de novo, the amount produced may be 
inadequate to support the DHA levels observed in breastfed infants. The cerebral and 
overall DHA status of breastfed babies is better than that of infants fed formula lacking 
DHA (Cunnane, 2000), with the accumulation of DHA and phosphatidylserine (PS) 
during development required to prevent inappropriate cell death and to support 
neuronal differentiation (Kim, 2007). Breast-fed infants are also uniquely provided with 
an additional digestive enzymes which are essential for the complete hydrolysis of 
triacylglycerols containing arachidonic acid or DHA (Chen, Blackberg et al., 1994).  
 
Feeding infant formulas devoid of preformed LCPUFA has been associated with 
decreased brain DHA and AA contents and with transiently impaired neurological 
maturation (Lauritzen, Hansen et al., 2001). The effect of postnatal omega-3 fatty acid 
deficiency on neurocognitive development of full term infants has previously been 
reviewed in detail (Carlson and Neuringer, 1999; Gibson, Neumann et al., 1996; McCann 
and Ames, 2005; Uauy, Hoffman et al., 2001), and include for example, delayed VEPs for 
retinal function, preferential looking activity, and means-end problem solving Findings 
from animal studies have been extended to understanding of the impact of EFA 
deficiency in human infancy (Innis, 2000), with findings replicated in infants fed 
formulas deficient in omega-3 fatty acids (Hoffman, Birch et al., 2000; Hornstra, 2000), 
see Lauritzen, Hansen et al. (2001) and Uauy, Mena et al. (2000) for reviews. 
 
Because of the high concentrations of omega-3 and -6 fatty acids in neural tissue 
membranes, all domains of neural and cognitive function are potentially influenced by 
LCPUFA status. The hypothesis that EFA deprivation should manifest as changes in 
broad-based measures of cognitive function, such as FSIQ is supported by a meta-
analysis of breastfeeding studies conducted by Anderson, Johnstone et al. (1999) which 
suggests that, after adjustment for appropriate key cofactors, including duration of 
breastfeeding, socio-economic status and age at gestation, breastfeeding was associated 
with significantly higher cognitive development scores (3.2 points; p< .001) for 
breastfed compared to formula-fed infants. 
 
More recent evidence from a randomised trial of nearly 14,000 children assessed at 6.5 
years of age with the Wechsler Abbreviated Scales of Intelligence (WASI) measures 
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found that that prolonged and exclusive breastfeeding improves cognitive development 
(Kramer, Aboud et al., 2008). Kramer et al. concede, however, that the variability of 
WASI scores and wide confidence intervals in both the experimental and controls 
groups means that the true magnitude of observed effects is uncertain.  
 
McNamara and Carlson (2006) summarised some of the more specific neurocognitive 
impairments in formula-fed versus breastfed children: lower visual acuity, slower 
processing speed on tests of visual recognition memory, deficits in problem-solving and 
more mature motor movement, problem-solving, and psychomotor function.  
 
A recent review of randomised control trials concluded that those studies with 
experimental formulas providing DHA close to the worldwide breast milk average of 
0.32% were more likely to yield functional beneﬁts, such as improvements in visual 
function and cognitive ability, than those formulas with less than this putatively optimal 
amount (Hoffman, Boettcher et al., 2009). For example, in a study considered to be of 
high-quality in a recent Cochrane review of cognitive outcomes in full-term infants 
supplemented with LCPUFAs (Simmer, Patole et al., 2008), Birch et al. found that visual 
acuity in the PUFA-supplemented group was significantly better than in the control 
group at ages 6, 17, 26, and 52 weeks (Birch, Castaneda et al., 2005).  
 
Tests of human infants in general use standardised global tests that screen broadly for 
cognitive-related functions, usually the Bayley Scales of Infant Development, which has 
scales for Mental and Psychomotor Development Index (MDI; PDI). Supplementation of 
term infant formula milk with 0.36% DHA and 0.72% AA during the first 4 months of 
life was associated with a mean increase of 7 points on the MDI at 18 months of age over 
the control formula group (Birch, Garfield et al., 2000). Improvements in MDI have also 
been observed over shorter periods, with Gibson et al. seeing an improvement of MDI in 
exclusively breastfed infants at 12 months of age following just 3 months postpartum 
maternal dietary supplementation (Gibson, Neumann et al., 1997). Improvements on 
Bayley indices following supplementation have not always been observed when 
followed up over a similar time period (Ben, Zhou et al., 2004; Makrides, Neumann et al., 
2000; Scott, Janowsky et al., 1998). 
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Taken together, findings from animal models, observational studies of breastfeeding 
effects and supplementation trials suggest that interference in the accumulation of EFAs 
by nutritional deprivation has lasting effects on neural functions and developmental 
processes which influence later cognitive outcomes. 
 
Chapter 3 outlines the converging methods used to investigate the effects of EFAs on 
cognitive outcomes using a paediatric liver disease model. 
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3 Methods 
 
The following chapter provides descriptive data for the primary clinical patient 
population and outlines the three converging analytical methods used: psychometric 
assessments, GC-MS for assessment of fatty acid status, and 1H-MRS for analysis of in 
vivo brain biochemistry. A brief summary of the background and utility of each 
technique is followed by details of the procedures and data acquisition parameters used 
in this study. 
 
3.1 Ethical considerations 
 
Informed consent was obtained from all participants and guardians under a protocol 
consistent with the tenets of the Declaration of Helsinki and with the approval of the 
Black Country Research Ethics Committee (08/H1202/38) and the Aston 
University’s Human Subjects Ethics committee (REG/00/175). Written consent was 
obtained from the participant’s parent or guardian. Verbal assent was obtained from 
children prior to testing. Participants were permitted to withdraw at any stage and 
were reassured that their withdrawal would not affect the level of clinical care they 
subsequently received. Oral and written debriefing was given after each session and 
procedure. Principal researchers had previously obtained Criminal Bureau Enhanced 
Disclosure for working with children and vulnerable adults. All blood samples were 
treated in compliance with the Human Tissues Act 2004. 
 
3.2 Participants 
 
Over a two and a half year period (2007–2010) all children under the age of 18 with a 
diagnosis of liver disease and their healthy siblings were recruited into study from the 
Liver Unit at the Birmingham Children’s Hospital. 
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3.2.1 Patient exclusion criteria 
 
 Children who cannot undergo neurophysiological testing before liver 
transplantation (for example fulminant liver failure) 
 Recipients of multi-organ transplants and re-transplants 
 Children of families who do not consent to the procedure 
 Participants with any contraindications for the MR procedure (ferrous metal 
implants, bone pins etc.) were specifically excluded from the 1H-MRS. 
 
3.2.2 Sibling control exclusion criteria 
 
Sibling control participants were screened prior to testing to exclude the presence of 
probable neurological dysfunction, including previous serious brain injury, history of 
learning disability, neurological disease, psychiatric diagnosis or current use of 
psychoactive medication. Sibling controls with any contraindications for the MR 
procedure (ferrous metal implants, bone pins etc.) were also excluded from the 1H-MRS 
portion of the study. 
 
3.2.3 Liver disease categorisation 
 
The liver disease patients were divided into three principal categories, which are 
outlined in Table 3-1. Descriptive data for the patient and control populations is 
provided in Table 3-2, page 50. 
 
Table 3-1 Categorisation of liver disease patients 
Disease category Criteria for classification 
Early-onset, pre-
transplant 
Patients with stable, well compensated congenital liver disease, 
who did not require transplantation, or were on the transplant 
waiting list at the time of participation in the study. 
Early-onset, post-
transplant 
Patients with severe congenital liver disease who had undergone 
liver transplantation prior to participation in the study. 
Acute liver failure, 
post-transplant 
Patients who developed postnatal liver disease after two years of 
age, usually presenting with acute liver failure, who had 
undergone liver transplantation prior to participation in the 
study. 
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3.2.4 Descriptive data for the sibling control and liver disease groups 
 
Table 3-2 Descriptive data for the sibling control and liver disease groups 
Group 
Total 
n 
Mean 
age 
(years) 
SD age 
(years) 
M:F 
Mean 
onset age 
(years) 
n Diagnoses 
Sibling controls 11 12.2 5.08 5:6       
Early-onset liver 
disease, pre-
transplant 
17 11.8 5.08 6:11 - 
9 Extra-hepatic biliary atresia 
1 Alpha 1-antitrypsin (A1AT) deficiency 
5 Progressive familial intra-hepatic cholestasis 
1 Neonatal haemochromatosis 
1 Alagille's syndrome 
Early-onset liver 
disease, post-
transplant 
8 15.5 3.2 3:5 - 
2 Progressive familial intra-hepatic cholestasis 
2 Extra-hepatic biliary atresia 
1 Aegeneas Syndrome 
2 Neonatal liver failure 
1 Alpha 1-antitrypsin (A1AT) deficiency 
Acute liver 
failure, post-
transplant 
6 13.7 3.7 2:4 5.4 
1 Autoimmune hepatitis 
1 Fulminant hepatitis A infection 
1 Wilson's disease 
3 Sero-negative hepatitis 
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The three principal methods employed in this study (psychometric assessment, blood 
sampling for GC-MS analysis of erythrocyte EFA status and 1H-MRS) were routinely 
administered in a single day. Due to the young age and nature of the patient’s 
conditions, successful completion of all three modes of assessment was not always 
possible. Specific descriptive data of the number and composition of each sample group 
with the appropriate data available is provided in each of the separate analyses in 
Chapters 5 and 7. 
 
3.3 Psychometric assessments 
 
Cognitive ability was assessed using the following age-appropriate Wechsler scales, 
depending upon the age of child at testing: 
 
 Wechsler Preschool and Primary Scale of Intelligence for Children – 3rd Edition 
(WPPSI-III), for children aged between 2 years 6 months and 7 years 3 months 
(Wechsler, 2002). 
 Wechsler Intelligence Scale for Children – 4th Edition (WISC-IV), for children 
aged between 6 years 0 months and 16 years (Wechsler, 2003).  
 Wechsler Adult Intelligence Scale – 3rd Edition (WAIS-III) or the Wechsler 
Abbreviated Scale of Intelligence (WASI), for those aged 16 years and over 
(Wechsler, 1997a; Wechsler, 1997b). 
 
The Wechsler scales provide a measure of general cognitive ability across both verbal 
and non-verbal dimensions. FSIQ is an estimate of overall IQ based on performance 
across 11 subtests. Separate estimates of verbal and performance IQ contribute to FSIQ; 
the Verbal dimension reflects language-mediated skills and the Performance dimension 
reflects non-verbal, visual-spatial and visuo-motor skills. In addition to the IQ scores, 
the Wechsler scales also yield sub-scores across a number of processing dimensions, 
such as the Information Processing Speed (IPS) index (aka Processing Speed Index), 
which is derived from the Symbol Search and Coding subscales. The IPS index is taken 
as an indicator of the mental and motor speed required to solve visuo-spatial problems 
as contributions of higher cognitive functions to task performance are minimised 
(Groth-Marnat, Gallagher et al., 2000). 
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Each of the Wechsler tests yields IQ indices with a population mean of 100 and standard 
deviation of 15. Performance on each of the individual subscales has a mean of 10 and 
standard deviation of 3. All standard scores can be converted to z-scores to enable 
comparison between standard scores with different population means and standard 
deviations. 
 
The WAIS, which consists of 6 subtests, was administered solely in the healthy adult 
population studied in Chapter 6. The WASI has high reliability (.98 for FSIQ in adult 
samples) and high validity characteristics (r=.92 with WAIS-III FSIQ). 
 
There is some overlap between these tests, with children aged 7 being able to complete 
the WPPSI or the WISC, and children aged 16 being able to complete the WISC or the 
WAIS. In cases where the patient fell in the intersecting age range, it was at the 
discretion of the patient’s referring Clinical Psychologist, who had knowledge of the 
patient’s case history and background, which assessment was administered. Different 
floor and ceiling effects can be achieved using the different tests, allowing for a greater 
understanding of the child’s abilities or deficits. In the current patient sample, the lower 
age limit was used in all cases: all patients above 6 years 0 months performed the WISC-
IV and all patients above 16 years 0 months performed the WAIS-III. 
 
All versions of tests were administered according to the standardised test protocol, in a 
single session, and within one week of completing the neuroimaging and blood 
sampling procedures. 
 
3.4 Essential fatty acid status 
 
3.4.1 Erythrocyte biomarkers of fatty acid status 
 
Biochemical analysis of biopsy samples is the traditional method for the determination 
of metabolite concentrations in tissue. Whilst histological evidence from animal and 
post-mortem data has revealed a great deal about the basic metabolic processes of the 
brain, the research has been hampered by the need make inferences of processes 
occurring in a highly dynamic tissue from either static or remote investigative tools, 
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revealing two distinct disadvantages: (1) labile metabolites may be altered or destroyed 
during the tissue extraction procedure and the decomposition products may become 
more abundant; and (2) tissue biopsies cannot be obtained from healthy, living human 
brain tissue. 
 
Histological evidence is certainly vital for the development of theory, but in vivo or 
surrogate biomarker techniques have important wider applications in the study of 
living tissues and individuals. A functional marker may reflect a biochemical (e.g. 
micronutrient-dependent enzyme activity) or physiological (e.g. cognitive ability) 
response upon current or imminent micronutrient deficiency. Kuratko and Salem 
(2009) outline the properties of acceptable biomarkers for fatty acid status: (1) the 
method of measurement is standardised, specific and sensitive; (2) the biological 
material used for biomarker determination is easily obtainable; (3) a correlation 
between the nutrient biomarker and intake of the nutrient is established; (4) the 
relationship of the biomarker status and nutrient intake is sensitive and specific; and 
(5) the biomarker status shows an association with important clinical outcome. 
 
Erythrocyte EFA levels are commonly used as an in vivo measure of EFA status in 
human studies, as samples are easily accessible through phlebotomy. Such measures 
provide a reliable estimate of cellular EFA status, reflecting bone marrow fatty acid 
availability and the plasma–RBC phospholipid exchange aggregated over the lifespan of 
the cell, or its 120-day half-life. Erythrocyte EFA has some clear advantages over plasma 
for EFA assessment. The fatty acid profile of plasma derives from at least four different 
lipid classes, which are located in various lipoproteins with different functions, origins, 
targets, turnover rates and inter-individual compositions. In erythrocytes, however, the 
fatty acids derive solely from plasma membrane phospholipids, which contain the full 
range of long-chain PUFAs and can be analysed using standard lipid quantification 
techniques (Arab and Akbar, 2002). 
 
Erythrocyte biomarkers are well-defined with respect to their dietary dependence and 
correlate with the fatty acid composition of brain. The strength of correlation between 
dietary intake and biomarker values, however, may vary considerably between 
individual fatty acids. Factors such as affinities to particular enzymatic pathways and 
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varying inter-conversion rates means that fatty acids are incorporated with different 
efficiencies (Katan, Deslypere et al., 1997). It is predicted that biomarkers of the omega-
3 and omega-6 PUFAs, such as LA and ALA, would have the strongest association with 
intake since the inability to generate double-bonds more than nine carbons from the 
carboxyl or delta end of the fatty acid ensure these PUFA may be derived from diet 
alone. 
 
EPA levels in cholesteryl esters reflect intake over the past week or two, in erythrocytes 
over the past month or two, and in adipose tissue over a period of years (Katan, 
Deslypere et al., 1997). Justification of the use of erythrocyte DHA as a marker for neural 
DHA comes primarily from the work by Carlson et al., which demonstrated that 
weanling rats fed a diet with a 240:1 ratio of LA to ALA (where ALA is the precursor to 
DHA) had lower concentrations of DHA in the phosphatidylethanolamine fraction of 
erythrocytes, brain cortex and cerebellum, compared to those fed a diet with a ratio of 
LA to ALA of 7:1 (Carlson, Carver et al., 1986). 
 
In humans, Makrides et al. have shown that erythrocyte DHA is a significant predictor of 
DHA levels in the cortex by demonstrating that infants who were breastfed had a 
greater proportion of DHA in both their erythrocytes and cortical tissue relative to those 
fed formula (Makrides, Neumann et al., 1994). A dietary intervention study of human 
adults showed that erythrocyte DHA was correlated with dietary intake over a period as 
short as 3 weeks (r= ~.4) (Poppitt, Kilmartin et al., 2005), confirming its potential as a 
reliable biomarker. In their summary of DHA biomarkers, Kuratko and Salem (2009) 
found that circulating DHA appears to show the strongest correlation with brain tissue 
when assessed in the context of background diet and when correlations are made with 
DHA as a percentage of total dietary fatty acids instead of absolute values. 
 
In addition to values of individual PUFAs of interest such as LA, ALA, DHA and EPA, 
biomarkers of EFA deficiency can potentially provide a more subtle analysis of fatty acid 
metabolism and utilisation. The body compensates for EFA deficiency in two ways: first 
through enhanced conversion of omega-3, -6, -9 fatty acids to their derivatives, and 
second through the accumulation of mono-unsaturated fatty acids. 
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Mead acid (20:3n-9) synthesis (see Figure 2-3, page 27) is ordinarily inhibited by 
adequate concentrations of ALA and LA. The presence of mead acid, therefore, acts as a 
functional marker for suboptimal levels of fatty acids of the omega-3 and -6 families 
(Fokkema, Smit et al., 2002). Similarly, if there is a functional shortage of DHA, the body 
begins to synthesise the analogous long-chain polyene of the omega-6 family: osbond 
acid (22:5n-6) (de Groot, 2003). Therefore, under steady state conditions, the ratio 
between DHA and osbond acid is a reliable indicator of the functional DHA status 
(Hornstra, 2000). Table 3-4 on page 61 summarises the various biomarkers in 
erythrocyte membranes used to assess fatty acid status. 
 
3.4.2 Gas chromatography-mass spectrometry 
 
Gas chromatography-mass spectrometry (GC-MS) is an instrumental technique, 
comprising of a gas chromatograph (GC) coupled to a mass spectrometer (MS), by which 
complex mixtures of chemicals may be separated, identified and quantified. The 
information provided by a GC-MS analysis of fatty acyl chains consists of GC retention 
times, which can subsequently be compared with known structural properties of 
various compounds, and the mass spectral data of the corresponding compounds 
derived from the mass spectrometer. Details of the GC-MS technique have been 
described by Harris (1999). A detailed discussion of the various chromatographic 
methods for the assessment of phospholipids in biological samples has been provided 
by Peterson and Cummings (2006). 
 
3.4.3 Lipid extraction and fatty acid methyl ester derivitisation 
 
3.4.3.1 Reagents 
 
All reagents and solvents (HPLC grade unless otherwise stated in Table 3-3, page 56) 
were purchased from Fisher Chemicals (Leicester, UK) and Sigma-Aldrich (Dorset, UK). 
Consumables for the Agilent 6890 GC were purchased from Agilent Technologies (West 
Lothian, UK). 
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Polyunsaturated fatty acids autoxidise rapidly when exposed to air; the more double 
bonds present, the more rapid the rate of oxidisation. Tissues will contain natural 
antioxidants such as a-tocopherol (Wang and Quinn, 1999), but the levels of these may 
not be sufficient to prevent deterioration on storage. The synthetic antioxidant 
butylated hydroxytoluene (BHT; 2,6-di-tert-butyl-p-cresol) was therefore added to all 
solvents used in the extraction and transmethylation process. Addition of BHT does not 
interfere with chromatographic analysis as it is relatively volatile and can be removed 
together with the solvents when evaporated under nitrogen. Any residual BHT elutes 
just after the isohexane peak and ahead of the fatty acid methyl esters (FAMEs). All vials 
were additionally flushed with nitrogen at various stages in the extraction procedure 
and before storage at -80°C. 
 
Table 3-3 List of reagents for fatty acid extraction and derivitisation 
Reagent Specific grade 
Butylated hydroxytoluene (BHT; 
2,6-di-tert-butyl-p-cresol). 
Technical grade 
Chloroform  
>99% HPLC certified, Fischer Scientific (+ 50 mg 
of BHT/litre) 
Deionised water HPLC certified, Fischer Scientific 
Ethanol >99.8% HPLC certified, Fischer Scientific 
Hydrochloric acid Optima Ultra Pure grade, Fischer 
Isohexane >99% HPLC certified, Fischer Scientific 
Methanol 
99.8+% HPLC certified, Fischer Scientific (+ 50 mg 
of BHT/litre) 
Phosphate buffered saline (PBS) 
Molecular Biology grade, 1X solution (0.137M 
sodium chloride; 0.0027M potassium chloride; 
0.0119M phosphates) 
Sodium chloride solution Technical grade; 5% in deionised water 
 
3.4.3.2 Phlebotomy and sample storage 
 
5ml of venous blood was obtained from each participant and dispensed into tubes 
containing 0.10ml of 15% anticoagulant solution (ethylene diamine tetra-acetic acid 
EDTA; 15 mg). The sample was centrifuged at 3,000 rpm for 10 minutes with the 
resulting plasma supernatant and buffy coat discarded. The sample was then washed 
twice with 5ml PBS at 3,000 rpm for 10 minutes. The RBC precipitate was then 
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resuspended in 5ml PBS, aliquoted into 2ml glass vials, and sealed under nitrogen and 
stored at -80 °C until required. 
 
3.4.3.3 Lipid extraction  
 
Prior to any analysis of fatty acids by GC-MS, the compounds of interest must be 
extracted and split into their constituent fatty acid methyl esters (FAMEs). First, the 
membrane lipids must be separated from the biological milieu of the blood sample to 
remove any other constituents such as proteins, sugars or other small molecules that 
would interfere with the chromatographic analysis. Secondly, before the fatty acid 
components of lipids can be analysed by GC, it is necessary to convert them to low 
molecular weight non-polar derivatives, such as methyl esters, through the process of 
derivitisation. 
 
Various solvents or solvent combinations have been suggested as optimal extractants of 
lipids from biological samples, but the most widely used are the Folch (Folch, Lees et al., 
1957) and the Bligh and Dyer (Bligh and Dyer, 1959) methods. Both methods were 
trialled and evaluated for efficacy based efficiency and quantity of fatty acid mass 
extracted from 1ml of RBC sample. Extractions using the Bligh and Dyer method 
resulted in approximately 3.5±0.5mg of fatty acid per 1ml sample, but by contrast the 
Folch method was able to extract 5.0±0.5mg per sample. A modified version of the Folch 
method (described in more detail below) was subsequently adopted as the standard 
procedure for lipid extraction from whole RBC samples. 
 
After removing the tissue from storage at -80°C the 1 ml suspension of RBC in PBS was 
brought to room temperature. The sample was transferred to a glass homogeniser and 
6ml chloroform containing BHT (0.1% w/v) was added. The mixture was homogenised 
for 60 seconds before adding 3ml methanol containing BHT (0.1% w/v) and the 
homogenisation was then repeated. 2ml sodium chloride was added to the extract to aid 
removal of any non-lipid contaminants and vortexed for 30 seconds. The mixture was 
centrifuged for five minutes at 3,000 rpm to aid phase separation. The lower chloroform 
phase contains the lipids, while the upper acidified methanol/water phase contains and 
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most of the non-lipid contaminants. Protein precipitates are present at the interface 
between the two layers. 
To maximise the removal of contaminants, the upper aqueous methanol layer was 
discarded and additional wash of 4.5ml methanol/water (1:1 v/v) was added to the 
remaining chloroform phase, followed by gentle mixing and centrifugation as previously 
described. The lower chloroform layer containing the purified lipid was transferred 
using a glass Pasteur pipette to a 10ml glass tube and evaporated to dryness under 
nitrogen at 25°C using a Techne "Dri-Block" sample concentrator. Evaporation of the 
final 1ml of solvent was carried out in a pre-weighed 2ml glass vial, which was re-
weighed on completion. The weight difference was taken as total weight of lipid 
extracted. The lipid sample was resuspended in 1ml chloroform, sealed under nitrogen 
and stored at -80°C. 
 
3.4.3.4 Fatty acid methyl ester derivitisation 
 
The determination of the fatty acids involves their derivitisation to give their 
corresponding FAMEs. The fatty acids undergo a reflux reaction with excess anhydrous 
methanol in the presence of an acidic catalyst, leading to the trans-esterification of the 
ester linked fatty acids, and producing a mixture of fatty acid methyl esters (Christie, 
1989).  
 
Purified lipid fractions were trans-methylated by reflux with methylating reagent (2.5% 
sulphuric acid: 97.5% methanol) at 80°C for 70 minutes. FAMEs were extracted into 
isohexane (1.5ml) partitioned against water (1ml) following thorough mixing of the 
phases. The isohexane phase containing the FAMEs was transferred to a 1.5ml glass vial 
and evaporated to dryness under nitrogen. The FAME were subsequently re-suspended 
in 100µl isohexane in a glass capillary insert and stored at -80°C, pending GC analysis. 
 
3.4.4 Gas chromatography methods 
 
Gas chromatography is used to separate volatile organic compounds (Harris, 1999). All 
systems of chromatography consist of a stationary and a mobile phase. The compounds 
to be separated are placed on a stationary phase, which for lipids is liquid, and then 
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volatilised and passed through a mobile phase where a stream of inert gas (helium) is 
allowed to pass through the system. Substances are separated according to their 
partition coefficients, yielded by the varying physical and chemical properties that 
impart different affinities for the two phases. The time point from the injection of the 
sample to that when the maximum amount of each component emerges (i.e. when the 
peak has reached its maximum height) is known as the retention time of the substance. 
 
The method of gas chromatography is both specific and sensitive for the determination 
of individual fatty acids, including DHA. Modern capillary columns are highly efficient 
and provide complete separation of longer-chain fatty acids DHA from other fatty acids 
(Masood, Stark et al., 2005), for measurement of values as low as 0.01 percent weight. 
In the present study, conventional GC analyses were performed on an Agilent 6890N 
with a DB-23 30m capillary column, coupled with an Agilent Technologies 5973 
Network Mass Selective Detector.  
 
Operating conditions were as follows: the split-splitless injector was used in split mode 
with a split ratio of 1:50. The injection volume of the sample was 1l. The injector and 
detector temperatures were kept at 250°C and 270°C respectively. Total run time was 
29 minutes per sample. Helium was used as the carrier gas, with a linear velocity of 
36cm/sec (average at 160°C). Pressure: 7.64psi; detector gas flows: H2: 1ml/min; air: 
350ml/min; make-up Gas (N2): 53.8 ml/min. Fatty acid methyl esters were separated by 
thermo gradient elution 180–240°C. The temperature program is illustrated in Figure 
3-1, total run time 29 minutes per sample. 
 
 
Figure 3-1 GC-MS temperature sequence 
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3.4.5 Mass spectrometry methods 
 
Mass spectrometry allows qualitative identification of the compounds extracted 
through chromatography (Harris, 1999). In the mass spectrometer, organic compounds 
in the vapour phase are bombarded with electrons and form positively charged ions, 
which can fragment in a number of different ways to give smaller ionised entities. The 
resulting ions are then passed through a powerful magnetic field and are separated 
according to their mass to charge ratio (m/z). The resulting mass spectrum displays the 
relative abundance of each fragment striking the detector of the mass spectrometer. As 
discussed previously, fatty acids differ not only in chain length, but also in the position 
of double bonds; the longer the chain length and the greater the number of double 
bonds, the longer the retention time (Christie, 1982). 
 
Data acquisition and processing were performed on Agilent Technologies 5973 
Network Mass Selective Detector standard software for the Agilent GC system. Peak 
identification was based upon comparison of spectra with known standards in the NIST 
library software. Having identified the fatty acid components using this method, 
samples were routinely run on under identical chromatographic conditions, but using a 
flame ionisation detector (FID), with fatty acid identification made based on retention 
times. 
 
3.4.6 Fatty acid biomarkers 
 
Fatty acid analysis was limited to a number of individual fatty acids and the four main 
fatty acid families: saturated (SFAs), monounsaturated (MUFAs), omega-3 PUFAs and 
omega-6 PUFAs.  
Table 3-5 summarises the biomarkers used to evaluate fatty acid status. Values in 
analyses are reported as percentages of the 12 fatty acids quantified in total. 
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Table 3-4 The major fatty acids detected in 
erythrocyte samples with conventional GC-MS 
Common name 
Carbon 
number 
Saturated fats  
myristic 14:0 
palmitic  16:0 
stearic  18:0 
Monounsaturated fats  
oleic  18:1 
Omega-9  
mead 20:3 
Omega-6  
linoleic (LA) 18:2 
dihomo-γ-linolenic (DHGLA) 20:3 
arachidonic (AA) 20:4 
Adrenic 22:4 
osbond 22:5 
Omega-3  
eicosapentaenoic (EPA) 20:5 
docosahexaenoic (DHA) 22:6 
 
Table 3-5 Summary of erythrocyte biomarkers of fatty acid status. 
Fatty acid biomarkers Fatty acids 
SFA 
stearic (18:0n-6) + palmitic (16:0n-6) + 
myristic (14:0n-6) 
MUFA oleic (18:1n-6) 
Omega-3 index  DHA (22:6n-3) + EPA (20:5n-3) 
Omega-6 index arachidonic (20:4n-6) + linoleic (18:2n-6)  
Omega-3:Omega-6  Omega-3 index/Omega-6 index 
EFA shortage marker mead acid (20:3n-9) 
Functional DHA shortage 
marker 
DHA/osbond acid (22:5n-6) 
 
3.4.7 Fatty acid biomarker reliability analyses 
 
The accuracy and reliability of fatty acid measurements are affected by a number of 
factors including intrinsic sample variability, sample handling and the extraction and 
quantification methodology employed (Arab and Akbar, 2002).  
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To ensure maximum reliability for fatty acid identification, only fatty acids that matched 
with 98% or greater accuracy with known standards in the NIST library software were 
included in analyses. To maximise quantification accuracy, all samples were run in 
duplicate, with the averaged value used in subsequent analyses. In cases where values 
for individual fatty acids exceeded 10% variance between runs, the sample was run a 
third time.  
 
3.5 Proton magnetic resonance spectroscopy (1H-MRS) 
 
Modern imaging paradigms, including conventional radiography, computerised 
tomography (CT), positron emission tomography (PET) and single photon emission 
computerised tomography (SPECT), now make it possible to study normal brain 
biochemistry in vivo. However, while these techniques may be used with paediatric 
patient populations when expressly clinically warranted, the ethics of exposing children 
to the radioactive isotopes required for these techniques solely for the advancement of 
science are less than clear (Casey and Cohen, 1996). 
 
By taking advantage of the unique electronic structure of molecules to characterise a 
wide variety of different chemical compounds (Govindaraju, Young et al., 2000), 
magnetic resonance spectroscopy (MRS) addresses the shortfall of histological methods 
by virtue of being a non-destructive procedure that does not require parenteral 
injections nor use radioactive materials evidence, to provide relatively region specific, 
quantitative, biochemical brain data in vivo. The physical properties of MRI facilitate 
investigations of the structure, metabolism and function of the brain in normal healthy 
individuals, and allow monitoring of progression and recovery in abnormal 
development. 
 
3.5.1 The magnetic resonance phenomenon 
 
The physics behind the magnetic resonance technique has been described in detail by 
Freeman (2003) and practical applications discussed by Ross and Bluml (2001). Nuclei 
that have an odd number of nucleons (protons and neutrons) possess both a magnetic 
moment and angular momentum (or spin). In the presence of a homogeneous external 
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magnetic field these nuclei precess around their axis at a rate proportional to the 
strength of the magnetic field, emitting electromagnetic energy in the process. 
 
In 1H-MRS, a large static magnetic field (B0) preferentially aligns hydrogen nuclei along 
the direction of the applied field. In clinical scanners, the strength of B0 is most often 1.5 
or 3 Tesla (T) and is oriented horizontally from head to toe along the long axis of the 
cylindrical magnet. A pulse of electromagnetic energy is applied at a specific 
radiofrequency (RF) with an RF coil placed around (or near) the head. The frequency is 
selected to be the same as the frequency of precession of the imaged nuclei at a given 
strength of B0; for hydrogen, this ‘resonant’ frequency is approximately 127.7 MHz at 
3T. The RF pulse rotates the precessing nuclei away from their axes and a receiver coil 
measures the time it takes for the nuclei to ‘relax’ back to their original position 
pointing along B0. The spatial origin of the signal is determined using subtle position-
related changes in B0 induced by gradient coils. 
 
The signals generated are subsequently amplified and displayed as a sinusoidal wave 
that decays with time, termed free-induction decay, and it is this transient signal that is 
amplified electronically, detected and then converted into a spectrum for high-
resolution MRS, or an image for MRI (see Figure 3-2, page 65 adapted from Chan 
(1985)). 
 
3.5.2 1H-MRS metabolite detection and quantification 
 
A brief overview of the MRS technique is provided below. Refer to Lambert and Mazzola 
(2004) for a comprehensive description of the physical basis of MRS, Ross and Bluml 
(2001) and Soares and Law (2009) for a broad discussion of the current understanding 
and applications, and Rosen and Lenkinski (2007) for a discussion of the most recent 
technical advances in the technique. 
 
Chemical bonding within a given molecule modifies the shape and density of its outer 
valence electrons, effectively creating a ‘magnetic shield’ that dictates the magnetic field 
of the nucleus. The corresponding change in the nuclear precession frequency is called 
the chemical shift and it is this parameter that permits identification of the chemical 
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environment of a given atom and gives rise to the individual peaks seen in MRS spectra. 
The chemical shift is measured using the dimensionless unit parts per million (ppm) 
and is the position on the δ scale where the peak occurs. It is defined in absolute terms 
by the frequency of the resonance expressed with reference to a standard compound, 
which is defined to be at 0 ppm. 
 
Most atoms have at least one isotope that possesses a magnetic moment, but the most 
widely used nuclei in biomedical MRS are hydrogen (1H), phosphorous (31P), carbon 
(13C) and sodium (3Na). 31P-MRS was the first to be applied to medicine in vivo and can 
be used to evaluate brain metabolic energy (Argov and Chance, 1991). The major 
motivation for using the proton nucleus (1H-MRS) is that hydrogen has the highest 
natural abundance in the body, which results in greater sensitivity of MR methods to 
this particular nuclei, compared with either 31P or 13C. 
 
Observing nuclei other than protons requires the development of radio-frequency coils 
and other specialised hardware tuned to their specific frequencies; 1H-MRS uses the 
same hardware, such as head coils, as standard MRI. The boundaries between MRI and 
MRS are becoming blurred as developments in MRI underline developments in MRS and 
vice versa. Cox (1996) suggests that to some extent, the proton-derived spectrum can be 
considered as another contrast parameter in the MRI examination, but adds that this 
does injustice to the wealth of chemical information available, and motivates the use of 
MRS as an MR paradigm with specific utility in the present study. Since Frahm, Bruhn et 
al. (1989) published the first reports of in vivo 1H-MRS, in which the methodology used 
in the detection and measurement of metabolite concentrations in the human brain was 
described, 1H-MRS has become the dominant tool in cognitive spectroscopy. 
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Figure 3-2 Simplified explanation of the magnetic resonance phenomenon, adapted from Chan 
(1985) 
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The initial intensity of the 1H-MRS signal is proportional to the number of nuclei giving 
rise to the signal. Protons attached to large macromolecules have short T2 values and 
are observed as broad, short peaks, whereas protons attached to small metabolites have 
longer T2 values and are observed as narrow, tall peaks in the proton spectrum. In 
principle it is the area under the individual peaks of the spectra which is indicative of 
the concentration of the particular chemical. In practice, however, there are so many 
variables that influence the signal intensity that absolute quantification is still relatively 
difficult to achieve (Freeman, 2003; Lambert and Mazzola, 2004). 
 
MRS is generally less sensitive than MRI because the concentrations of atoms measured 
by MRS are orders of magnitude less than the concentration of hydrogen used in 
anatomical MRI; only compounds in or near the millimolar range can be detected in vivo. 
Compounds of interest in biological systems are typically in the order of 1–10 mmol/L 
and are masked by the presence of a large background signal arising from water, which 
can have a concentration approaching 90 mol/L in protons (Rosen and Lenkinski, 
2007). Techniques such as water suppression are therefore employed to minimise these 
intense proton signals, which would otherwise interfere with detection of the signals of 
interest (Freeman, 2003). 
 
In the brain, the strongest and most reliable metabolite signals in 1H-MRS are generated 
by N-acetyl aspartate (NAA), creatine and phosphocreatine (Cre), choline (Cho), and 
myo-Inositol (mI). These four metabolites, and other reasonably well-resolved 
compounds such as glutamate/glutamine (Glx) and lactate, form the principal focus of 
1H-MRS research (Imamura, 2003; Inder and Huppi, 2000; Lambert and Mazzola, 2004; 
Rosen and Lenkinski, 2007; Ross and Bluml, 2001). Hunter’s Angle is the nominal 45 
degree ratio between the major metabolites, deviation from which is taken as an 
indication of abnormality (Danielsen and Ross, 1999). A typical, representative MRS 
spectrum is illustrated in Figure 3-3, page 67. 
 
67 
 
 
Figure 3-3 Representative 1H-MRS spectrum of normal human brain 
The five major metabolite peaks (choline, myo-Inositol, creatine, N acetyl aspartate and Glx) and Hunter’s 
Angle, the putative 45° ratio signifying ‘normal’ adult spectra, identified. 
 
3.5.2.1 Metabolite quantification as ratios 
 
All analyses reported in the present work adopt the standard convention of expressing 
metabolite ratios to an internal creatine standard. The creatine peak is thought to be 
relatively constant between individuals and in most brain areas, and is therefore used 
as an internal reference, where creatine equals 1 in the expression of all ratios 
(Danielsen and Ross, 1999). The explicit rationale for this approach is that the use of 
ratios will correct for several unknown, difficult to obtain or uncontrollable 
experimental conditions. These include static (B0) and radiofrequency (RF, B1) field 
inhomogenieties, instrumental gain drifts, imager and localisation method differences, 
and voxel partial volume contamination with metabolite-free cerebral-spinal fluid (CSF) 
(Li, Wang et al., 2003). 
 
3.5.3 Single-voxel 1H-MRS acquisition parameters 
 
All MR acquisitions were carried out on a Siemens 1H-Magnetom 3T (Siemens Medical 
Solution, Berkshire, UK) using standard software and quadrature head coil. 
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Scout images for localising the volume of interest (VOI) were acquired using a 5-plane 
localiser (Relaxation time (TR); 20msec, Echo time (TE); 5msec, 10 slices at 5mm 
thickness). 
 
1H-MRS data were acquired in a 2cm3 volume using a stimulated echo acquisition mode 
(STEAM) pulse sequence (TR; 2000msec, TE; 30msec, 96 averages). The choice of TE 
and TR reflects a compromise between a number of factors including scan time, patient 
tolerance and obtaining optimal information. With increasing TE, those neurochemical 
compounds with the shorter spin-spin (T2) relaxation times (mI and Glx) disappear, 
while those with longer T2 values (NA, Cr, Cho) become more prominent. With TEs 
shorter than 30ms, the mI and Glx region of the spectrum become even more 
prominent; however, water and lipids become more difficult to suppress adequately 
and the pulse sequences become more prone to artefacts. Voxel size is limited by a trade 
off between the signal-to-noise ratio (SNR) and tissue specificity; with smaller voxel 
sizes, specificity of voxel localisation is increased but SNR is reduced (Freeman, 2003). 
The acquisition parameters summarised in Table 3-6  consistently produce a high-
quality spectra containing all the major MR-visible compounds within the brain in an 
examination time of approximately 3 minutes per voxel.  
 
Table 3-6  1H-MRS acquisition parameters 
Repetition time (TR) 2000 msec  
Echo time (TE) 30 msec 
Number of averages 96 
Flip angle 90o 
Voxel size 2 x 2 x 2 cm3 
Pixel resolution 1024 
 
Water suppression was achieved by using three chemical shift-selective radio-
frequency pulses followed by a dephasing gradient applied on each of the three axes. 
Localiser scans were performed after each acquisition to compensate for potential 
participant movement between scans. Scan sequences and duration are summarised in 
Table 3-7, page 69. 
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Table 3-7 1H-MRS scan sequences and duration 
Scan sequence 
Duration 
(min:secs) 
Localiser 0:09 
5-plane localiser 0:40 
STEAM occipitoparietal cortex 3:20 
STEAM frontal cortex 3:20 
 
The technical limits of magnet construction, coupled with the presence of the 
participant in the scanner, introduces inhomogenieties in the magnetic fields over the 
whole of the brain volume located within the detection coil. This results in distorted 
lineshape of the spectra, leading to poor resolution and sensitivity. Small gradients in B0 
are compensated for by ‘shimming’, which is the application of a small DC current 
through x, y, z gradient shim coils. An active, automated first-order shim was performed 
prior to each acquisition for each participant introduced in the scanner.  During the 
shim process, a 3D gradient echo sequence acquires volumetric data of the region to be 
shimmed. The Siemens 1H Magnetom 3T scanner software analyzes the collected data to 
estimate the current needed in each shim coil to compensate for deficiencies in field 
homogeneity and  optimize the magnetic field homogeneity 
 
3.5.3.1 Voxel localisation 
 
Whilst differences in grey/white tissue composition affect the metabolite values 
obtained (Wang and Li, 1998), the brain region that is measured may be of more 
importance with respect to the cognitive domain that is tested. In the present study, 
voxels in the frontal cortex were selected because of the association between this region 
and executive cognitive function (Baddeley, 1996; Duncan, Seitz et al., 2000). A volume 
in the occipitoparietal cortex was selected as a control region to assess the functional 
specificity of the brain-behaviour relationship, and the comparatively homogenous 
nature of the cortical tissue in this region aids in providing consistent high-quality 
comparison spectra. Inter-hemispheric metabolite differences in metabolite values have 
been observed (Jayasundar, 2002; Jayasundar and Raghunathan, 1997). In the present 
study, a single hemisphere was focused on in the interest of parsimony, as reductions in 
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the number of variables and statistical comparisons required, decreases the 
probabilities of Type 1 error. 
 
Positioning of the voxel in the region of interest was achieved using anatomical 
references and ventricle landmarks from the 5-plane scout images. For the left frontal 
VOI, the voxel was placed as close possible to the anterior of the brain, centred superior 
to the lateral ventricles and avoiding overlap into the skull and corpus callosum. For the 
left occipitoparietal VOI, the voxel was placed in the region encompassing both occipital 
cortex and the inferior parietal lobule, with placement preferentially positioned in the 
anterior of the brain to avoid overlap into the skull or cerebellum. In all cases, manual 
positioning ensured that the voxel did not encroach upon non-neural sources such as 
skull, meninges, ventricles and major blood vessels and avoided as many of the cerebral 
sulci as possible. 
 
Figure 3-4 shows the location of the voxels in occipital and frontal cortex. Using a rule-
based approach to identifying anatomical landmarks for head positioning and voxel 
placement provided a straightforward method for effective and consistent voxel 
localisation. 
 
  
 
Figure 3-4 Localisation of 1H-MRS voxels shown in the saggital and transverse planes 
Voxel in frontal cortex is shown in orange and occipitoparietal cortex in blue.  
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3.5.4 LCModel 
 
The metabolite values obtained were subsequently modelled with LCModel software 
(Provencher, 2001), a user-independent fitting routine which provides spectral 
quantification and metabolite detection optimised for short echo time spectroscopy by 
fitting spectra in the frequency domain using a basis set of spectra of in vitro metabolite 
solutions acquired under conditions identical to those under which in vivo data are 
acquired. By using a nearly model-free constrained regularisation method to 
automatically estimate the smoothest lineshape and baseline consistent with the data, 
the model has the potential to improve the reliability of the metabolite values obtained 
(see below) and specifically addresses the problems of spectra complexity and baseline 
formation, in addition to providing results with a broader basis of comparability. 
 
3.5.5 1H-MRS reliability analyses 
 
In order for 1H-MRS to be a valid technique in metabolite quantification, data needs to 
be accurate and reliable. Accuracy refers to the degree of conformity of the measured 
quantity to its actual or true value. In living tissue it is difficult to quantify, as many 
standard measurement techniques, being invasive, are impractical. Reliability and 
precision refers to the variation in replicated readings, for example, as a result of 
variance introduced by scanner-related factors such as that caused by field 
inhomogenieties. 
 
To validate data quality and assess reliability, data from two successive scans of the 
same voxel were obtained and averaged at each voxel placement. Standard software 
with the Siemens 1H Magnetom 3T scanner produced metabolite values which were 
reliable when intra-voxel values are compared; all metabolites both in frontal and 
occipital regions were significantly correlated (p< .05). These values were, however, 
susceptible to large and unexpected distortions such as residual water signal, 
macromolecules and lipid signals, which may account for the range of correlation 
coefficients (.29 to .82) observed. The coefficients of variance were approximately 9% 
for frontal and 8% for occipitoparietal voxels, values which demonstrate acceptable 
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precision of the technique and which are consistent with data from previous 
reports (Ross et al., 2005). 
 
The LCModel (Provencher, 2001) specifically addresses the problems of spectra 
complexity and baseline formation. By accounting for unexpected distortions in the 
baseline, correlations between values for the first and second scan improved to a range 
between .773 and 0.976 (p <.01), and produced mean metabolic concentrations 
consistent with literature values (Danielsen and Ross, 1999). Coefficients of variance 
with LCModel were now between 6 and 8%. Chard, McLean et al. (2002) contend that 
with use of the LCModel, biological factors contribute a greater proportion to 
measurement variability than 1H-MRS measurement errors. In comparison with the 
AMARES (Advanced Method for Accurate, Robust and Efficient Spectral fitting) tool 
(Vanhamme, van den Boogaart et al., 1997), Kanowski, Kaufmann et al. (2004) found 
that metabolite-to-creatine ratios, estimated by LCModel with extended prior 
knowledge, are more accurate than absolute concentrations, and are nearly 
independent of SNR and line broadening. 
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4 Cognitive outcomes in paediatric liver disease 
 
4.1 Summary 
 
The aim of the present cross-sectional study was to evaluate neuropsychological 
function in children with liver disease and to investigate the impact of the disease on 
cognitive ability compared to sibling controls, in the context of covariates such as the 
age of onset and transplant intervention. 
 
Chronic liver disease appears to have significant negative effects on cognitive 
development, with age at the onset of disease an important moderator of this effect. 
Significant differences were observed between the early onset, post-transplant group 
and age-matched sibling controls on a measure of IPS (p= .017; (d)= 1.36), with 31% of 
the variance in IPS accounted for by the early onset of liver disease coupled with 
transplantation. 
 
There is a general pattern in the literature that supports the theory that early-onset 
liver disease has a significant impact on cognitive outcomes, possibly through the 
disruption of early neurodevelopment processes. Whilst greater numbers of 
participants are required to achieve the statistical power required to genuinely probe 
the effects of disease onset and some of the cofactors which may contribute to the 
cognitive deficits observed, the results of the present study show that the effects in this 
sample of this rare population is considerable. Enrolling children with liver disease in a 
large-scale, longitudinal study would help illuminate the extent and persistence of the 
cognitive deficits observed in paediatric liver disease. 
 
4.2 Introduction 
 
Liver transplantation (LTx) is now a standard treatment for children with end-stage 
liver disease (Muiesan, Vergani et al., 2007). With improving survival rates, resulting 
from innovations in operative techniques and the development of more effective 
immunosuppressant drugs (Kelly, 2008; Kelly, 1998), the life-expectancy of children 
with end-stage liver disease has significantly improved. One-year survival rates now 
74 
 
exceed 90% across most centres, and long-term survival figures for 10–15 years are 
greater than 80% (Soltys, Mazariegos et al., 2007). With a rapidly growing population of 
children who are long-term survivors of liver disease, there is an increased focus on 
variables associated with longer-term survival and cognitive and psychosocial outcomes 
(Alonso, 2008; Andrews, Sommerauer et al., 1996; Fouquet, Alves et al., 2005; Park, Rim 
et al., 2005). 
 
Some of the earliest investigations of children who had undergone LTx compared their 
neurocognitive outcomes to those of disease control groups, for example cystic fibrosis. 
Compared to cystic fibrosis patients, Stewart, Hiltebeitel et al. (1991) and Stewart, 
Silver et al. (1991) identified deficits specific to post-liver transplant patients in a 
variety of cognitive domains, including learning and memory, abstraction and concept 
formation, visual-spatial function, and motor function. However, a more recent study 
with the same experimental and control groups found no statistically significant 
differences between them on measures of visual-perceptual and visual-motor skills, but 
found deficits in language abilities in the liver disease group (Krull, Fuchs et al., 2003). 
 
A group of studies conducted in the late-1980s through early 1990s by Stewart et al. 
found that the child’s age at the onset of disease correlates with levels of physical and 
cognitive impairment. Children who developed liver disease in infancy had significantly 
lower IQ scores compared with children who became symptomatic later in life (Stewart, 
Campbell et al., 1992; Stewart, Uauy et al., 1988; Stewart, Uauy et al., 1989). In addition, 
the developmental delay which appears to be a frequent problem in infants awaiting 
liver transplantation does not reverse quickly after transplant (Wayman, Cox et al., 
1997). 
 
Given these age of onset related effects, the majority of children receiving liver 
transplants may be at risk of cognitive impairment, since the median age of paediatric 
liver transplant recipients is less than 2 years (Krull, Fuchs et al., 2003). Although 
specific cognitive deficits have been identified previously in liver disease patients, there 
have been few additional studies since the early work of Stewart et al. 
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4.2.1 Aims 
 
The aims of this cross-sectional study were to: 
 
1 Examine neuropsychological function in children with liver disease in order to 
investigate the impact of the disease on cognitive ability in comparison to sibling 
controls. 
2 Assess the effects of age of onset and transplant intervention on cognitive outcomes, 
specifically, FSIQ and IPS. 
 
4.2.2 Hypotheses 
 
1 Children with liver disease would score lower than the comparison control group on 
global measures of cognitive ability, specifically FSIQ and IPS. 
2 Children with early-onset liver disease would show greater deficits in cognitive 
ability than sibling controls and those who developed the disease later in childhood. 
 
4.3 Methods 
 
4.3.1 Participants 
 
Psychometric data was available for a total of 32 participants, 23 patients with a liver 
disease diagnosis and 9 healthy sibling controls (16 females, 16 males; mean age 13.1, 
SD: 5.0), from the larger sample described in Chapter 3 (Table 3-2, page 50). 
Psychometric data was not collected for two sibling controls and four patients in the 
early onset, post-transplant group who had consented into the study because of lack of 
availability at the time of testing. One patient in the early onset, pre-transplant group 
and one in the early onset, pre-transplant group were not available to complete the 
psychometric assessment battery. Table 4-1, page 76 shows the descriptive data of the 
patients consented into the study and the mean and standard deviation of psychometric 
scores. 
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Table 4-1 Descriptive data for the sibling control and liver disease groups with available psychometric data 
 
 Group 
Total 
n 
Mean 
age 
(years) 
SD age 
(years) 
M:F 
Mean onset 
age 
(years) 
n Diagnoses 
Sibling controls 9 13.2 4.5 6:3 
   
Early-onset liver 
disease, pre-
transplant 
10 14.9 4.0 4:6 - 
7 Extra-hepatic biliary atresia 
1 Alpha 1-antitrypsin (A1AT) deficiency 
1 Progressive familial intrahepatic cholestasis 
1 Neonatal haemochromatosis 
Early-onset liver 
disease, post-
transplant 
7 16.3 2.4 3:4 - 
2 Progressive familial intrahepatic cholestasis 
2 Extra-hepatic biliary atresia 
2 Neonatal liver failure 
1 Alpha 1-antitrypsin (A1AT) deficiency 
Acute liver failure 
(late onset), post-
transplant 
6 13.7 3.7 3:3 5.4 
1 Autoimmune hepatitis  
1 Fulminant hepatitis A 
1 Wilson's disease + acute liver failure 
3 Sero-negative hepatitis  
Dash indicates that liver disease was diagnosed from birth 
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4.3.2 Psychometric assessments 
 
The standardised protocol for administration of psychometric assessments is described 
in Chapter 3 (section 3.3, page 51). 
 
An age-appropriate battery of the Wechsler Preschool and Primary Scale of Intelligence-
III, Wechsler Intelligence Scale for Children-IV or Wechsler Adult Intelligence Scale-III 
was administered for each child to derive scores for Verbal, Performance, Working 
Memory, FSIQ, and IPS. 
 
4.4 Results 
 
4.4.1 Descriptive data and psychometric scores 
 
Table 4-2 shows the mean and standard deviation of psychometric scores of sibling 
controls and liver disease groups. Table 4-3, page 78 provides descriptive data for the 
patients consented into the study.  
 
Table 4-2 Summary of psychometric scores for sibling control and liver disease groups 
Psychometric measure 
Sibling 
controls 
EOLD 
pre-Tx 
EOLD  
post-Tx 
ALF 
post-Tx 
FSIQ 103.8 (21.9) 91.6 (19.2) 80.9 (21.3) 102.3 (21.4) 
IPS 104.7 (12.8) 91.7 (10.7) 81.6 (21.2) 102.5 (12.0) 
Verbal IQ 104.2 (23.3) 91.0 (20.1) 81.4 (22.0) 101.2 (22.2) 
Performance IQ 99.1 (20.7) 94.7 (15.8) 83.7 (22.4) 105 (20.2) 
Working Memory* 102.6 (12.0)a 89.0 (16.1)b 89.3 (20.9)c 97.3 (15.7)d 
EOLD: Early-onset liver disease, ALF: Acute liver failure, Tx: liver transplant. 
Mean z scores and standard deviations are shown. Wechsler assessments have a population mean of 100 
and standard deviation of 15. 
* n= 17; an=7, bn=3, cn=3, dn=4 
 
4.4.2 Cognitive outcomes in paediatric liver disease 
 
A one-way ANOVA was conducted to assess the differences in performance on the 
various psychometric indices based on diagnostic grouping. The results are shown in 
Table 4-3. 
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Table 4-3 Differences in psychometric scores between sibling 
controls and liver disease groups 
 Psychometric measure ANOVA 
  F df P 
FSIQ 1.949 3,28 .145 
IPS 4.124 3,28 .015* 
Verbal IQ 1.708 3,28 .188 
Performance IQ 1.423 3,28 .257 
Working Memory† 1.181 3,13 .355 
*p<.05, †n=17 
 
The ANOVA showed no significant difference between groups for FSIQ (p>.5). IPS was, 
however, identified as significantly different between groups (Table 4-3). Descriptive 
statistics (Table 4-1, page 76) show that mean IPS score was lower in the early onset, 
post-transplant group than the other two patient groups and the sibling controls. A one-
way ANOVA showed that this difference was statistically significant (F= 4.124 (p .015)), 
which represented an effect size Eta2 of .31, showing that 31% of the variance in IPS can 
be accounted for by the early onset of liver disease coupled with transplantation. 
 
A post hoc Tukey’s Honestly Significant Difference test, which corrects for Type 1 error, 
confirmed that the difference between the early onset, post-transplant group and 
sibling controls was unlikely to have arisen due to sampling error (p= .017, effect size 
(d)= 1.36). The Tukey test also showed that difference between the early onset, post-
transplant group and acute liver failure (late onset), post-transplant group approached 
statistical significance p= .06; effect size (d)= 1.26) (see Figure 4-1, page 79). 
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Figure 4-1 Comparison of IPS performance between control and liver disease groups 
Error bars represent ±1 standard error mean. The early onset, post-transplant cohort had significantly 
lower IPS scores compared to sibling controls (p= .017, effect size (d) = 1.36). 
 
4.5 Discussion 
 
The present study presents cross-sectional psychometric data from a total of 23 
patients with liver disease who were categorised into three independent groups: early 
onset pre-transplant, early-onset post transplant and acute liver failure, post-transplant. 
Performance on tests of cognitive ability was compared between the liver disease 
patient groups and with nine age-matched healthy sibling controls. 
 
As hypothesised, chronic liver disease appears to be associated with impaired cognitive 
development and the age of liver disease onset appears to be important. A statistically 
significant difference between the early onset, post-transplant group and age-matched 
sibling controls on IPS scores (p= .02, (d)= 1.36 was observed. The difference between 
the early onset, post-transplant group and acute liver failure, post-transplant group for 
this measure also approached statistical significance (p=. 06; (d)= 1.26). Cognitive 
deficits appear to be specific to processing speed; no statistically significant difference 
was observed for FSIQ scores, although the pattern of results between groups was the 
same. 
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It has been previously demonstrated that the cognitive effects of liver disease cannot be 
accounted for by the general effects of chronic, life-threatening disease. Compared to a 
group of cystic fibrosis (CF) disease controls, Stewart, Hiltebeitel et al. (1991) found 
that children studied at one-year post-LTx showed deficits in the areas of learning and 
memory, abstraction and concept formation, visual-spatial function, and motor function. 
They did not demonstrate differences in Verbal IQ, alertness and concentration, 
perceptual-motor, and sensory-perceptual areas.  
 
Building on this work, Stewart, Silver et al. (1991) narrowed the age range of the cohort 
and concentrated on a more selective neuropsychological test battery to study potential 
lateralisation effects associated with vocabulary performance. They found that children 
between the ages of 4 and 9 years showed similar deficits to the previous older age 
group studied by Stewart, Hiltebeitel et al. (1991), with no differences in lateralisation, 
but with the addition of deficits in Verbal IQ. 
 
Krull, Fuchs et al. (2003) also found that post-transplant children tended to have lower 
scores, particularly on receptive language tasks, but observed no significant difference 
between 15 liver and 15 CF patients on measures of academic achievement or visual-
spatial performance. As with Stewart, Hiltebeitel et al. (1991), Krull, Fuchs et al. (2003) 
found specific effects on verbal ability, something which was not seen in the cohort in 
the present study. 
 
Whilst significant difference for IPS between the early and late-onset groups were 
observed, the significant difference in FSIQ seen in the studies conducted by Stewart et 
al. was not replicated. Despite variations in the cognitive abilities assessed, the present 
findings are in accordance with previous evidence that the onset of liver disease may 
interfere with important early stages of cognitive development. In a heterogeneous 
group of 36 children who were 4 years old or older when they were referred for liver 
transplant, cognitive assessments pre- and one year post-transplant showed that 
children who developed liver disease in infancy had significantly lower IQ scores than 
children who became symptomatic later in life (mean ± SD for FSIQ; 85 ± 8.8 versus 99.5 
± 13.8) (Stewart, Uauy et al., 1988). 
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A subsequent study of 43 school-age children with advanced liver disease confirmed the 
findings that the onset of symptoms of liver disease in the first year of life had a 
stronger negative impact on cognitive function than those who were older at the time of 
transplantation, independent of diagnosis (Stewart, Campbell et al. 1992). In the 
present study, the acute liver failure transplantation group had comparable 
psychometric scores to the age-matched sibling controls (Table 4-2, page 77, and Figure 
4-1, page 79), lending support to the idea that time of onset is a key factor. 
 
Stewart, Silver et al. (1991) suggested that deficits found on performance tasks, rather 
than reflecting decreased visual-spatial function, may be indicative of diminished ability 
for other skills that underlie many of the visual-spatial tasks, such as timed 
performance. Given the systemic nature of liver disease, effects on global, rather than 
domain-specific, measures of cognitive ability would be anticipated. In the present 
study, a specific deficit it processing speed measures was observed in the early onset, 
post-transplant cohort, which may be related to myelination in so much that the 
primary function of myelin is the acceleration of neural impulses. The degree of and 
integrity of myelination is strongly related to processing speed measures, including the 
Wechsler measures of IPS employed in this study (Turken, Whitfield-Gabrieli et al., 
2008), and processing speed is thought to underlie, but is not synonymous with, general 
cognitive ability (Miller, 1994; Salthouse, 1996; Vernon, 1983). Myelination begins in 
the second trimester of gestation and continues into adulthood (Lenroot and Giedd, 
2007). Early onset of liver disease may specifically interfere with key 
neurophysiological developmental mechanisms such as myelination, resulting the 
deficits observed in this study. One of the potential mechanisms by which this may 
occur, related to EFA status, is discussed in the following chapter.  
 
As with the present work, the studies conducted by Stewart et al. used a cross-sectional 
design, which has the limitation of introducing heterogeneity (i.e. inter-individual 
confounders) into the population and data. However, when Stewart et al. studied 
children longitudinally, both before and after transplantation, the same pattern of 
results was observed: children with persistent cognitive deficits after transplant were 
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more likely to have had onset of disease in the first year of life (Stewart, Uauy et al., 
1989).  
 
Another finding of note in the present study was that deficits in cognitive performance 
were not uniform across both early-onset groups, but were largely limited to the post-
transplant patients. Whilst this non-uniformity may be a result at least in part from the 
small sizes typically employed in studies of this kind, there is also evidence that 
transplantation coupled with early onset has specific detrimental effects, which is to be 
anticipated as transplanted patients are usually the most severely ill. Kennard, Stewart 
et al. (1999) suggest that developmental delay, secondary to chronic liver disease in 
infancy, and acute or chronic hepatic encephalopathy in older children may result in 
enduring cognitive deficits and learning disabilities even after successful liver 
transplantation. This may explain the findings observed in early onset, post-transplant 
patient group. 
 
Wayman, Cox et al. (1997) found that infants who received LTx before 2 years of age 
had standardised scores of mental and motor developmental that dropped below pre-
transplant levels at 3 months post-transplant, and recovered to pre-transplant levels 
only at 12 months after the procedure. Similar deterioration preceding recovery in both 
cognitive and physiological outcomes has also been reported by van Mourik, Beath et al. 
(2000). The study by Wayman et al. was conducted in a young population 12 months 
post-transplant. These results cannot be easily compared to findings from the present 
study, which studied children at around 12 years of age, in some cases years after 
having received a transplant. Whilst the cognitive deficits observed in these children 
could improve over time, Wayman et al. suggest that post-operative effects, lasting up to 
one year post-transplant, are likely to persist in the longer term.  
 
The results from Wayman et al. and the present study demonstrates the need for a 
longitudinal investigation with a considerable follow-up period in order to probe the 
longer-term, potentially persistent effects of transplantation on cognitive development. 
The children in the current study were recruited post-transplant and therefore pre-
transplant evaluations were unavailable. It is possible that some of the deficits are 
related to the major surgery of liver transplantation and/or immunosuppressant 
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medication following transplantation, which may also explain the post-operative effects 
identified by Wayman et al. 
 
Krull, Fuchs et al. (2003) also highlight a number of cofactors which need to be taken 
into consideration. In a group of 15 liver transplant patients, they observed that the 
number of days in the intensive care unit, the total number of days spent in the hospital 
during the first year following the transplant, and elevated pre-transplant bilirubin 
levels, significantly predicted the speech and language delays. Only data for bilirubin 
levels at the time of study were available in the present study, and no correlation was 
observed between this marker of disease severity and IQ performance (p <.05). 
Hyperbililirubinemia (>342 µmol/L (20mg/dL)) in infancy is, however, associated with 
a higher risk of for low IQ scores (<85) at age 17 (Seidman, Paz et al., 1991), which again 
supports the theory that greater disease severity in early infancy is associated with 
poorer cognitive outcome in later childhood. Data for a number of co-factors, including 
length of hospitalisation and periodic measures of bilirubin levels was collected in a 
number of the patients in the current study (see Appendix A), but analysis was 
considered beyond the scope of this thesis. 
 
In the present study, age-matched healthy children were used as a control group. 
Employing an intra-subject design would alleviate the problem of identifying an 
appropriate comparison group. Given the ongoing complications associated with liver 
failure and post-transplant recovery, an age-matched chronic disease group, such as 
cystic fibrosis patients used in previous studies, has greater utility in controlling for co-
factors such as number of days missed from school, hospital visits and similar 
potentially confounding effects. 
 
4.6 Conclusion 
 
The most important finding of the present study is that post-transplant children with an 
early onset of liver disease show deficits in cognitive ability, specifically in Information 
Processing Speed, compared to age-matched acute liver failure transplant patients and 
sibling controls. This highlights the need to assess the developmental and cognitive 
status in children with liver disease and the importance of the timing of the onset of 
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illness. Whilst the results of the present study are in keeping with the literature 
demonstrating age of onset-related cognitive deficits in children with liver disease, the 
limited number of participants in each group, and the heterogeneity in specific 
diagnoses, is a significant limitation and the findings of the present study must be 
interpreted with caution, despite the large effect sizes.  
 
The numerous activities of the liver that are disturbed as a consequence of liver disease 
may each contribute in some small degree to the observed deficits in cognitive 
functioning. One possible mechanism that may explain the results is the reduced 
exposure to molecules important in development of brain, such as EFAs, which is 
investigated Chapter 5.  
 
Greater numbers of participants are needed to achieve the statistical power required to 
genuinely probe the effects of disease onset and some of the cofactors identified which 
may contribute to the cognitive deficits observed. Longitudinal studies would help 
illuminate the extent and persistence of the cognitive deficits observed in paediatric 
liver disease. The availability of patients is, however, a significant limiting factor to 
large-scale studies with this group, which means that in general there is a shortage of 
studies assessing the impact of liver disease, and treatment-related variables, on 
neuropsychological function. 
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5 Polyunsaturated fatty acids and cognitive 
outcomes in paediatric liver disease 
 
5.1 Summary 
 
Using a paediatric liver disease model, the aim of this study was to evaluate whether 
sub-optimal concentrations of EFAs, as a result of fat malabsorption or dependence on 
inadequate dietary sources, is associated with deficits in cognitive ability, particularly as 
specific deficits in processing speed measures were observed in children with early-
onset congenital liver disease who had received a liver transplant (see Chapter 4). 
Specifically, the aim was to measure and evaluate the range of EFA biomarker 
concentrations in cross-sectional cohorts of children with a variable onset of liver 
disease, some of whom with more severe manifestations of liver disease had received a 
liver transplant, and determine if cognitive ability in these children is related to their 
EFA status. 
 
GC-MS analysis of erythrocytes was used to quantify biomarkers of fatty acid status, 
including the major omega-6 fatty acids (LA and AA), LCPUFA omega-3 fatty acids (DHA 
and EPA), and specific functional deficiency markers (osbond and mead acid). Fatty acid 
status was compared between groups of patients with liver disease and age-matched 
sibling controls and relationships between EFAs and the cognitive outcomes described 
in Chapter 4 were investigated. 
 
Compared to sibling controls, no signs of fatty acid deficiency were observed in any of 
the cohorts of patients with liver disease. This suggests that: (1) these patients were not 
deficient in their dietary intake of EFAs, LA and AA and (2) these patients are able to 
sufficiently metabolise these precursor lipids to synthesise LCPUFAs, DHA and EPA, to 
levels comparable to sibling controls. Duration of breastfeeding was not correlated with 
later cognitive outcomes in this cohort, but a strong correlation was observed between 
omega-6 (LA and AA) status and FSIQ and IPS (r= -.62 and -.39; p< .001), independent of 
disease diagnosis. 
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5.2 Introduction 
 
The advent of paediatric liver transplantation has placed additional emphasis on the 
importance of optimum nutritional management of children with chronic liver disease, 
as improvement of nutritional status in the pre-transplantation period maximises 
success of the liver transplant itself. There is also a growing awareness of active 
nutritional support for children with end-stage liver disease in order to maintain a state 
of health that supports normal physical and psychological development (Alonso, 2008; 
Bavdekar, Bhave et al., 2002; Protheroe, 1998). 
 
Whatever its original cause, chronic liver disease in children is characterised by an on-
going inflammatory process that injures the liver tissues causing fibrosis and in severe 
cases, cirrhosis. Some children require a liver transplant to survive, although many can 
be managed with medical treatments such as drugs to regulate the immune system and 
food supplements to compensate for fat malabsorption (Kelly, 2008; Kelly, 1997; Kelly, 
2006; Kelly and Sibal, 2006). 
 
The liver has a diverse range of functions including the production of bile, constituents 
of which are required for efficient intestinal fat absorption. Additionally, biliary 
secretion of cholesterol (as such, or after incorporation into bile salts) and 
phospholipids from the liver into the intestine is of major importance in body lipid 
homeostasis. Most importantly, the liver is the site of active synthesis, metabolism 
and/or oxidation of a wide range of proteins and carbohydrates, as well as EFAs and 
LCPUFA, which are the subject of this study. For a more detailed discussion of lipid 
absorption and metabolism in cholestasis refer to Werner, Kuipers et al. (2003). 
As a result of the importance and functions of EFA, which were described in Chapter 2, 
interest in the role of EFAs in liver disease has been growing rapidly in recent years (de 
Meijer, Le et al., 2010; Diamond, Sterescu et al., 2008; Lee, Gura et al., 2007). Isolated 
omega-3 deficiency has attracted attention since its recognition in a 6-year-old girl who 
received long-term total parenteral nutrition that lacked adequate omega-3 fatty acids 
(Holman, Johnson et al., 1982). 
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5.2.1 Dietary EFA deficiency in paediatric liver disease 
 
Malnutrition and consequent EFA and PUFA deficiency can be a result of multiple 
factors, such as increased energy requirements, malabsorption and abnormal hepatic 
metabolism (Motta, Sterling et al., 1999; Protheroe, 1998). Patients are at risk of 
malnutrition if under 2 years of age, or having severe cholestasis, or progressive liver 
disease, such as biliary atresia or severe neonatal hepatitis, and if awaiting liver 
transplantation intervention (Protheroe, 1998). Malnutrition is however recognised as 
a risk factor that is potentially reversible, making nutritional support a cornerstone of 
therapeutic management of these children. 
 
Malabsorption of lipids is a critical nutritional issue, particularly in cholestasis, because 
a fundamental energy source is lost. Inadequate energy intake due to malabsorption of 
fat can be compensated for by using  soluble medium-chain triglycerides (MCTs), which 
are fatty acids with carbon chain lengths between 6 and 12 (primarily octanoic (C8) and 
decanoic (C10) acids). Most infant formulas used by children with liver disease contain 
MCTs (for examples of feeds, see Table 5-1, page 88). MCTs do not require extensive 
biochemical transformation or incorporation into chylomicrons during intestinal 
absorption and MCT oil supplemented diets have been successfully used in reducing 
steatorrhea, improving energy balance, and promoting growth in liver disease patients 
(Cohen and Gartner, 1971; Kaufmann, Murray et al., 1987). 
 
Concerns have been raised that MCT-based nutritional feeds, lacking adequate levels of 
EFAs lead to deficiency states (Hirono, Suzuki et al., 1977; Pettei, Daftary et al., 1991). 
Furthermore, EFA deficiencies in patients on parenteral feeds are not easily reversed, at 
least in the short term (Deurksen, Nehra et al., 1999). Table 5-1, page 89, shows the 
fatty acid content of Pregestimil and Peptisorb, two feeds used by the Birmingham 
Children’s Hospital to treat children with cholestasis and which contain no AA, EPA or 
DHA. Table 5-2, page 89, shows the fatty acid content of Pepti Junior, an alternative feed 
that contains appreciable levels of LCPUFAs.  
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Table 5-1 Fatty acid content of two feeds used by the Birmingham 
Children’s Hospital to treat children with cholestasis 
Brand of feed MCT (%) Fatty acid content 
(mg/100ml) 
   
18:1 18:2 
18:3n-
3 
Pregestimil 54 179 220 28.9 
Peptisorb 47 408 1010 92.7 
Data retrieved from http://nutritiondata.self.com/facts/baby-
foods/440/2 
 
Table 5-2 Fatty acid content of Pepti Junior, an MCT-based feed with appreciable levels of LCPUFAs 
Brand of feed 
MCT 
(%) 
Fatty acid content (%/100g FA) 
    18:1 18:2 18:3n-3 18:3n-6 20:4 20:5 22:6 
Pepti Junior 50 22.7 14.4 2.7 0.02 0.2 0.05 0.2 
 
5.2.1.1 EFA deficiency due to fat malabsorption 
 
Even with adequate intake, up to half of dietary fat, along with fat-soluble vitamins and 
the essential PUFAs, may be malabsorbed due to reduced intraluminal bile 
concentration (Beath, Hooley et al., 1993; Glasgow, Hamilton et al., 1973). Fat 
malabsorption has also been shown to decrease EFA serum concentration, whilst total 
unsaturated fatty acid concentration is maintained through increases in nonessential 
fatty acid endogenous production (Jeppesen, Christensen et al., 1997). Abnormalities in 
the hepatic omega-6:omega-3 PUFA ratio impacts hepatic lipid homeostasis through 
modulation of transcription factors, and also impacts fatty acid desaturase (FADS) 
enzymes which have a major role in fatty acid metabolism and fat accumulation in the 
liver (El-Badry, Graf et al., 2007). 
 
In summary, infants with cholestatic liver disease are at risk of DHA deficiency as a 
result of malabsorption of LCTs, prescription of diets rich in MCT, or suboptimal liver 
desaturase enzyme activity. The critical role of PUFAs such as DHA in neuronal 
development (Chapter 2) suggests that adverse effects of inadequate levels of these 
nutrients may manifest as deficits in cognitive ability in later life and may be one of the 
mechanisms that explains, at least in some part, the specific deficit in processing speed 
measures observed in the early-onset liver disease patients in Chapter 4. 
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5.2.2 Aims 
 
Using a paediatric liver disease model, the aim of this study was to evaluate whether 
sub-optimal concentrations of EFAs, as a result of fat malabsorption or dependence on 
inadequate dietary sources, is associated with deficits in cognitive ability. Specifically, 
the aims were to: 
 
1. Measure and evaluate the range of EFA biomarker concentrations in cross-
sectional cohorts of children with a variable onset of liver disease who may also 
have had a liver transplant. 
2. Determine if cognitive ability in these children is related to their current EFA 
status. 
 
5.2.3 Hypotheses 
 
1. Patients with liver disease would show biomarkers of EFA and PUFA deficiency 
compared to the sibling control group. 
2. Omega-3 fatty acids (particularly DHA) would be positively correlated with 
broad-based measures of cognitive ability. 
 
5.3 Methods 
 
5.3.1 Participants 
 
Blood sample data was available for a total of 39 participants, of which 28 patients had a 
liver disease diagnosis and 11 were sibling controls (24 females, 15 males; mean age 
13.8, SD: 4.2), from the larger sample described in Chapter 3 (Table 3-2, page 50). EFA 
data was not available for three of the early onset, pre-transplant patients. One patient 
did not provide a blood sample on the study day and blood samples from two patients 
were not of sufficient quantity to permit adequate lipid analysis. Descriptive details of 
the subsample included in this study are provided in Table 5-3, page 90. 
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Table 5-3 Descriptive data for the sibling control and liver disease groups with available psychometric and EFA data 
 
Group 
Total 
n 
Mean 
age 
(years) 
SD age 
(years) 
M:F 
Mean 
onset age 
(years) 
n Diagnoses 
Sibling controls 11 12.2 5.1 5:6       
Early-onset liver 
disease, pre-
transplant 
(EOLD pre-Tx) 
14 13.6 4.6 5:9 - 
8 Extra-hepatic biliary atresia 
1 Alpha 1-antitrypsin (A1AT) deficiency 
4 Progressive familial intrahepatic cholestasis 
1 Neonatal haemochromatosis 
Early-onset liver 
disease, post-
transplant 
(EOLD post-Tx) 
8 15.5 3.2 3:5 - 
2 Progressive familial intrahepatic cholestasis 
2 Extra-hepatic biliary atresia 
1 Aegeneas Syndrome 
2 Neonatal liver failure 
1 Alpha 1-antitrypsin (A1AT) deficiency 
Acute liver 
failure, post-
transplant (ALF 
post-Tx) 
 
6 13.7 3.7 2:4 5.4 
1 Autoimmune hepatitis 
1 Fulminant hepatitis A infection 
1 Wilson’s disease 
3 Sero-negative hepatitis 
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The sample provides the study with statistical power in excess of 80% to detect 
moderate correlations of .4 and above, with statistical significance evaluated at an α 
level of .05 (Friedman, 1968). 
 
5.3.2 Quantification of fatty acid biomarkers in erythrocyte 
membranes 
 
The total lipids were extracted from the erythrocytes, transesterified to the methyl 
esters and analysed with conventional GS-MS. Details of the procedures and 
reagents are described in Chapter 3 (section 3.4, page 52). Fatty acid analyses were 
limited to a number of individual fatty acids and the four main fatty acid families: 
saturated (SFAs), monounsaturated (MUFAs), omega-3 and -6 PUFAs (refer to 
Chapter 3, page 60 for details). Table 5-4 summarises the biomarkers used to 
evaluate fatty acid status. 
 
Table 5-4 Summary of erythrocyte biomarkers of fatty acid status 
Fatty acid biomarkers Fatty acids 
SFA 
stearic (18:0n-6) + palmitic (16:0n-6) + 
myristic (14:0n-6) 
MUFA oleic (18:1n-6) 
Omega-3 index  DHA (22:6n-3) + EPA (20:5n-3) 
Omega-6 index arachidonic (20:4n-6) + linoleic (18:2n-6)  
Omega-3:omega-6  omega-3 index/omega-6 index 
EFA shortage marker mead acid (20:3n-9) 
Functional DHA shortage marker DHA/osbond acid (22:5n-6) 
 
5.3.3 Psychometric assessments 
 
An age-appropriate battery of the either the Wechsler Preschool and Primary Scale 
of Intelligence-III, Wechsler Intelligence Scale for Children-IV or Wechsler Adult 
Intelligence Scale-III, was administered to derive scores for Verbal IQ, Performance 
IQ, Working Memory and FSIQ, and IPS. The standardised protocol for 
administration of psychometric assessments was described in Chapter 3. 
Psychometric test scores were converted to scaled scores to standardise the data 
across age groups according to the standard Wechsler administration instructions 
(refer to section 3.3, page 51). 
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5.3.4 Breastfeeding data 
 
Breastfeeding data was collected by a physician who interviewed the mothers 
about both the timing and duration of breastfeeding.  
 
5.4 Results 
 
5.4.1 Summary of erythrocyte fatty acid biomarker data 
 
Figure 5-1 provides an example of a high-quality GC-MS spectrum of fatty acids 
extracted from erythrocyte membranes. Table 5-4, page 91, summarises the fatty 
acid data for each of the four participant groups.  
 
 
Figure 5-1 Example of high-quality GC-MS spectra of erythrocyte EFAs  
Spectra shown is from one sibling control participant. Fatty acids are identified by their relative 
retention times and are labelled on the spectra. The integral of the peak indicates relative quantity 
of each fatty acid. 
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Data for each of the biomarkers assessed consistently satisfied distributional 
assumptions of normality (evaluated with the Shapiro-Wilk statistic at an α level of 
.05), therefore justifying the use of parametric statistics in subsequent analyses.  
 
Psychometric data was available for 32 of the 39 participants, permitting 
correlational analyses of the relationship between cognitive outcomes and current 
fatty acid status. Mean and SD psychometric scores of the participants included in 
this study have been described previously in Table 4-2, page 77). 
 
Table 5-5 The distribution of erythrocyte EFAs in sibling controls and liver disease groups 
  
Sibling 
controls 
EOLD    
pre-Tx 
EOLD    
post-Tx 
ALF    
post-Tx 
N 11 14 8 6 
Fatty acid % Total (SD) 
SFA 27.95 (5.26) 27.93 (6.21) 30.21 (5.0) 27.76 (5.54) 
palmitic (16:0n-6)  7.02 (1.07) 6.86 (.93) 6.64 (.65) 6.64 (.49) 
stearic (18:0n-6)  9.21 (.80) 9.49 (1.02) 8.92 (1.57) 8.85 (1.03) 
MUFA 
8.64 (.63) 8.82 (1.15) 9.16 (1.71) 8.98 (.55) 
oleic (18:1n-6) 
Total omega-6  19.28 (1.86) 16.66 (2.71) 20.10 (3.11) 19.29 (1.74) 
linoleic (18:2n-6)  9.43 (.97) 9.58 (1.39) 9.89 (1.78) 9.16 (1.14) 
arachidonic 
(20:4n-6)  
9.85 (1.02) 10.06 (1.49) 10.22 (1.60) 10.13 (.76) 
Total omega-3  17.64 (1.70) 17.03 (3.40) 15.59 (2.68) 18.29 (2.37) 
EPA (20:5n-3) 8.68 (.87) 7.61 (3.51) 7.28 (3.13) 8.55 (.94) 
DHA (22:6n-3)  8.96 (.97) 9.41 (1.59) 8.63 (1.49) 9.73 (1.50) 
Omega-3:omega-6  .92 (.05) .91 (.17) .86 (.14) .95 (.13) 
DHA/osbond acid 
(22:5n-6) 
1.06 (.08) 1.07 (.25) 1.0 (.08) 1.14 (.20) 
Mean percentage total and standard deviation of fatty acids quantified in erythrocyte membranes 
are shown. Percentage values do not total 100% as only selected fatty acids were included in 
analyses (see Chapter 3). 
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5.4.2 Inter-diagnostic differences of EFA and PUFA and 
biomarkers 
 
Table 5-6 Differences in levels of fatty acid erythrocyte biomarkers 
between sibling controls and liver disease groups 
Fatty acid biomarkers ANOVA 
  F df p 
SFA .355 3, 35 .79 
MUFA .369 3, 35 .78 
Omega-3 index 1.030 3, 35 .39 
Omega-6 index .202 3, 35 .89 
Omega-3:omega-6 1.005 3, 35 .40 
Functional DHA shortage marker .585 3, 27* .63 
*Osbond acid (the denominator in this ratio) was below the detection 
threshold, in six of the participants 
 
No significant differences were observed between diagnostic groups and controls 
for any of the six EFA status biomarkers assessed (p> .05). 
 
5.4.3 Relationships between fatty acids and cognitive ability in a 
paediatric sample 
 
Findings from Chapter 4 showed that there was no statistically significant 
difference between diagnostic groups for FSIQ. This justified the investigation of 
correlations between this broad-based measure of cognitive ability and fatty acid 
levels across the entire cohort, including both sibling controls and clinical groups. 
Whilst group difference in IPS were observed (see section 4.3.2, page 77) analysis 
was also conducted to test the relationship between fatty acid levels and this 
measure, independent of disease diagnosis. 
 
To minimise susceptibility to Type I error, a Bonferroni correction was performed 
and the alpha level was set at .0014. No significant correlation was observed 
between total SFA (a composite of myristic, palmitic and stearic acid) for VIQ and 
PIQ (p>.03) or FSIQ and IPS (p> .05).  
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Table 5-7 Correlations between erythrocyte fatty biomarkers and cognitive ability 
FA 
biomarkers 
Correlation with cognitive indices; r (p value) 
  FSIQ IPS PIQ VIQ WM 
N 32 32 32 32 17 
SFA .33 (.07) -.01 (.97) .39 (.03) .38 (.03) .13 (.61) 
MUFA -.29 (.10) -.05 (.98) .23 (.20) -.34 (.06) -.20 (.45) 
Omega-3 
index 
.03 (.87) .20 (.26) -.71 (.70) .13 (.95) .44 (.08) 
DHA -.35 (.05) -.28 (.12) -.42 (.02) -.16 (.37) -.17 (.50) 
Omega-6 
index 
-.62 (.00)* -.39 (.03) -.60 (.00)* -.66 (.00)* -.48 (.05) 
Omega-3: 
omega-6 
.40 (.02) .32 (.08) .32 (.08) .39 (.03) .60 (.01) 
Functional 
DHA shortage 
marker 
-.24 (.90) .16 (.42) .03 (.86) .16 (.42) .21 (.44) 
FSIQ= Full-scale IQ, IPS= Information Processing Speed, VIQ= Verbal IQ, PIQ=Performance IQ,  
WM= Working memory, SFA= saturated fatty acids, MUFA = monounsaturated fatty acids,  
Omega-3 Index= EPA+DHA, omega-6 index= LA + AA 
EFA data were normally distributed justifying the use of parametric Pearson’s correlation 
coefficients 
*p<.0014 (Bonferroni-corrected α value) 
 
No significant correlation was observed between the omega-3 index (comprised of 
the percentage total of EPA and DHA) and any of the cognitive indices measured 
(p>.05). As DHA is putatively the most important long-chain PUFA, analyses were 
also targeted at this fatty acid specifically. However, no statistically significant 
correlation was observed between DHA values and FSIQ performance (r= -.35; 
p=.05, see Table 5-7). 
The omega-6 index (comprised of the percentage total of LA and AA) showed a 
strong, negative correlation with FSIQ (r= -.62; p< .001, see Figure 5-2 , page 96), 
and a trend towards moderate negative correlation with IPS (r= -.39; p= .03, see 
Figure 5-3, page 96), although this relationship was not statistically significant at 
the Bonferroni-corrected α level of .0014.  
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Figure 5-2 Correlation between % total omega-6 (LA and AA) and FSIQ 
r= -.62 p< .001; n= 32 
 
Figure 5-3 Correlation between % total omega-6 (LA and AA) and IPS 
r= -.39 p= .03; n= 32 
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The omega-3:omega-6 ratio showed a trend towards a moderate positive 
correlation with FSIQ (r= .40; p= .02, see 5-4), and a strong, positive correlation 
with Working Memory (r= .60; p= .01, n= 17). The functional DHA index (the ratio 
of DHA to osbond acid) was weakly and not statistically significantly correlated 
with cognitive indices (p>.05). 
 
Figure 5-4 Correlation between the omega-3-omega-6 ratio and FSIQ 
r= -.40, p= .02; n= 32.   
A small subset of participants (circled in red) appear to be qualitatively different to the rest of the 
group, falling well below an omega-3omega-6 ratio of .70(blue dashed line) 
 
Analysis of  Figure 5-4, page 97, shows that there may be a sub-group of four 
participants (circled in red) that are qualitatively distinct from the rest of the 
group, with an omega-3omega-6 ratio below an arbitrary threshold of .70 (blue 
dashed line). Removal of these four outliers negates the previously significant 
linear relationship between the omega-3:omega-6 ratio and FSIQ (r= .31, p= .27; n= 
28). The potential for categorical associations, rather than traditionally assumed 
linear relationships between EFA levels and cognitive variables is discussed in 
section 5.5.2.3. 
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5.4.4 Effect of breastfeeding on cognitive outcomes  
 
Breastfeeding data was collected for 34 of the 39 patients and controls. Data from 
one patient and their sibling control was removed as duration of breastfeeding 
exceeded three standard deviations from mean duration. 26 of the remaining 32 
participants had a full set of psychometric data. The numbers in each group are 
summarised in Table 5-8. 
 
Table 5-8 The number of breastfed children in each 
diagnostic group 
Diagnostic group Breastfed 
 
Yes No Total 
Sibling controls 3 6 9 
EOLD pre-Tx 5 7 12 
EOLD post-Tx 4 3 7 
ALF post-Tx 1 3 4 
 
Participants were first grouped into breastfed/non-breastfed categories to assess 
the overall impact of breastfeeding on later cognitive outcomes. The results are 
shown in Table 5-9. 
 
Table 5-9 Cognitive outcomes in breastfed vs non-
breastfed children 
  Breastfed vs non-breastfed 
  t Df p 
FSIQ -2.19 26  .04* 
IPS -1.43 26 .17 
VIQ -2.17 26    .04* 
PIQ -1.65 26 .11 
WM -1.97 15 .07 
FSIQ= Full-scale IQ, IPS= Information Processing 
Speed, VIQ= Verbal IQ, PIQ= Performance IQ,  
WM= Working memory 
Analyses were performed for the aggregated 
cohort of 26 children to assess the impact of 
breastfeeding on IQ, independent of disease 
diagnosis 
*p<.05 
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Independent-samples t tests showed that FSIQ was higher in the non-breastfed 
groups than the breastfed group (t= -2.19 (26); p= .04), largely as a result of 
differences in the VIQ performance (t= -2.17 (26); p= .04). 
 
Correlations between duration of breastfeeding (in weeks) and later cognitive 
outcomes in the 17 children with data available are shown in Table 5-10. 
 
Table 5-10 Correlation between duration of breastfeeding and cognitive outcomes 
  Correlation with cognitive ability; r (p value) 
  FSIQ IPS VIQ PIQ WM 
n 17 17 17 17 7 
Duration of 
breastfeeding 
.18 (.49) .37 (.15) .15 (.57) .40 (.12) -.49 (.26) 
FSIQ= Full-scale IQ, IPS= Information Processing Speed, VIQ= Verbal IQ, PIQ= Performance IQ,  
WM= Working memory 
Data were analysed with non-parametric statistics, Spearman’s Rho due to the small sample 
size 
 
Non-parametric correlations showed that duration of breastfeeding (number of 
weeks) was not significantly correlated with FSIQ (r= .18; p=.49). 
 
5.5 Discussion 
 
5.5.1 EFA deficiency in paediatric liver disease  
 
The risk of developing EFA deficiency depends on the amounts of different EFAs in 
the diet, the ability to absorb ingested fat, the demand for EFAs, and the amount 
and availability of endogenous stores. A poor EFA intake in the setting of a 
generally inadequate food intake has been considered as one of the major factors 
responsible for potential EFA deficiency in patients with liver disease. A lack of 
essential precursors certainly would be expected to lead to a deficit in LCPUFAs. 
The severity of the deficiency in the EFAs and LCPUFAs is related to the degree of 
overall malnutrition in these patients (Cabre and Gassull, 1996).  
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The evidence from this study, however, suggests that these patients do not show 
signs of EFA deficiency (see Table 5-5, page 93) as they had EFA levels comparable 
with the sibling control group. To prevent EFA deficiency, the diet requires only 
approximately .5% of the total caloric requirement as .7% ALA and 2% as LA 
(ISSFAL, 2010). Given that the average western diet provides 10–20 times more 
than these required amounts (Simopoulos, 2000), it is probable that levels of EFAs 
in the diets of the present cohorts was sufficiently high to prevent EFA deficiency. 
Examples of dietary data collected from a small number of patients involved in the 
current study (and additional disease control patients) are provided in Appendix 
A, Table A, page 206. Analysis of this small set of data is beyond the scope of the 
current study, but dietary data in future studies would be useful for providing 
greater context for investigations of deficiency and the erythrocyte biomarker 
data. 
 
No evidence was found of LCPUFA deficiency in the patient groups, suggesting that 
these patients are able to adequately synthesise long-chain fats from the levels of 
EFAs that are present. It has been suggested that PUFA deficiency may be more 
closely related to rates of very long-chain PUFA biosynthesis rather than 
inadequate intakes of LA and ALA (Burke, Ling et al., 1999), but only in cases 
where diets are not entirely fat-free, as is the case with present cohort. It has been 
observed that children with liver disease may have a specific problem with 
malabsorption that is characterised by decreased linoleic and arachidonic acids 
and increased non-essential fatty acids (Gourley, Farrell et al., 1982; Jeppesen, 
Christensen et al., 1997; Pettei, Daftary et al., 1991). Socha et al., also reported 
decreased plasma AA levels in paediatric cholestatic patients, which they 
attributed to impaired hepatic microsomal desaturase and/or elongase activity 
(Socha, Koletzko et al., 1998). In the current study, however, no decreases in either 
linoleic or arachidonic acid were observed in the patients compared to the sibling 
controls (see Table 5-4). 
 
In the absence of dietary DHA, Rapoport et al found that a normal brain DHA 
content can be maintained by liver conversion of ALA to circulating DHA, provided 
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sufficient ALA is present in the diet (Rapoport, Rao et al., 2007). In the present 
study, the question of whether DHA can be synthesised by older children in the 
absence of dietary sources of DHA was followed up in a clinical case study of a 
patient who was given an oral diet consisting of a specialised feed devoid of DHA 
for 12 months (see Appendix B, page 212). This individual (aged 11) was able to 
maintain erythrocyte DHA concentrations comparable to sibling controls, 
supporting the idea that dietary absence may not cause DHA deficiency, at least not 
detectable via erythrocyte biomarkers, provided EFA precursors are available for 
endogenous synthesis. 
 
It has been suggested that PUFA deficiency may be closely related to genetic 
factors. The conversion of EFAs to LCPUFAs is dependent on fatty acid desaturases 
(FADs), which show phenotypic variability within the human population 
(Simopoulos, 2010). In the context of end-stage liver disease and profoundly 
cholestatic conditions such as Alagille’s Syndrome, genetic-based variations in 
biosynthesis may be as important as inadequate intakes of LA and ALA (Burke, 
Ling et al., 1999), as these gene variants may be exacerbating the potentially higher 
than normal requirements for these nutrients in these patients. The genetic 
contribution to fatty acid metabolism is discussed as a future direction of research 
in Chapter 8, section 8.5.2. 
 
5.5.1.1 Functional biomarkers of PUFA deficiency: osbond and mead acid 
 
In addition to percentage values of the various lipids, biomarkers which provide a 
more subtle measure of EFA metabolism were also assessed. Osbond acid (22:5n-
6) is synthesised specifically in response to DHA shortage. For example, dietary 
ALA deficiency (the DHA precursor) promotes accumulation of osbond acid in 
brain tissue (Rapoport, Rao et al., 2007). Under steady state conditions, the ratio 
between DHA and osbond acid (22:5n26) is a reliable indicator of functional DHA 
status (Hornstra, 2000), that is, the amount of DHA that is available for use. No 
difference between the disease groups for levels of functional DHA marker 
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(DHA/osbond) were observed, which provides further support to the finding of a 
specific lack of deficiency in the liver disease cohorts. 
 
However, the near uniform presence of osbond acid in the patient and control 
groups (see Table 5-4) may indicate that, according to biomarkers representing 
three months dietary intake, even the sibling control group showed signs of DHA 
deficiency, which is in keeping with the hypothesis that modern western diets 
generally contain excessive amounts of omega-6 fatty acids and have a high ratio of 
omega-6 fats to omega-3 (Benatti, Peluso et al., 2004; Simopoulos, 2002a).  
 
However, the use of osbond acid as a functional DHA shortage marker is not 
without question. In the present study, a moderate, but not statistically significant, 
correlation was observed between osbond and DHA levels (r= -.30 p> .05). Innis, 
Vaghri et al. (2004) found no evidence that low DHA concentrations in humans are 
accompanied by high osbond acid concentrations when erythrocyte fatty acids are 
used as a measure of fatty acid status, which they propose is suggestive of the fact 
that metabolic markers of deficiency traditionally seen in animals may not be 
easily translated to humans fatty acid metabolic processes.  
 
Elevations in the triene:tetraene (arachidonic:mead) ratio have also been observed 
in patients with suboptimal lipid absorption (Pettei, Daftary et al., 1991). The 
failure to identify appreciable amounts of mead acid in any of the participants, a 
lipid that is produced in classic EFA deficiency by elongation and desaturation of 
oleic acid (18:1n-9) (see Figure 2-3, page 27), when LA and ALA are limited, may 
be a further explanation why the liver disease cohort did not present with EFA 
deficiency despite their illness. As with osbond acid, however, the use of mead acid 
as a deficiency biomarker is not unequivocal. Lands (2008) argued that detectable 
levels of mead acid may actually be a biomarker of the potentially beneficial 
restricted intake of omega-6 PUFAs, and may become a valid surrogate endpoint in 
future efforts to avoid excessive PUFA intakes and excessive omega-6 eicosonoid 
actions (see section 8.2.1). 
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5.5.2 EFA status and cognitive ability  
 
There is increasing evidence that EFAs have a central role in cognitive 
development, with EFA deficiency linked to cognitive impairment; The 
fundamental importance of EFAs, and their LCPUFA metabolites, particularly DHA, 
for brain development and cognitive function is beyond dispute (McCann and 
Ames, 2005).  
 
Results from Chapter 4 showed that early onset, post-transplant patients showed 
significant deficits in processing speed compared to sibling controls (p= .017, (d)= 
1.36; see Table 4-3 and Figure 4-1, page 78). Analysis of current fatty acid status, 
measured using erythrocyte biomarkers, showed that this patient group was not 
significantly different in EFA levels compared to controls, which means that 
deficits in processing speed in these individuals cannot be attributed to their 
current fatty acid status, or at least that the effects are negligible. 
 
The need for liver transplantation is an important indicator of disease severity so 
the finding that deficits were specific to the early onset, post-transplant group is in 
keeping with the hypothesis that EFAs may have a crucial role in later cognitive 
outcomes, given the relative importance of EFAs in early infancy (discussed in 
Chapter 2) and potential for EFA intake and metabolism to be disturbed in patients 
with liver disease (Beath, Hooley et al., 1993; Glasgow, Hamilton et al., 1973). That 
the acute liver failure group (with a mean age of onset of 5.4 years) did not show 
significant deficits compared to controls may be indicative of the fact that fatty acid 
intake and metabolism, as a result of liver disease, was undisturbed until after the 
crucial period of perinatal development, which is when EFAs are deemed 
especially important (Innis, 2007; Innis, 2008). 
 
One explanation for the specific deficit in processing speed may be the action of 
EFAs on the myelination process (section 2.3.1, page 37) and ion channel function 
and (section 2.3.2, page 37).  Rat models have shown that EFA deficiency during 
early development can give rise to aberrations in the process of myelination and 
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myelin composition (McKenna and Campagnoni, 1979; Trapp and Bernsohn, 
1977). The integrity of the myelin is of utmost importance for the proper functions 
of axons in the nervous system and for facilitating the synchronous integration of 
information across the many spatially segregated associative regions of the brain 
that are involved in higher cognitive functions (Nicholls, Martin et al., 2001).  
 
During maturation in humans, a shift from short chain saturated fatty acids to the 
long-chain unsaturated forms has been observed (O'Brien and Sampson, 1965; 
Svennerholm, Vanter et al., 1978). If myelin formation is compromised, particularly 
by a deficiency in LCPUFAs, nerve conduction velocity (NVC) may be suboptimal, 
resulting in a deficit in the ability to perform timed tasks of cognitive ability. NVC 
in brain nerve axons has been suggested to underlie general cognitive performance 
(McRorie and Cooper, 2004; Reed and Jensen, 1992). One way to probe the 
potential effects of liver disease on axons and myelination is to use 1H-MRS which 
is able to detect NAA, a metabolite found exclusively in the brain that has a role in 
myelination and is regarded as a marker of neuronal viability. The findings from 
the 1H-MRS study of the cohort of liver disease patients are presented in Chapter 7.  
 
The current study retrospectively recruited patients with liver disease and as a 
result, what is necessarily lacking are measures of EFA status at birth/infancy that 
would have allowed us to directly probe the effects of liver disease on EFA status at 
a time when intake may be most crucial. A limited number of prospective studies 
have investigated the direct effects of early PUFA exposure on later cognitive 
outcomes by assessing LCPUFA content of umbilical plasma and erythrocytes as a 
surrogate measure of the LCPUFA availability during late gestation, but the 
association does not appear robust. Neither plasma nor erythrocyte phospholipid 
DHA and AA levels showed any significant correlation with cognitive development 
at four years of age (Ghys, Bakker et al., 2002) and in a similar study performed in 
a Dutch cohort, B Bakker, Ghys et al. (2003) found no evidence of a positive 
relationship between cognitive performance at age seven and LCPUFAs measured 
both at birth (in umbilical plasma samples) and also at seven years of age (in 
venous plasma).  
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The studies described above show no relationship between perinatal EFA status 
and cognitive outcomes in later childhood in healthy individuals, but the 
disturbances to EFA metabolism in liver disease are considerable (Dupont, 
Ameedee-Manesme et al., 1990) and therefore a more significant impact on 
cognitive outcomes may be anticipated. Conclusions from the current study remain 
speculative without a prospective study collecting periodic measures of EFA status 
and cognitive outcomes from birth. 
 
5.5.2.1 Relationship between current omega-3 fatty acid status and 
cognitive ability 
 
The finding that FSIQ and EFA status was not significantly different between 
groups allowed aggregation of the cohort of 39 in order to assess the association 
between current levels of the various lipids and cognitive performance. The 
hypothesis that current levels of omega-3 fatty acids would have a positive 
relationship with cognitive performance was not confirmed when a strict α level of 
.0014 was applied to the data. The biomarker for omega-3 status (comprised of the 
sum of EPA and DHA, putatively the most important LCPUFAs), did not correlate 
with FSIQ or IPS performance (p> .05). 
 
Across the cohort of 39 participants, DHA was moderately, negatively correlated 
specifically with Performance IQ (r= .42; p=.02). Whilst the result is surprising, 
given the common consensus in the literature regarding the ‘positive’ effects of 
DHA such as increasing membrane fluidity and efficiency (Chapter 2), other studies 
have also found negative correlations between DHA levels and cognitive 
performance. For example, plasma DHA levels were associated with a slower 
learning curve on general speed of information processing as measured by the 
Stroop Colour Word Interference Test in a group of healthy adult women (de 
Groot, Hornstra et al., 2007). This suggests that the IQ relationship, at least for 
omega-3 fatty acids, is possibly not clear cut and this is certainly a reason for 
further research. 
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5.5.2.2 Relationship between current omega-6 fatty acid status and 
cognitive ability 
 
The most striking finding from the current results is the strong correlation 
between omega-6 fatty acids and cognitive measures. The omega-6 index 
(comprised of the percentage total of LA and AA) was negatively correlated with 
FSIQ (r= .62; p< .001; Figure 5-2 ), which appears to be a robust result given the 
strict  Bonferroni-corrected α level employed. Trend results were also observed for 
IPS (r= -.39; p= .03; see Figure 5-3, page 96), and Working Memory (r= -.48 =; p= 
.05). Whilst this negative relationship between omega-6 fatty acids and IQ 
measures was not predicted, it is in keeping with the present understanding of the 
functions of this group of fatty acids and their potential physiological effects.  
 
The difficulty in placing these findings in sufficient context, however, is that the 
vast majority of the literature has focused almost exclusively on the positive and 
potentially ameliorative effects of omega-3 on cognitive outcomes, at the expense 
of considering the effects of omega-6 fatty acids (negative or otherwise), a problem 
also identified by Eilander, Hundscheid et al. (2007). Furthermore, there has been 
far less research on the role of brain AA specifically, partly because it is difficult to 
deplete brain AA levels by dietary deficiency studies. 
 
5.5.2.3 The omega-3:omega-6 ratio and cognitive ability 
 
As discussed in Chapter 2, omega-6 and omega-3 fatty acids share metabolic 
pathways and thus interact with each other through a complex system involving 
several factors including dietary substrate availability, competition for the same 
metabolic enzymes for synthesis and membrane incorporation (see section 2.2, 
page 26). An improved understanding of the role of free EFA in mediating cognitive 
and biochemical functions was derived from a series of findings that indicate that 
not only are the levels of EFAs or PUFAs critical, but also the ratio between the 
omega-3 and omega-6 fatty acids, both in terms of cognition (Simopoulos, 2002a) 
and chronic disease (Simopoulos, 2008).  
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Generally, higher ratios of omega-3 to omega-6 fatty acids are associated with 
improved cognitive status (Yehuda, 2003). The effects of omega-3 deprivation 
were discussed in detail in Chapter 2, section 2.4, page 40. In the majority of cases, 
the ratio between omega-3 and omega-6 fats is not studied directly, but chronic 
supplementation or deprivation of fatty acids, such as DHA, is regarded as 
manipulating the physiologically active ratio through changes in bioavailability. 
For example,  in rats, administration of ALA and LA preparations with ratios of 
fatty acids ranging between 1:3.5-1.5 led to a significant improvement in learning, 
measured by performance on a Morris Water Tank task (Yehuda and Carasso, 
1993), and reduced reference memory errors on a radial tasks was associated with 
cerebral DHA/AA ratios, after chronic administration DHA supplementation 
(Gamoh, Hashimoto et al., 1999). 
 
Studies of humans, using erythrocyte biomarkers specifically relevant to the 
present study, appear to reinforce the importance of a higher omega-3:omega-6 
ratio.  In children  with attention deficit hyperactivity disorder (ADHD) for 
example, it has been negatively related with oppositional, restlessness and 
problematic behaviour scales (Colter, Cutler et al., 2008), and eight weeks of EFA 
supplementation has been shown to reduce the AA/EPA ratio, which was 
significantly higher in ADHD children than controls at baselinel, with changes in 
the AA/EPA ratio linked with significant improvements in Inattention and 
Hyperactivity using Connor’s short-term inventory (Germano, Meleleo et al., 2007). 
 
Studies of adults report associations between an imbalance in the erythrocyte 
omega-3:omega-6 ratio in psychiatric disorders such as depression (Maes, Smith et 
al., 1996), schizophrenia (Yao, van Kammen et al., 1994). Higher total omega-3 
fatty acids and DHA/AA ratios have been linked with better cognitive performance 
at the age of 64, even after accounting for IQ at age 11 (Whalley, Fox et al., 2004),  
and ratios of omega-3 to omega-6 fatty acids have also been inversely associated 
with mild cognitive decline (Heude, Ducimetiere et al., 2003). 
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In the present study, initial analysis with a bivariate, linear Pearson correlation 
showed a moderate, positive correlation between the omega-3:omega-6 ratio and 
FSIQ (r= .40; p=.02) and working memory (r= .60; p= .01, n= 17) .  More careful 
analysis of the data, however, showed that this regression was skewed by four sets 
of outliers (see Figure 5-4, page 97). Removal of these data resulted in a non-
significant linear relationships between the omega-3:omega-6 ratio and FSIQ and 
WM but also highlighted the need for a more subtle approach to analysing these 
complex relationships. 
 
It may not be as simple as treating these four outliers as anomalies, as they point to 
an important alternative method of approaching the data. Given the competitive 
metabolism and function of omega-3 and omega-6 fatty acids, and the robust 
nature of the cellular membrane, it is not unreasonable to speculate that effects of 
variations in omega-3:omega-6 ratios may not manifest until a critical threshold 
has been exceeded (in the current data, an arbitrary value of ~.70), revealing a 
categorical, as opposed to the traditionally assumed linear, association between 
EFAs and cognitive outcomes.  
 
Confined to data from only 39 participants, the idea of categorical dissociations 
must be treated with caution, but it is at least an idea worthy of consideration for 
future studies, particularly as much of the work in this field is still largely 
exploratory in nature. 
 
5.5.2.4 Mechanisms by which EFA levels can effect cognitive function 
 
The physiological roles that may explain the effects of omega-3 and omega-6 fatty 
acids on physiological function and therefore cognition were introduced in Chapter 
2. Yehuda, Rabinovitz et al. (2005) have summarised the potential effects of PUFAs 
on membrane function into six nominal categories: (1) modifications of membrane 
fluidity; (2) modifications of the activity of membrane bound enzymes; (3) 
modifications of the number and affinity of receptors; (4) modifications of the 
function of ion channels; (5) modifications of the production and activity of 
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neurotransmitters; and (6) signal transduction, which controls the activity of 
neurotransmitters and neuronal growth factors. There are two mechanisms of 
action: (1) a long-term action on the composition and functioning of the 
membranes; and (2) a short-term action that would involve the metabolism of 
phospholipids (with subsequent modulation of signal transduction) and the action 
of EFA-derived metabolites such as eicosanoids. 
 
The changes of greatest potential significance to the human infants and adults are 
those related to the physical properties of the membrane that impact membrane 
excitability. Both the chain length and the number of double bonds of the fatty acyl 
chains that constitute membrane phospholipids have substantial and significant 
effects on the dynamic properties of the membrane such as fluidity, permeability 
and rigidity (Hac-Wydro and Wydro, 2007). 
 
Membrane fluidity may be one of the most salient mechanisms of effect that may 
explain the negative relationship between omega-6 levels and cognitive 
performance. The cis configuration at each double bond produces ‘coiling’ of the 
hydrocarbon backbone, resulting in a reduction in fatty acid length and a more 
curved, or ‘kinked' structure. This results in longer-chain poly-cis unsaturated fatty 
acids (PUFAs; which have greater numbers of double bonds) occupying increased 
space in the membrane, resulting in bilayers that are thinner and more flexible 
than saturated/ monounsaturated chain bilayers (Rawicz, Olbrich et al., 2000). 
DHA (six double bonds) and EPA (five double bonds) confer the greatest level of 
fluidity from the major membrane fatty acids (Feller, Gawrisch et al., 2002; 
Gawrisch, Eldho et al., 2003). Arachidonic acid-containing phospholipid bilayers 
are, for example, more disordered and deformable than DHA-containing 
phospholipid bilayers (Rajamoorthi, Petrache et al., 2005). 
 
The ever-changing mobility and proximity relationships of lipid and protein 
molecules in the plasma membrane also has a significant impact on essential 
cellular processes, including signal transduction, carrier mediated cellular 
transport, membrane bound enzyme activity and receptor function (McNamara 
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and Carlson, 2006). The capacity for omega-6 fatty acids to regulate neuronal 
excitability, for example, has been shown by Tsutsumi, Yamauchi et al. (1995), who 
demonstrated that rats fed high LA sunflower oil exhibited decreased Na+, K+ 
ATPase activity in myelin, together with 5'-nucleotidase activity in the rat cortex 
and hippocampus following a decline in DHA levels. Numerous animal models have 
also shown how PUFA levels my may influence several pathways with different 
neurotransmitters such as serotonin, noradrenalin, dopamine and acetylcholine 
(Chalon, 2006; Yehuda, Rabinovitz et al., 1999). 
 
The finding that erythrocyte omega-6 fatty acids are inversely related to cognitive 
ability has also been observed in the elderly. Higher omega-6 PUFAs are associated 
with greater risk of cognitive decline, whilst omega-3 fatty acids may exert a 
neuroprotective effect (Heude, Ducimetiere et al., 2003). The competitive 
immunological functions of the two groups of PUFAs, may provide another 
explanation for their downstream cognitive effects, as cognitive decline, and 
psychiatric disorders including Alzheimer’s, have been linked to 
neuroinflammation (Gorelick, 2010). 
 
EFA in plasma membranes serve as substrates for a number of important, very 
active, short-lived, hormone-like compounds referred to as eicosanoids, which 
have numerous metabolic activities including platelet aggregation, inflammation, 
haemorrhage, vasoconstriction and vasodilatation, blood pressure and immune 
functions (Calder, 2007; Shaikh and Edidin, 2008; Simopoulos, 2002b). AA is the 
precursor of 2-series prostaglandins and 4-series leukotrienes, which are highly-
active mediators of inflammation, generally pro-inflammatory and pro-aggretory, 
leading to a predominantly inflammatory state (Calder, 2002; Calder, 2006; 
Simopoulos, 2002b). EPA and DHA serve as the precursors for potent 
neuroprotective and anti-inflammatory lipids termed resolvins and 
neuroprotectins (Serhan, 2005), which exert their anti-inflammatory actions by 
blocking transendothelial migration, reduce dendritic cell function and regulate IL-
12, thereby promoting the resolution of the inflammatory cycle.  
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PET studies have demonstrated increased brain AA incorporation in patients with 
Alzheimer’s disease compared with healthy age-matched controls, particularly in 
neocortical regions with high levels of inﬂammatory cytokines (Esposito, 
Giovacchini et al., 2008) and EFA-derived eicosanoid precursors are also involved 
in the brain in oxidative stress, memory and learning (Tassoni, Kaur et al., 2008). 
Again, studies in psychiatric disorders and inflammation have largely concentrated 
on the damaging effects of potential omega-3 deficiency or ameliorative effects of 
omega-3 supplementation (Maclean, Issa et al., 2005), making it difficult to draw 
strong conclusions about the effects of omega-6 specifically. How well results from 
studies investigating cognitive decline and inflammatory status can be translated 
to studies of variation in cognitive ability in an ostensibly cognitively ‘normal’ 
population is still a matter for investigation. 
 
5.5.2.5 Evidence from supplementation studies 
 
The cross-sectional correlational analysis performed here means that firm 
conclusions about the causality of the associations observed cannot be made. Aside 
from disease models, such as the one adopted in the present study, intervention 
studies offer the strongest model to study the potential dose-dependent linear 
effects of EFA status on cognitive performance. Studies into the effects of 
variations in EFA levels on cognition in humans have largely focused on the effects 
of EFA supplementation in pre and peri-natal development in infants (Simmer, 
Patole et al., 2008; Simmer, Schulzke et al., 2008), with mixed results. Although, 
there is evidence for a relationship between omega-3 intake and cognitive and 
visual development in infants, to date, there have not been enough randomised, 
controlled trials investigating the effects of fatty acid supplementation as a model 
for studying the effects of EFAs on cognition in older children (Eilander, 
Hundscheid et al., 2007).  
 
In contrast with the limited data in healthy children, there is more potential 
evidence for a beneficial effect of PUFA supplementation in children with 
neurodevelopmental disorders such as ADHD (Germano, Meleleo et al., 2007; 
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Richardson, 2006). Double-blind randomised controlled trials have shown 
promising results of supplementation with a combination of omega-3 and omega-6 
fatty acids on diminishing some behavioural symptoms, including inattention and 
impulsivity, in school-aged children with ADHD (Hirayama, Hamazaki et al., 2004; 
Richardson and Puri, 2002; Stevens, Zhang et al., 2003; Voigt, Llorente et al., 2001). 
The potential mechanisms accounting these for effects, however, remain to be 
explained. 
 
5.5.3 Breastfeeding 
 
Breastfeeding is a vital source of EFAs in infancy and is therefore and important 
factor for consideration in the wider context of the study. The importance of EFAs 
in infant nutrition was suggested by the rapid accretion of these fatty acids in the 
brain during the first postnatal year (Martinez, 1992) and last intrauterine 
trimester. After birth, infants are reliant on maternal breast milk (or formula) as 
the sole source of DHA, with substantial accumulations of DHA and AA in the 
human brain during the first postnatal months (Heird and Lapillonne, 2005). 
Neuronal accretion of DHA and phsophatidylserine (PS) during development is 
required to prevent inappropriate cell death and to support neuronal 
differentiation (Kim, 2007). Interference in their accumulation by nutritional 
deprivation or in pathological states may diminish protective capacity in the 
central nervous system, with significant implications for neuronal dysfunction. 
 
Although infants are able to synthesise DHA, the amount produced may be 
inadequate to support the DHA levels observed in breast-fed infants. In terms of 
fatty acid physiology, the cerebral and overall DHA status of breast-fed babies is 
better than that of infants fed formula lacking DHA (Cunnane, 2000). Breast-fed 
infants are also uniquely provided with an additional digestive enzyme known as 
bile-salt stimulated lipase, which Chen, Blackberg et al. (1994) demonstrated is 
essential for the complete hydrolysis of triacylglycerols containing AA or DHA. 
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The effect of breastfeeding on cognitive outcomes in the present sample, 
independent of disease diagnosis, was also investigated. When comparing 
breastfed vs non-breastfed participants, the breastfed group had significantly 
lower FSIQ scores (t(26)= -2.19, p= .04). This effect was not observed for IPS or 
Working Memory. Whilst this surprising finding may be a result of the small sizes 
of each group, split across the four diagnostic categories, the data is confounded by 
the fact that manufacturers introduced PUFAs to infant formulas (for example 
Pepti Junior, see Table 5-2, page 88) from around 1997 and almost as standard 
since 2000. 
                                           
In this group of 17 participants with available dietary and psychometric data, the 
duration of breastfeeding was not significantly correlated with FSIQ in later 
childhood (r= .18; p= .49). Although the majority of studies suggest that 
breastfeeding promotes intelligence, (Anderson, Johnstone et al., 1999; Innis, 
2008), with the positive effects of increased duration of breastfeeding potentially 
persisting into adulthood (Mortensen, Michaelsen et al., 2002), they have not 
always yielded consistent results. 
 
The interpretation of findings from breastfeeding studies must be made with 
caution, particularly because of strong confounders such as maternal IQ and 
socioeconomic status (SES), as well as physiological mechanisms such as the 
variability in foetal brain DHA accrual during gestation, variability in maternal 
breast milk DHA concentrations (discussed in Chapter 2) and differences in the 
test instruments used, testing procedures, or outcomes studied (McCann and 
Ames, 2005). A meta-analysis of all randomised trials in which full-term infants 
were fed with formula supplemented with omega-3 and -6 PUFA declared that 
‘there is little evidence’ that such supplementation is beneficial for visual or 
general development of full-term healthy infants (Simmer and Patole, 2004). 
 
A systematic review of the literature, conducted by Jain, Concato et al. (2002), 
concluded that the evidence from higher-quality studies, which had stringent 
control of susceptibility bias (for example controlling for SES) and used 
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appropriate outcome measures, was less persuasive. Jacobson, Chiodo et al. (1999) 
found that after adjusting for maternal IQ and parenting skills the child’s IQ was 
related to genetic and socio-environmental factors, rather than to the nutritional 
benefits of breastfeeding on neurodevelopment. The potential genetic contribution 
to EFA metabolism is discussed in greater detail in section 8.5.2, page 180. 
 
5.6 Conclusion 
 
There are two important findings from the present study, which was undertaken to 
assess the EFA status of patients with liver disease compared to sibling controls, 
and to investigate potential relationships between fatty acid status and cognitive 
ability. 
 
First, compared to sibling controls, no signs of fatty acid deficiency were observed 
in any of the cohorts of patients with liver disease. This suggests that: (1) these 
patients were not deficient in their dietary intake of the EFAs LA and ALA; and (2) 
these patients are able to sufficiently metabolise these precursor lipids to 
synthesise LCPUFAs, DHA and EPA, to levels comparable to sibling controls.  
 
Second, omega-6 (LA and AA) status was observed to have a strong inverse 
relationship with FSIQ and IPS, independent of disease diagnosis. EFA-derived LC-
PUFAs in particular, have significant direct and indirect actions on cerebral 
function, not only through their function as membrane phospholipid components, 
but their function as active substances such as eicosanoids. The influence of fatty 
acids on the biological mechanisms that explain the co-variation of omega-6 lipids 
with broad-based measures of cognitive ability require further investigation, 
particularly in light of the fact that the majority of the research has focused on the 
positive effects of omega-3 fatty acids. The potential for categorical, as opposed to 
linear relationships between EFA measures and cognitive outcomes, particularly 
with regards to the omega-3:omega-6 ratio, is also worthy of consideration. 
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This study has shown that the onset of liver disease does not appear to have long-
term effects on the ability of patients with liver disease to synthesise vital 
LCPUFAS.  Without specific information about EFA status and dietary intake data 
in infancy to provide context, however, cross-sectional studies of retrospectively 
recruited patients are limited in what they are able to reveal about the cognitive 
consequences of liver disease in infancy with relation to fatty acid metabolism. 
Prospective studies collecting periodic measures of EFA status and cognitive 
outcomes from birth are required to directly probe the early effects of liver disease 
on EFA status and later cognitive outcomes. 
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6 Investigating biomarkers of cognitive ability 
with 1H-MRS 
 
6.1 Summary 
 
1H-MRS is a non-invasive imaging technique that enables quantification of 
neurochemicals in vivo and thereby facilitates investigation of the neurochemical 
underpinnings of human cognitive variability. Studies in the field of cognitive 
spectroscopy have typically focused on relationships between measures of N-
acetylaspartate (NAA) and choline (cho) on broad measures of cognitive 
performance. In the present study, 1H-MRS was used to interrogate single-voxels in 
occipitoparietal and frontal cortical white matter in parallel with assessments of 
psychometric intelligence (FSIQ) in a sample of 38 healthy, adult participants. 
 
Correlations between 1H-MRS detectable neurometabolites and IQ were observed 
that were within the range reported in previous studies. However, the magnitude 
of these effects was dependent upon the extent to which outlying values were 
accounted for in statistical analyses. Coupled with the wide range of effect sizes 
reported in the literature, the substantial methodological variability between 
studies poses a significant challenge for drawing inferences about the strength of 
the relationship between neurometabolites obtained with proton spectroscopy 
and IQ variables at the population level. 
 
While 1H-MRS offers a sensitive tool for assessing neurochemistry non-invasively, 
the relationships between brain metabolites and broad aspects of human 
behaviour are subtle. In a field of research that is still largely exploratory, there is a 
need to develop an increasingly rigorous analytical and interpretive framework for 
reporting data obtained from studies of this kind. 
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6.2 Introduction 
 
Parallel refinements in neuropsychological assessment and neuroimaging 
techniques now make it possible to probe the neurophysiological basis of 
individual variation in cognitive ability with increasing methodological 
precision (Haier, 2009; Jung and Haier, 2007). 1H-MRS provides a neuroimaging 
paradigm that enables non-invasive quantification of neurochemicals and their 
metabolites in a pre-defined region of tissue, with a typical spatial resolution on 
the order of cubic centimetres (see Chapter 3). 
 
 In the brain, the strongest and most reliable metabolite signals are generated by 
N-acetyl aspartate (NAA), creatine and phosphocreatine (Cre), choline (Cho; 
predominantly glycerophosphocholine and phosphocholine), and myo-Inositol 
(mI). These four metabolites, and other reasonably well-resolved compounds such 
as glutamate/glutamine (Glx) and lactate, form the principal focus of 1H-MRS 
research (Ross and Sachdev, 2004; Soares and Law, 2009). Figure 3-3 on page 67 
illustrates a representative proton MRS spectrum that shows these main 
metabolite peaks. 
 
6.2.1 N acetyl aspartate (NAA) 
 
In human brain, the most prominent and stable signal obtained with 1H-MRS is that 
of N-acetyl aspartate (NAA), particularly beyond the age of three years (Danielsen 
and Ross, 1999). The three hydrogen atoms of the acetate group resonate a single 
sharp peak, with a chemical shift of 2.02 ppm relative to the tetramethylsilaneb 
standard (Moffett, Ross et al. 2007). While this peak at 2.02 ppm is mainly 
attributable to NAA, this signal includes smaller contributions from other 
acetylated compounds, such as the neuron-specific dipeptide, N-acetyl aspartyl 
glutamate (NAAG) (Caramanos, Narayanan et al., 2005), and underlying coupled 
resonances of glutamate and glutamine. 
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NAA is one of the most highly concentrated free amino acids in the brain, second 
only to glutamate. It is almost exclusively present in the central nervous system, 
where it is predominantly located in the soma of pyramidal cells, dendrites and 
axons (Simmons, Frondoza et al., 1991), oligodendrocyte type 2 astrocyte 
progenitor cells, and in immature (Urenjak, Williams et al., 1992) and mature 
oligodendrocytes (Bhakoo and Pearce, 2000).  As an osmolyte, NAA constitutes 1% 
of the dry weight of the brain and 3-4% of total brain osmolarity (Baslow, 2000). 
 
The functional role of NAA in the central nervous system and its metabolism has 
been extensively reviewed by Moffett, Ross et al. (2007). Amongst its many 
proposed roles, NAA is involved in osmoregulation and the control of cell volume 
(Davies, Gotoh et al., 1998). It is also linked with neuronal energy metabolism, as 
demonstrated by decreases in NAA that have been observed in a number of 
conditions of impaired energy metabolism in the brain (Clark, 1998). In addition, it 
has been proposed that NAA, NAAG and their intermediates are exchanged 
between neurons and glia as a mechanism of intercellular signalling (Baslow, 
2000). NAA has also been implicated in enhancing mitochondrial energy 
production from glutamate (Moffett, Ross et al., 2007); functioning as a molecular 
water pump (Baslow (2002) cf. Moffett et al. (2007)) to increase the speed and 
efficiency of neuronal signalling; osmoregulation and the control of neuronal 
volume (Davies, Gotoh et al., 1998), and in intercellular signalling (Baslow, 2000). 
 
NAA has been suggested to serve an important regulatory role within myelin lipid 
synthesis during postnatal axonal myelination (Namboodiri, Peethambaran et al., 
2006). Abnormal NAA metabolism has been implicated in the pathophysiology of 
Canavan’s disease, characterised by a progressive loss of myelin (Matalon, Michals 
et al., 1988; Namboodiri, Peethambaran et al., 2006). The NAA resonance within 
white matter regions is thought to reflect both the metabolic function of the 
neuronal axons as well as the extent and efficiency of myelination of those axons. 
The finding of approximately equal concentrations of NAA in white and grey 
matter of the human brain makes it clear that NAA is a component of the axon or 
the axonal sheath in man (Ross and Bluml, 2001). 
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Levels of NAA in various tissues of the brain have been found to correlate with 
neuronal health or integrity. Decreased levels of NAA have been interpreted to 
indicate neuronal/axonal loss, or compromised neuronal metabolism, leading to 
the idea that NAA is a neuronal marker (Moffett, Ross et al., 2007). This is, 
however, still a matter of debate, with some suggesting NAA is taken as a marker of 
functioning neurons rather than as a mere indicator of the presence of nerve cells 
(Pouwels, Brockmann et al., 1999); others refute the role of NAA as a marker 
altogether (Martin, Capone et al., 2001). 
 
6.2.2 Choline 
 
The major components of myelin and the cell membrane lipid bilayer 
(phosphatidylcholine (PCho), phosphatidyl -ethanolamine, -serine and -inositol; 
see Chapter 2) are most likely entirely immobile and MR-invisible (Ross and Bluml, 
2001), but their putative breakdown products are a normal feature of cerebral 
proton  spectra. The choline peak at 3.22 ppm is a narrow singlet originating from 
nine identical protons ((CH3)3) and reflects combined total choline including 
choline containing compounds such as PCho, glycerophosphocholine (GPCho) and 
a comparatively small amount of free choline (<5%) (Miller, Chang et al., 1996). 
The 1H-MRS choline peak is therefore thought to reflect the concentration of 
water-soluble choline-containing compounds and cellular density (Miller, Chang et 
al., 1996), as well as degradation of choline-containing phospholipids, which are 
abundant in cell membrane and in myelin (Alberts, 2002). 
 
Choline (Cho) and its metabolites are needed for the structural integrity and 
signalling functions of cell membranes. In addition, they are precursors in the 
synthesis and breakdown products of membrane phospholipids such as 
phosphatidylcholine (PC) and sphingomyelin. They are central to the production of 
potent lipid mediators such as platelet-activating factor and 
lysophosphatidylcholine, and in the syntheses of acetylcholine (Zeisel, Da Costa et 
al., 1991). Quantitatively, PC is the most important metabolite of choline and 
accounts for approximately one-half of the total membrane lipid content of the 
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brain (Zeisel, Da Costa et al., 1991). A comprehensive review of choline metabolism 
and production is provided by Freeman (1996). 
 
Free choline detectable by MRS is commonly associated with membrane turnover 
and inflammation, and negatively associated with cognitive ability (Danielsen and 
Ross, 1999). The signal intensity of choline may be increased by the acceleration of 
membrane synthesis and breakdown, or pathological conditions, where visible 
choline may be released from this pool. Further to its role in membrane 
composition, deprivation and supplementation studies of rats (Zeisel, 2004) have 
suggested that choline may have significant effects on gene regulation of cell 
division, apoptosis, migration and differentiation, through regulatory effects on 
DNA methylation. 
 
6.2.3 myo-Inositol 
 
The major nutritionally active form of inositol, myo-Inositol (mI), is vital to many 
biological processes of the body, participating in a diverse range of activities 
(Alberts, 2002). mI is a strongly coupled system and resonates at four chemical 
shift positions: 3.55, 3.61, 3.29 and 4.07ppm (Srinivasan, Vigneron et al., 2004). At 
3T these resonances are resolved, but the C4/C6 peak will be partially overlapped 
with the glutamine-glutamate (Glx) C2 triplets. Due to its short T2 relaxation times, 
mI is detected better at shorter echo times. 
 
mI plays an important role in the maintenance of osmotic equilibrium within the 
brain. For example, decreased brain mI has been measured in subjects with hypo-
osmolarity. With normalisation of serum osmolarity, mI levels returned to the 
normal range (Häussinger, Kircheis et al., 2000). In addition to its chemically inert 
function as an osmolyte or cell marker, mI is at the centre of a complex metabolic 
pathway that contains, among other products, the inositol-polyphosphate 
messengers, inositol-1-phosphate, phosphatidyl inositol, glucose-6-phosphate and 
glucuronic acid (Ross and Bluml, 2001). 
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6.2.4 Creatine 
 
Creatine is present in all neural cells, with in vitro work suggesting higher 
concentrations in oligodendrocytes (Urenjak, Williams et al., 1993). The creatine 
peak at 3.03 ppm, a narrow singlet peak originating from the CH3 group of the 
molecule, indexes the sum of creatine and phosphocreatine (PCr), except at high 
magnetic fields where the two can be separated (Danielsen and Ross, 1999). The 
Cr/PCr system plays a number of roles in regulating cellular bioenergetics, 
including serving as a temporal energy buffer for the cell, and as an energy carrier, 
transporting high-energy phosphate groups from sites of synthesis to the specific 
subcellular compartments in which they are required (Saks, Ventura-Clapier et al., 
1996).  
 
Because 1H-MRS sees both Cr and PCr as a single peak, the creatine signal cannot 
be strictly interpreted as either an index of current energy use or available energy 
reserves. The creatine peak is thought to be relatively constant between 
individuals and in most brain areas, and is therefore used as an internal reference, 
where creatine equals 1 in the denominator of expression of all neurometabolite 
ratios (Danielsen and Ross, 1999). 
 
6.2.5 1H-MRS metabolites and cognition 
 
The putatively important role of the metabolites most commonly resolvable at 1.5 
and 3T in neural tissue has been extended to investigations at more macroscopic 
levels of analysis, for example toward developing an understanding of the potential 
biochemical correlates of cognitive ability. One general approach has been to 
obtain measures of the NAA, choline and mI in cortical tissue with 
concurrent psychometric measures of cognitive skills, such as those provided by 
standardised IQ tests. 
 
The clinical utility of MRS in cases of aberrant neurometabolism is well established 
(Cox, 1996; Hollingworth, Medina et al., 2006; Ross and Bluml, 2001; Soher, 
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Doraiswamy et al., 2005; Steen, Hamer et al., 2005). Work in healthy individuals 
has largely concentrated on NAA in young adults, typically between the ages of 18 
and 25. NAA in occipitoparietal white matter has been reported to correlate 
moderately with timed measures of neuropsychological performance, but not with 
metrics of ability derived from non-timed tests (Jung et al., 1999a; Jung et al., 
1999b). NAA has also been demonstrated as a predictor of moderate effect for 
FSIQ, a construct derived from both timed and non-timed psychometric 
subscales (Jung et al., 2005). Choline has been positively correlated with 
vocabulary ability (Pfleiderer, Ohrmann et al., 2004) and, as with mI, negatively 
correlated with IPS in older, healthy adults (Ross, Sachdev et al., 2005). 
 
Table 6-1 on page 125 summarises the results from the published literature in this 
area. The lack of consistency in the methodology demonstrates that work in this 
field is still largely exploratory. Correlations between neurometabolites and IQ 
variables vary according to the particular IQ subscale assessed and with the 
cortical region and tissue type in which the MRS voxel was located, an effect that 
has also been observed in children (Ozturk, Degaonkar et al., 2009; Yeo, Hill et al., 
2000), adolescents (Gimenez, Junque et al., 2004) and in older populations 
(Charlton, McIntyre et al., 2007; Ferguson, MacLullich et al., 2002; Ross, Sachdev et 
al., 2005; Valenzuela, Sachdev et al., 2000). 
 
6.2.6 Aim 
 
The aim of this study was to build on previous work in an effort to examine the 
presence and strength of the relationships between 1H-MRS detectable metabolites 
and cognitive ability in healthy individuals, with the eventual aim of clarifying its 
use in the paediatric liver disease cohort. 
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6.2.7 Hypotheses 
 
1 Given its putative regulatory role in both myelination and in 
neurophysiological processing speed, positive associations between levels of 
NAA in frontal white matter and the IPS were predicted that would be stronger 
than those found for general cognitive ability (FSIQ). 
2 As 1H-MRS-detectable choline is associated with neuronal membrane turnover 
and breakdown, levels of this metabolite were predicted to negatively correlate 
with cognitive performance. 
 
The role of mI in neural function is still largely unknown and no specific 
predictions regarding this metabolite were made. As a control condition, measures 
of NAA, choline and mI were obtained for voxels in occipitoparietal cortex, for 
which the same pattern of covariance with IQ measures was not predicted. 
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Table 6-1 Summary of published investigations into the relationships between common 1H-MRS-detectable metabolites and cognitive abilities in 
healthy populations 
Study N 
Age in 
years 
(SD) 
Region(s) Key result 
Effect 
sizes (r2) 
Jung, Brooks et al. (1999) 26 
22 
(4.6) 
Left OP WM 
NAA, but not choline, positively correlated with 
FSIQ. 
.45 
Jung, Yeo et al. (1999) 45† 
23 
(4.9) 
Left OP WM 
NAA correlated with timed tasks to greater 
degree than general IQ. Choline was negatively 
correlated with FSIQ. 
.43; .23 
Yeo, Hill et al. (2000) 20 12.5 Right frontal WM 
NAA positively correlated with Working 
Memorya. Crb and Choc negatively correlated 
with DI. 
.45a; .31b; 
.30c 
Jung, Yeo et al. (2002) 37 
25 
(5.8) 
Left frontal WM 
Individuals with  high’ levels of Cho scored 10.55 
points lower on the PIQ than those with  low’ 
levels. No group difference in FSIQ. 
.22 
Pfleiderer, Ohrmann et al. 
(2004) 
62 
38.5 
(15.4) 
DLPFC, left anterior 
cingulate cortex 
(ACC) 
Choline correlated with vocabulary scoresd. NAA 
positively correlated with Verbal Intelligence in 
women in left DLPF and left ACCe. 
.13d; .53e 
Charlton, McIntyre et al. 
(2007) 
78 58.2 
Centrum semiovale 
WM 
NAA positively correlated with general 
composite measure of cognitive performancef. Cr 
positively correlated with Executive Functiong 
and long-term memoryh, but not after age is 
controlled for. 
.33f; .45g; 
.47h 
 
Jung, Gasparovic et al. 
(2009) 
 
63 
23.7 
(4.2) 
Left/right, 
posterior /anterior 
grey/white matter 
Lower right anterior GM NAA predicted Verbal 
IQi. Higher posterior GM NAA predicted 
Performance IQj. 
.10i; .12j 
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Study N 
Age in 
years 
(SD) 
Region(s) Key result 
Effect 
sizes (r2) 
Jung, Haier et al. (2005) 27 
24.8 
(5.9) 
Left OP, left frontal 
and right frontal 
WM 
Combination of higher left occipital WM and 
lower frontal WM NAA correlated with FSIQ in 
women. 
.82 
Valenzuela, Sachdev et al. 
(2000) 
20 72 
Left OP and left 
frontal and WM 
Frontal WM NAA/Cr correlated with executive-
attentional cognitive ability. 
.61 
(Ferguson, MacLullich et 
al. (2002) 
88 65–70 Left parietal WM 
Cho/Crk and NAA/Crl correlated with Logical 
Memory, but effect due to Creatine (Cr 
negatively correlated with Logical Memory). 
.14k; .24l 
Ozturk, Degaonkar et al. 
(2009) 
51 
12.3 
(3.6) 
Frontal WM, 
DLPFC, parietal 
WM, inferior 
parietal cortex, 
dorsal parietal 
cortex 
Left frontal WM NAA/Cr correlated with Purdue 
Pegboard right-hand raw scoresm. Right frontal 
WM NAA/Cr correlated with SB-IV “Bead 
Memory” raw scoresn. 
.12m; .10n 
Gimenez, Junque et al. 
(2004) 
21 
14 
(2.3) 
Left medial 
temporal cortex 
NAA/Cho related to free recallo and recognitionp 
memory abilities 
.56o; .51p 
Ross, Sachdev et al. (2005) 59 70.8 
Left frontal WM, 
midline OP GM 
Frontal WM NAA/H2O correlated with a 
composite measure representing speed of 
information processing, attentional function and 
visual memoryq. Cho/Crr, Cho/H2Os and mI/H2Ot 
negatively correlated with speed of processing. 
.32q; .07r; 
.08s; .08t  
Key inter-study variables such as the size of the populations and their age are described as well as the primary cortical regions studied. The principal research 
findings from each study are presented with the wide range of associated effect sizes  (r2).  
DLPFC: Dorsolateral prefrontal cortex; OP: Occipitoparietal; WM: White matter; GM: Grey matter 
†26 participants’ data previously published in Jung et al. (1999a) 
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6.3 Method 
 
6.3.1 Participants 
 
42 healthy volunteers (29 females, 13 males) were recruited from the local population 
and from the Aston University student body (mean age: 21.4, SD: 3.4). Informed consent 
was obtained from all participants under a protocol consistent with the tenets of the 
Declaration of Helsinki and with the approval of the University’s Ethics committee 
(REG/00/175). 
 
Participants were screened prior to testing to exclude the presence of probable 
neurological dysfunction, including previous serious brain injury, history of learning 
disability, neurological disease, psychiatric diagnosis or current use of psychoactive 
medication. The sample provides the study with statistical power in excess of 80% to 
detect moderate correlations of .4 and above, with statistical significance evaluated at 
an α level of .05 (Friedman, 1968). 
 
6.3.2 Neuropsychological assessment 
 
The Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 1997a) was 
administered to obtain scores for IPS and FSIQ, comprised of the Verbal and 
Performance IQ subtests). Refer to Chapter 3 for details. 
 
6.3.3 Neuroimaging 
 
Single-voxel 1H-MRS (2cm3) was performed following localisation of the volume of 
interest (VOI) using a 5-plane localiser (TR: 20 msec, TE: 5 msec, 10 slices at 5mm 
thickness). Automated shimming was followed by a stimulated echo acquisition mode 
(STEAM) pulse sequence (TR: 2,000 msec, TE: 30 msec, 96 averages), including water 
suppression, for voxels in frontal (Fro) and occipitoparietal (OP) cortex. Refer to 
Chapter 3 for details of the scanning procedures and acquisition parameters. 
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6.3.4 Data analysis 
 
The metabolite values were estimated post hoc using LCModel (Provencher, 2001). This 
software provides spectral quantification and metabolite detection optimised for short 
echo time spectroscopy. All analyses reported here adopt the standard convention of 
expressing NAA and choline and mI as a ratio to creatine (/Cr). 
 
6.3.5 1H-MRS data screening 
 
Two levels of screening were applied to the spectroscopy data to ensure accurate and 
reliable data before statistical analyses. The first pass for data screening was the 
rejection of spectral data based on on-line visual inspection of the acquired spectra. 
High-quality spectra were identified by their narrow, well resolved peaks, a reasonably 
flat baseline and the presence of Hunter’s Angle (in normal tissue). Poor quality spectra 
were recognised by a distorted baseline, reduced chemical shift dispersion and 
broadened linewidths (increased full-width half maximum peak height), see Figure 6-1. 
On-line data screening allowed reacquisition of data following necessary adjustments to 
the voxel location, maximising the possibility of acquiring high-quality data from every 
participant.  
 
 
Figure 6-1 Examples of high-quality (left) and poor quality (right) 1H-MRS spectra in frontal 
cortex, modelled with LCModel.  
During on-line data screening, high-quality spectra were identified by their narrow, well resolved peaks, a 
reasonably flat baseline and the presence of Hunter’s Angle (in normal tissue). Poor quality spectra were 
recognised by a distorted baseline (a), reduced chemical shift dispersion (b) and broadened linewidths 
(increased full-width half maximum peak height) (c) 
 
(c) 
(b) 
(a) 
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All subsequent data was run through LCModel. The second pass of data screening was 
the exclusion of data if metabolite values had a %SD (the estimated standard deviations, 
expressed in percent of the estimated concentrations) exceeding 20%, the approximate 
criterion for acceptable reliability suggested by Provencher (2008).  Based on visual 
inspection of the spectra and the 20%SD criteria, data from four participants were 
excluded due to unreliable, poor quality spectra, resulting from susceptibility or motion 
artefact (See Figure 6-1, page 127). 
 
6.4 Results 
 
38 participants (27 females, 11 males) from a total of 42 were included in the final 
analyses.  
 
6.4.1 Summary of spectroscopy data 
 
A summary of spectroscopy and psychometric data is provided in Table 6-2, page 129. 
Mean metabolite ratios to creatine were consistent with those reported previously. FSIQ 
scores were available for 29 participants, and IPS scores for 36 participants, out of the 
total 38 participants. MRS data for occipitoparietal cortex was obtained for all 38 
participants and for 36 out of 38 for the frontal cortex volumes. 
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Table 6-2 Summary of psychometric and spectroscopy data 
  
Mean SD Min Max 
Age (years) 21.3 3.5 18 34 
FSIQ†  111 16.2 52 153 
IPS‡ 108 15.1 57 140 
VIQ 114 15.2 57 147 
PIQ 110 17.0 54 150 
Frontal voxel 
Cho/Cr 0.25 0.06 0.01 0.35 
NAA/Cr 1.54 0.26 0.42 1.95 
mI/Cr 0.67 0.12 0.34 0.86 
Occipitoparietal voxel 
Cho/Cr 0.23 0.04 0.16 0.34 
NAA/Cr 1.61 0.22 0.78 1.88 
mI/Cr 0.65 0.08 0.46 0.85 
FSIQ: Full-scale IQ; IPS: Information Processing Speed 
OP: Occipitoparietal; Fro: Frontal 
†n=29; ‡n=36 
 
6.4.2 Correlations between neurometabolites and cognitive 
variables 
 
Distributions of data prior to the removal of outliers did not 
consistently satisfy distributional assumptions of normality (evaluated with the 
Shapiro-Wilk statistic at an α level of .05) and were first analysed using non-parametric 
statistics. Following the removal of participants with outlying data points, the same data 
distributions did not deviate significantly from normality, thereby justifying the use of 
parametric statistics for these analyses. All correlations were evaluated for statistical 
significance at a Bonferroni-corrected α level of .002 (.05/24 correlations). 
 
Table 6-3 and Table 6-4, page 130, present the correlations between the spectroscopic 
and IQ variables in two complementary ways. First, the metabolite values obtained from 
all participants were included in the analyses and assessed correlations using non-
parametric Spearman rank-order correlation coefficients (Table 6-3). Second, three 
multivariate outliers whose NAA/Cr, Cho/Cr or mI/Cr values were ±2SD the overall 
sample mean were removed, justifying the use of Pearson correlation coefficients (Table 
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6-4) as the data were now normally distributed. All correlations were evaluated for 
statistical significance at a  Bonferroni-corrected α level of .002 (.05/24 correlations). 
 
Table 6-3 Non-parametric correlations between unscreened 1H-MRS metabolite values and 
psychometric measures 
  Unscreened data 
 Correlation with cognitive ability; r (p value) 
  FSIQ IPS PIQ VIQ 
Frontal (n) 27 36 27 27 
Cho/Cr .03 (.94) -.15 (.37) .11 (.57) .04 (.85) 
NAA/Cr .09 (.65) -.13 (.44) .22 (.27) .11 (.58) 
mI/Cr -.02 (.94) -.07 (.70) .09 (.66) .12 (.54) 
Occipitoparietal (n) 29 38 29 29 
Cho/Cr -.07 (.73) -.07 (.67) .08 (.70) -.23 (.99) 
NAA/Cr .21 (.27) -.16 (.71) .34 (.07) .05 (.78) 
mI/Cr -.09 (.63) -.01 (.93) .02 (.92) .00 (.99) 
Unscreened metabolite values were not normally distributed and analysed with non-
parametric statistics (Spearman’s Rho) 
 n=27 
 
Table 6-4 Parametric correlations between screened 1H-MRS metabolite values and 
psychometric measures  
  Screened data 
 Correlation with cognitive ability;  r (p value) 
  FSIQ IPS PIQ VIQ 
Frontal (n) 24 33 24 24 
Cho/Cr -.08 (.72) .03 (.88) -.08 (.72) -.05 (.83) 
NAA/Cr .06 (.77) -.24 (.18) .06 (.78) .02 (.42) 
mI/Cr -.03 (.89) -.01 (.96) .12 (.59) -.10 (.63) 
Occipitoparietal (n) 26 35 26 26 
Cho/Cr -.04 (.85) .00 (.98) .21 (.32) -.17 (.40) 
NAA/Cr .11 (.60) .09 (.60) .21 (.31) .05 (.80) 
mI/Cr -.17 (.40) -.17 (.32) -.18 (.390) -.16 (.44) 
Three outlier values (±2SD) excluded; 
Normally distributed data analysed with parametric statistics (Pearson Product Moment 
Correlation) 
 n=24 
 
Correlation coefficients for the unscreened data showed that the relationships between 
IPS or FSIQ and NAA/Cr, Cho/Cr and mI/Cr were neither strong, nor statistically 
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significant, a pattern that was consistent across both occipitoparietal and frontal 
voxels. This pattern of result was upheld with parametric analyses when multivariate 
outliers were removed. 
A Related-samples Wilcoxon Signed-rank was used to assess inter-regional differences 
in metabolite values. No significant differences in mean NAA/Cr, Cho/Cr or mI/Cr were 
observed between frontal and occipitoparietal voxels (p= .07, .09 and .30, respectively). 
An Independent-samples Kruskall Wallis test showed no main effect of gender on 
metabolite values (p> .05). 
 
6.5 Discussion 
 
Neurometabolite changes, particularly for NAA, have been linked previously to 
psychometric and performance variables in a number of disorders of cognitive 
function, including traumatic brain injury, schizophrenia and Alzheimer’s disease (Ross 
and Sachdev, 2004). Such demonstrations of the utility of MRS in tracking neural 
viability in cognitive neuropathology has motivated the study of normal populations in 
order to assess the validity of using this paradigm to identify biomarkers of human 
cognitive variability. 
 
Several studies have demonstrated statistically significant correlations between 1H-MRS 
detectable metabolites and broad measures of cognitive ability, with typically small to 
moderate effect sizes in samples of putatively normal populations (see Table 6-1, page 
124). In the present study, measures of NAA, choline and mI were obtained with proton 
spectroscopy for a group of healthy adults. The principal finding is that quantitative 
estimates of these metabolites did not correlate strongly with standardised measures of 
IQ, including the IPS index, a construct of cognitive ability for which particularly strong 
relationships were predicted.  
 
The small correlations obtained between metabolite concentrations and measures of 
cognitive function echo other findings that have reported poor strength of association 
between IQ and neurometabolite variables in healthy cohorts (Filippi et al., 2002; 
Friedman et al., 1998; Gimenez et al., 2004; Shim et al., 2001). However, they also 
contrast with other demonstrations of strong and significant relationships 
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between these variables obtained with similar research designs (Jung et al., 1999a; Jung 
et al., 1999b; Jung et al., 2005; Yeo, Hill et al., 2000). 
 
6.5.1 NAA and cognition 
 
The general theory in the literature is that if NAA is taken as a functional neuronal 
marker with natural variation in the population, reduced levels of NAA may be reflective 
of increased neuronal death, or decreased neuronal metabolism or myelination, which 
may then manifest as the subtle changes in general cognitive ability. 
 
Weak to moderate positive and negative associations between NAA/Cr were observed 
in this cohort. These were within the range observed by others (Table 6-1, page 124), 
but were not statistically significant. Studies exclusively focusing on white matter have 
found associations between NAA and processing speed. NAA in occipitoparietal white 
matter has been reported to correlate moderately with timed measures of 
neuropsychological performance, but not with metrics of ability derived from non-
timed tests (Jung, Brooks et al., 1999; Jung, Yeo et al., 1999).  
 
NAA has also been demonstrated as a predictor of moderate effect for FSIQ (Jung, Haier 
et al., 2005). This association between occipitoparietal NAA with FSIQ was later 
replicated in a sample of 27 healthy volunteers, with a combination of left frontal and 
left occipitoparietal NAA strongly predicting performance in women, but not 
statistically significant in men (Jung, Haier et al., 2005).  
 
Corroborating evidence for this potential gender difference is work by Pfleiderer, 
Ohrmann et al. (2004), who found that, in women only, NAA in the left dorsolateral 
prefrontal cortex and in the left anterior cingulated cortex was positively correlated 
with raw, not age-corrected and standardised vocabulary assessment scores. In contrast 
to these two studies, no differences in gender were observed in the present cohort for 
any of the metabolites assessed. 
 
Valenzuela, Sachdev et al. (2000) observed a correlation between NAA/Cr in the left 
frontal subcortical white matter and attentional processing ability, which is functionally 
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associated with this region. In keeping with the findings of the present study, but unlike 
(Jung, Haier et al., 2005; Jung, Yeo et al., 1999), Valenzuela et al found no associations 
between measures in the occipitoparietal grey matter and cognition in these subjects. 
Ross, Sachdev et al. (2005) have shown a significant correlation between frontal white 
matter NAA/H2O and a composite measure of neuropsychological performance 
representing speed of information processing, attentional function and visual memory, 
controlling for age and sex, in a population of 5885 year old healthy individuals. 
 
6.5.2 Choline and cognition 
 
Weak, negative correlations, which were not statistically significant, were observed 
between choline and IQ measures (see Table 6-3, page 134). Choline concentration is 
reported to vary with the production and degradation of the choline-containing 
phospholipids, which are abundant both in cell membrane and myelin (Alberts, 2002). 
The free choline detectable by MRS is more commonly associated with membrane 
turnover and inflammation. An abnormality in membrane structure or myelination 
could potentially precipitate decreased synaptic strength and efficiency, manifesting in 
cognition as small, but significant, changes in ability. 
 
For example, weak negative correlations between choline and cognitive ability have 
been observed by Ross, Sachdev et al. (2005), but this was in healthy, elderly men and 
with choline value expressed as ratios to both creatine and water. Jung, Yeo et al. (2002) 
split participants into ‘high’ and ‘low’ choline groups (details of cut-off criteria were not 
provided), and found that individuals in the ‘high’ group performed significantly higher 
on the Performance IQ subtests, and specifically the processing speed index. No 
differences between the groups were observed for Full-scale and Verbal IQ or Working 
Memory performance. 
 
6.5.3 myo-Inositol and cognition 
 
The relationships between mI and cognition are understudied in comparison to NAA 
and choline. Two studies from those listed in Table 6-1 reported data for mI in healthy 
populations. No relationship between mI concentrations and broad-based measures of 
 134 
 
cognitive ability were observed in healthy young adults (Jung, Yeo et al., 1999), but in a 
healthy elderly population Ross, Sachdev et al. (2005), report correlations of -.33 
between mI/Cr and mI/H2O and executive function, and -.28 between mI/H2O and 
speed of information processing. Studies of the role of mI in disease states and cognitive 
outcome in the elderly have been more fruitful, particularly in mild cognitive 
impairment and Alzheimer’s disease. mI has, for example, been shown to be strongly 
negatively correlated with Mini Mental State (MME) scores (r2= .54) (Salvan, Ceccaldi et 
al., 1998), and mI/H2O correlates with language function in left prefrontal cortex (r= -
.60) and visuoconstructional abilities in right prefrontal cortex (r= .68) in Alzheimer’s 
disease patients (Chantal, Labelle et al., 2002). However, elevated mI is has not always 
been found to be related to the presence of MCI (Metastasio, Rinaldi et al., 2006; Ross 
and Sachdev, 2004), and the relationship between mI and cognitive abilities is still 
largely unknown. The role of mI as a potential clinical biomarker in the specific context 
of liver disease is discussed in Chapter 7. 
 
6.5.4 Methodological issues in cognitive spectroscopy studies 
 
Examination of the existing literature reveals a number of methodological or research 
design features that vary greatly between studies (see Table 6-5, page 135). Differences 
in the age of the participants, the cortical regions in which the MRS voxels were placed, 
the constructs of cognitive abilities assessed and the quality of data screening applied 
(see Table 6-1, page 124) may all be factors which explain the the inhomogeneous 
effects found across the population of published studies. In the following section the aim 
is to place the results of the present investigation within the context of these inter-study 
differences and outline recommendations for reporting future studies in cognitive 
spectroscopy. 
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Table 6-5 Summary of inter-study variables in cognitive spectroscopy studies as a result of the 
methodological approach and data analysis employed 
Study 
 No. of comparisons 
 
Outliers 
screened 
Metabolite 
quantification 
No. of 
regions 
No. of 
psychometric 
sub-tests 
Total no. of 
comparisons 
Jung et al. 
(1999a) 
Absolute  
values 
1 11 9 N 
Jung et al. 
(1999b) 
1 10 9 N 
Yeo et al. 
(2000) 
1 7 9 N 
Jung et al. 
(2002) 
1 10+ 10+ N 
Pfleiderer et 
al. (2004) 
3 1 12 Y 
Charlton et al. 
(2007) 
1 14 20 N 
Jung et al. 
(2009) 
8 5 24 N 
Jung et al. 
(2005) 
3 12 30 Y 
Valenzuela et 
al. (2000) 
Cr ratio 
2 16 9 N 
Ferguson et 
al. (2002) 
1 11 33 Y 
Ozturk et al. 
(2009) 
6 4 20 N 
Gimenez et al. 
(2004) 
Cho ratio 1 18 7 N 
Ross and 
Sachdev 
(2005) 
H2O and Cr 
ratio 
2 15 8 N 
Differences in the method of metabolite quantification and expression, the number of comparisons 
made in statistical analyses as a function of the number of regions and psychometric measures 
assessed, and whether data were appropriately screened, may contribute to the variable strength and 
size of effect sizes reported in the literature. 
 
6.5.4.1 Age 
 
Previous studies of healthy populations varied substantially in the age of the population 
sampled, ranging from late childhood (Ozturk et al., 2009; Yeo et al., 2000) to older ages 
(Ferguson et al., 2002; Ross et al., 2005; Valenzuela et al., 2000) (see Table 6-1). In the 
present study of younger healthy adults with a mean age of 21 years, no significant 
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correlations were observed between the metabolites in either frontal or occipitoparietal 
voxels in the present study, yet the mean age and standard deviation of the participants 
was similar to that of other investigations of young, healthy adults, some of which 
have reported particularly large effects (Jung et al., 1999a; Jung et al., 2005; Jung et al., 
1999b) (see Table 6-1; for example r2= .45). Although previous reports suggest the 
presence of age-related metabolic changes across the lifespan (Angelie et al., 2001; 
Pouwels et al., 1999), there is no systematic relationship apparent between the age of 
the study sampled and the strength of the IQ/neurometabolite correlations (Table 6-
1). The most reasonable interpretation of these data is that age does not account for the 
variability in effect size of the NAA/IQ relationship in this cohort of studies. 
 
6.5.4.2 Metabolite quantification 
 
Published studies vary according to whether absolute concentrations of NAA are 
reported or whether NAA values are expressed as a ratio to another neurometabolite 
(typically creatine, or alternatively choline). Expressing NAA as a ratio to creatine 
confers the advantage of correcting for potentially important unknown or 
uncontrollable, yet correlated, experimental factors, such as static (B0) and radio 
frequency (RF, B1) field inhomogeniety. However, the validity of using such ratios may 
be undermined by the potentially under-conservative assumption of the stability of the 
reference metabolite (Li et al., 2003). Alterations in creatine may be observed not only 
in disease states, but also in healthy aging (Haga, Khor et al., 2009; Maniega, Cvoro et al., 
2008). 
 
A study by Ferguson, MacLullich et al. (2002) provides an example of the cautionary 
approach required when using creatine ratios. In contrast to the negative relationships 
between choline and cognitive performance observed by others, Ferguson et al. 
observed that Cho/Cr values were moderately and positively correlated with tests of 
visual and logical memory in an elderly, healthy population. To account for the fact that 
creatine may not be constant, and therefore inappropriate in ratio analyses, Ferguson et 
al. regressed each metabolite value (NAA, Cho, Cr) against the remaining two, creating 
standardised residual or ‘adjusted’ metabolite value. When they accounted for the 
potential association between creatine and psychometric measures by including 
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‘adjusted’ creatine as a cofactor in the regression, choline levels did not correlate 
significantly with any cognitive variables. Elderkin-Thompson, Thomas et al. (2004) 
have shown that among normal participants, cognition was positively correlated with 
Ch/Cr and negatively correlated with PCh/Cr in the four domains of verbal learning, 
recognition, recall and hypothesis generation. By contrast, depressed patients showed 
no consistent relationships between Ch/Cr or PCh/Cr and cognition. 
 
To remove issues of creatine as a confounder, a more optimal strategy may be to use 
one of a number of absolute quantification methods (Jansen, 2006), particularly using 
the water signal as reference. This may provide the most robust method for ensuring 
reliable results as the internal water standard technique can be readily implemented 
provides suitable precision and inter-laboratory reproducibility (Keevil et al., 1998). 
However, the differential water fractions of grey and white matter volumes necessitate 
precise tissue identification and is most reliably obtained with voxels of small spatial 
extent and verified following data acquisition. This in turn raises potential issues for the 
trade-off between ensuring sufficient sample sizes and tissue homogeneity across the 
voxels included in statistical analyses (see section 6.5.4.3 below). 
 
Despite these issues, analysis of the studies in Table 6-1 (page 124) did not identify any 
systematic relationship between the method of metabolite quantification adopted and 
the size and strength of the reported findings between IQ and NAA. Improved 
methodology for 1H-MRS data acquisition and analysis of absolute metabolite values is 
leading to the increased use of absolute metabolite values as a method of best practice 
(Jansen, 2006), but until such a standard referencing procedure is widely adopted, 
comparing data across studies that differ in this variable will remain difficult (De Beer 
et al., 1995; Knight-Scott et al., 2003). Investigating multivariate relationships using 
multiple metabolite expressions (for example ratios to water, choline and creatine 
(Ross, Sachdev et al., (2005)) compounds difficulties in interpretation, since this 
procedure increases greatly the number of potential statistical comparisons within a 
given study. 
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6.5.4.3 Tissue type 
 
The typically large spatial extent of the voxel from which data is acquired in MRS 
studies makes it difficult to obtain measures from homogeneous tissue. However, 
decreasing the spatial extent of the voxel size leads to a corresponding decrease in the 
SNR (Freeman, 2003). The extent to which MRS samples grey or white matter can 
modulate the metabolite values obtained (McLean et al., 2000; Wang and Li, 1998; 
Wiedermann et al., 2001). Jung et al. (2009) have reported that the patterns of 
relationship between NAA and IQ variables may also vary according to the tissue 
sampled. 
 
The precision gained from obtaining measures from homogeneous tissue, or after post-
hoc correction for tissue inhomogeniety, something which was not implemented in the 
current study, is a reasonable aspiration for future studies, yet few studies in this area 
have applied such procedures to their data. As an exception, Charlton et al. (2007) 
excluded voxels containing less than 75% white matter in their study, but acknowledge 
the inevitable reduction in sample size (and correspondingly in nominal statistical 
power) that potentially results from applying such screening criteria post hoc. 
 
6.5.4.4 Region 
 
A volume in the occipital cortex was selected because of the homogenous nature of the 
cortical tissue (Swanson, 2003), which aids in providing consistent high-quality spectra. 
Furthermore, metabolites in this region have been shown to correlate with cognitive 
abilities in both diseased (Modrego, Fayed et al., 2005) and healthy (Jung, Yeo et al., 
1999) cohorts. 
 
No significant differences in neurometabolites were observed between frontal and 
occipitoparietal voxels in the present analyses, a result that is in accordance with some 
studies using single-voxel 1H-MRS (for example Ozturk et al., 2009), but which contrasts 
with others that have observed significant inter-regional differences using both single 
(Minati et al., 2010) and simultaneous multiple voxel acquisitions (Angelie et al., 2001; 
Maudsley et al., 2009). 
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Assessments of metabolite concentrations in different tissues have not, however, always 
yielded the same pattern of effects (Wiederman et al., 2001). While the NAA/Cr and Cho, 
for the present study and for those listed in Table 6-1, are generally consistent with 
published normative data, it would not be surprising if the correlations between 
neurometabolites and cognitive function varied according to the cortical region 
investigated, given the functional specialisation of the cerebral cortex. Measures were 
obtained from voxels in frontal cortex, given the important role of this region in the 
higher cognitive functions assessed with the WAIS measures (Baddeley, 1996; Duncan 
et al., 2000), and from a control volume in occipitoparietal cortex, an approach that has 
also been adopted in other studies (Ozturk et al., 2009). 
 
6.5.4.5 Assessments of cognitive ability 
 
Most previous studies have used broad and non-specific measures of cognitive skill, 
such as those afforded by standardised assessments of general intelligence. As well as 
FSIQ, and its constituent Verbal and Performance subscales, other studies have adopted 
data reduction techniques to derive a composite score as a dependent variable (Ross et 
al., 2005; Valenzuela et al., 2000). Other studies have adopted a contrasting approach, 
measuring increasingly specific cognitive abilities such as working memory (Yeo et al., 
2000) or IPS (Jung et al., 1999b). 
 
In the present study a hybrid approach was adopted, assessing both FSIQ and the IPS 
subscale, measures that reflect both general cognitive ability and the mental and motor 
speed required to solve visuo-spatial problems respectively (Groth-Marnat et al., 2000). 
Given NAA’s putative role in myelination and in neural efficiency, IPS may be more 
closely linked to neurophysiological functions for which NAA is a mediator than to 
broad-based IQ measures. It was hypothesised that NAA would co-vary with general 
cognitive ability, but specifically more strongly with IPS. However, no relationships of 
note between NAA/Cr and either FSIQ or IPS (see Table 6-4, page 130) were observed. 
 
Whereas some studies have taken an exploratory approach to investigating 
relationships between neurometabolites and cognitive ability (Ferguson et al., 2002; 
Jung et al., 2009; Jung et al., 2005), others have either predicted a dissociation between 
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broad psychometric constructs (Jung et al., 1999b; Ross et al., 2005) or focused on 
increasingly specific cognitive attributes such as Executive Function (Charlton et al., 
2007; Valenzuela et al., 2000) or Working Memory (Yeo et al., 2000). Studies that used 
broad-based measures such as FSIQ, or a composite score for IQ derived by factor 
analysis, showed an average effect size of .50, compared to .32 for those studies 
reporting findings for specific cognitive measures (Table 6-1, page 124). 
 
A minority of studies have framed more specific hypotheses, for example regarding 
gender differences in NAA and verbal processing ability (Pfleiderer et al., 2004) or 
hemispheric specificity with relation to verbal working memory and motor 
speed (Ozturk et al., 2009). In the present study, broad-based FSIQ measure were used, 
but specific hypotheses relating to specific measures of IPS were made, with small 
effects observed in both instances. 
 
The methodological approach to data analytic strategy should be directly informed by 
the a priori hypotheses adopted (or lack thereof) as this will govern the choice and 
range of psychometric assessments and how subscales are treated in statistical analysis. 
Given the potentially diffuse role of NAA in brain function, broad-based measures of 
cognitive function may be the most fruitful variables to consider for further 
investigation. 
 
The relative merits of hypotheses that invoke brain plasticity, or subtle weak effects due 
to variations in neurometabolites, require considerable attention and are a reflection of 
the gap between molecules and manifest behaviour. The former hypothesis suggests 
that there may be no genuine consequence of relatively small variations in 
neurometabolites, whereas the latter suggests that these small natural variations could 
result in subtle performance deficits that are simply difficult to detect with current 
broad-based psychometric tools. 
 
6.5.4.6 Data screening and analysis 
 
Differences between studies are also apparent in their choice of analytical strategies, 
including procedures for data screening to ensure robust correlational data (Tabachnik 
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and Fidell, 2001). The validity of the data depends on several factors, including the 
assumption of univariate and multivariate normality and how outlying values are 
handled in statistical analyses. To date, most investigations have employed highly 
varying screening procedures, with little homogeneity of practice in the methods of 
analysis and presentation of data across studies. Levels of screening range from basic 
level removal of poor quality spectra (Jung et al., 1999b; Ross et al., 2005) to exclusion 
of metabolite values exceeding a critical statistical cut-off following post hoc 
quantification (Ferguson et al., 2002; Jung et al., 2005; Pfleiderer et al., 2004), or 
following screening for voxel tissue composition but not for the metabolite values 
obtained (Charlton et al., 2007). Other studies (Gimenez et al., 2004; Jung et al., 1999a; 
Valenzuela et al., 2000; Yeo et al., 2000) have neither reported the extent nor the 
methodology of data screening procedures. 
 
The procedures used for data screening and the suitability of statistical analysis strategy 
may critically underpin the validity of the findings from a given study. Normality of 
spectroscopy data cannot be assumed, yet none of the studies reviewed here (see Table 
6-1) included information on the normality or distributional assumptions of their data. 
However, all of the studies employed parametric statistics (Pearson correlation or 
linear regression analyses) in their data analyses. 
 
Had the unscreened data in the present study been analysed with parametric measures 
(which were not justified in this case), significant correlations reported would have 
between NAA and IQ variables on the order of r= .4, a finding similar to those in the 
published literature (Table 6-1). Given the potential impact of outliers and non-
Gaussian distributions of data on the validity of the results, a concerted effort should be 
made to report the extent of data screening employed in future studies. 
 
6.5.4.7 Multiple comparisons and a priori hypotheses 
 
Quantitative assessment of the data from healthy cohorts (Table 6-1) reveals a 
particularly strong negative correlation (r= -.68; p= .015) between the number of 
participants studied and the effect size for the main finding reported, indicating that the 
strongest relationships between NAA and cognitive abilities are typically found in 
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studies with smaller sample sizes. One interpretation of this effect is that insufficient 
screening of the data from relatively small samples, combined with the large number of 
variables investigated and a lack of specifically identified a priori research hypotheses, 
renders the typical study susceptible to inflated Type 1 error resulting from the large 
number of statistical comparisons employed. 
 
Furthermore, a key consideration for future studies in cognitive spectroscopy is the 
distinction between statistical significance and statistical relevance, and whether the 
correlation between NAA (or any other metabolite) and a specific psychometric sub-test 
is meaningful for the development and refinement of theory, particularly in cases where 
effect sizes may not be large enough to survive with adjustments in α such as Bonferroni 
corrections or relate to results that were not hypothesised a priori. 
 
The subtlety of the relationships that may exist between neurometabolites obtained 
with MRS and measures of cognitive ability motivates the collection of larger-sized 
samples of participants than have been typically obtained, to achieve the statistical 
power necessary to reliably detect multiple effects and their interactions (Jung et al., 
2009; Ozturk et al., 2009). With an anticipated effect size in the range of 0.15, at an α 
level of .01, a study would require a sample of at least 82 participants to have an 80% 
chance of detecting a noteworthy relationship. 
 
6.6 Conclusion 
 
1H-MRS provides a valuable and sensitive tool for quantification of brain tissue 
composition and viability in vivo, but the lack of a cohesive direction and consensus in 
the patterns of relationships across studies suggests that conclusions drawn from these 
types of studies need to be tempered by awareness of the methodological issues that 
complicate the work. 
 
In the present study, where particular care was taken with data acquisition and 
screening in order to maximise the reliability of the data and strict and specifically 
appropriate statistical analyses were applied, no significant relationships were 
observed between 1H-MRS detectable neurometabolites and measures of cognitive 
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ability. In future studies of this kind, emphasis must be placed on the need for specific, 
hypothesis-driven enquiry and awareness of the subtlety of the data analysis and 
psychometric measures being used and how they are reported. Despite its limitations, 
there is the potential for 1H-MRS to make a significant contribution towards 
understanding some of the neurobiological correlates of cognitive ability. 
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7 1H-MRS-dectable metabolites as biomarkers in 
paediatric liver disease 
 
7.1 Summary 
 
The aim of this study was to evaluate the extent to which non-invasive 1H-MRS can add 
information to the study of children with liver disease by revealing abnormalities in 
cerebral metabolism and to evaluate if performance on cognitive indices is related to 
concentrations of 1H-MRS-detectable neurometabolites. 
 
In a sample of 23 patients with liver disease and 11 sibling controls, single voxel 1H-MRS 
in occipitoparietal and frontal cortical white matter was used to assay concentrations of 
4 principal metabolites: NAA, choline, mI and Glx, in parallel with assessments of 
psychometric intelligence (FSIQ). 
 
The most important finding of the present cross-sectional study, which used 
quantitative short echo-time proton spectroscopy, is that there were neither significant 
differences in metabolite concentrations among the three groups of children with 
different stages of liver disease, nor between these patients and sibling control children 
matched for age. The similarity of the metabolite values observed between the patient 
and control groups suggests that neurodevelopment, assayed by surrogate 
neurometabolite markers, is normal in this cohort. 
 
When used in paediatric cohorts, 1H-MRS may supplement neuropsychological test 
batteries to enable evaluation of the neurophysiological impact of liver disease and 
patient’s response to clinical interventions designed to minimise disease progression. 
However, the use of 1H-MRS is still largely exploratory and what is currently missing is 
careful quantification, age-specific, reproducible, regional studies in newborns, infants, 
children and adolescents to provide context for the clinical data. 
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7.2 Introduction 
 
MRI studies have been used to probe the interplay between neuroanatomical and 
physiological changes in neural circuitry during cognitive maturation and development 
(Casey, Giedd et al., 2000; Casey, Tottenham et al., 2005; Paus, 2005). 1H-MRS was 
identified as a technique of emerging importance in the investigation of paediatric brain 
development in a major review by Novotny et al. over a decade ago (Novotny, Ashwal et 
al., 1998). Since then, substantial progress has been made in understanding the 
relationship between 1H-MRS-detectable metabolites and neurophysiological and 
neuropsychological development, both normatively and in abnormality. 
 
When applied in a clinical environment, the biochemical profiles generated by 1H-MRS 
reflect levels of endogenous metabolites involved in key cellular pathways. This data 
can therefore indicate the physiological status of neural tissue and potentially offer 
pointers to underlying pathophysiological processes to facilitate diagnosis of hereditary 
and acquired brain disorders in children (Grodd, Krageloh-Mann et al., 1991), and assist 
in the detection of functional abnormalities, potentially before the appearance of 
symptoms. This is discussed in greater detail below in the context of liver disease. 
 
As a diagnostic tool, 1H-MRS research has concentrated on the effects of diseased states 
such as metabolic (Zimmerman and Wang, 1997) and neurodegenerative (Tzika, Ball et 
al., 1993) disorders, hypoxic–ischaemic brain injury (Amess, Penrice et al., 1999), in 
utero drug exposure (Goncalves Rde, Vasconcelos et al., 2009; Smith, Chang et al., 2001) 
and epilepsy (Ranjeva, Confort-Gouny et al., 2000). 
 
7.2.1 Subclinical hepatic encephalopathy 
 
Hepatic encephalopathy (HE) is a syndrome encompassing a wide range of 
neuropsychiatric consequences of liver disease, which typically results from 
hepatocellular failure and/or portal-systemic shunts. The terms subclinical or ‘minimal’ 
hepatic encephalopathy (SHE) is used to describe the presence of cognitive impairment 
on psychometric testing and/or slowing of electroencephalographic (EEG) mean cycle 
frequency (for example reduced frequency of the α rhythm and disturbances by random 
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waves in the θ range over both hemispheres) in the absence of any clinically overt signs 
(Amodio, Montagnese et al., 2004; Ferenci, Lockwood et al., 2002). The broad definition 
of SHE reflects the existence of a spectrum of neuropsychiatric manifestations, which 
are typically diagnosed using neuropsychological or neurophysiological tools (Ortiz, 
Jacas et al., 2005), including composite measures such as the psychometric hepatic 
encephalopathy score (PHES) (Weissenborn, Ennen et al., 2001), which examines the 
motor speed and accuracy, visual perception and construction and attentional deficits 
which characterise the condition. The neuropsychological features of SHE are defined as 
a disorder of executive functioning, particularly selective attention and psychomotor 
speed (Amodio, Montagnese et al., 2004). 
 
When evaluated using standard tools of psychometric assessment, the results from 
Chapter 4 indicated that liver disease is associated with good long-term cognitive 
outcome, as indexed by broad-based metrics such as FSIQ. However, whilst 
neuropsychological test batteries are the current gold standard measures for cognitive 
ability, a considerable problem in using these tests alone is that the results are not 
specific to the disorder and are limited in what they are able to reveal about the 
mechanisms underlying changes in cognitive behaviour. The term subclinical HE 
highlights the need for complementary tests to diagnose degrees of brain dysfunction 
that may not be detected through standard clinical examination or assessment. 
 
7.2.2 1H-MRS biomarkers of subclinical hepatic encephalopathy 
 
As a non-invasive, non-destructive procedure that does not require parenteral 
injections, or use of radioactive materials, 1H-MRS is ideally suited for repeated 
measures of adult and paediatric populations where in vivo biochemical data is 
required. It has been shown repeatedly that for HE and SHE, a specific pattern of 
cerebral metabolic change exists in the brain, which even in the mildest form of HE can 
be detected using short echo-time MRS (Grover, Dresner et al., 2006). This typical 
pattern, largely observed in studies of adults, is a reduction in the mI and choline 
resonances and an increase in the glutamate/glutamine composite resonance (Glx) 
(Atkison, Ross et al., 2002; Kreis, Ross et al., 1992; Taylor-Robinson, Sargentoni et al., 
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1994b). Figure 7-1 illustrates a representative 1H-MRS spectra from a healthy 
individual. 
 
 
Figure 7-1 Representative 1H-MRS spectra of normal human brain 
 
In one of the few studies of metabolite changes in children, Tkac, Hamernick et al., 
(2004) observed that pre-transplant paediatric candidates had pronounced differences 
in neurometabolite levels, including increase of glutamine and the decrease of mI and 
NAA compared to controls, a pattern of results consistent with that from adult studies. 
 
If liver disease causes the cerebral metabolite changes described for SHE, reversibility 
of metabolite levels after liver transplantation can be predicted if no persistent brain 
damage has already occurred. This effect has been observed in several studies with 
adult liver transplant patients (Naegele, Grodd et al., 2000; Ross, Jacobson et al., 1994; 
Shawcross, Balata et al., 2004; Thomas, Huda et al., 1998) and in paediatric patients 
studied pre- and post-transplant (Tkac, Hamernick et al., 2004). The finding by Tkac et 
al. that only four of the eight patients studied showed improvement of neurometabolic 
status post-transplant motivates studies using convergent measures to understand the 
variability of metabolite values in these populations compared to sibling controls. 
 
 148 
 
7.2.3 1H-MRS and cognitive ability in children 
 
1H-MRS has also proved useful in terms of relating potential deficits in cognitive 
development with changes in neurometabolic concentrations, for example in traumatic 
brain injury (Brooks, Friedman et al., 2001; Friedman, Brooks et al., 1998) and 
developmental dyslexia (Rae, Lee et al., 1998). It has even been suggested that 1H-MRS 
has the potential sensitivity to identify clinical subtypes of autism spectrum disorders 
(Gabis, Wei et al., 2008). 
 
1H-MRS has also been extended to assessment of developmental delay, whereby the 
metabolites provide supplementary information in cases where the cause of cognitive 
disturbance remains unknown. Filippi, Ulug et al. (2002) found that in children with 
normal MRIs, decreases in the NAA/Cr ratio and elevations of Cho/Cr in frontal and 
occipitoparietal subcortical white matter were associated with developmental delay in 
children over the age of two. This data in clinical populations of children point to the 
potential utility of 1H-MRS as an adjunctive investigative technique to the traditional 
methods of psychometric tests typically used to assess for the presence of HE and 
cognitive deficits in liver disease. 
 
1H-MRS studies of healthy human cognition have mainly examined adults (see Chapter 
6). Whilst methodological flaws are evident (see section 6.5.4), the findings from these 
studies suggest that NAA, measured across different cortical regions, co-varies with 
different constructs of cognitive ability, an effect that has also been observed in healthy 
younger populations. In healthy children, NAA/Cr ratios have been associated with 
measures of manual speed and dexterity, visual working memory (Ozturk, Degaonkar et 
al., 2009) and working memory (Ozturk et al., 2009; Yeo et al., 2000). In adolescents, 
Gimenez, Junque et al. (2004) have observed correlations between NAA and a 
composite measure of cognitive skill representing speed of information processing, 
attentional function and visual memory. 
 
In a recent study, Lightsey et al. employed multi-voxel spectroscopy, sampling both 
white and grey matter, in a cohort of healthy six to 19 year olds (Lightsey, 2010). They 
observed that higher NAA/Cr mean and lower NAA/Cr standard deviations in grey 
 149 
 
matter is associated with higher memory performance in boys, while lower NAA/Cr 
mean and higher NAA/Cr standard deviations in gray matter is associated with higher 
memory performance in girls. As with the studies of adults described in Chapter 6, the 
general approach has been to obtain in measures of 1H-MRS metabolites in cortical 
tissue with concurrent psychometric measures of cognitive skills, such as those 
provided by standardised IQ tests. 
 
7.2.4 Aim 
 
The aim of the present study was to investigate whether children with liver disease 
have a neurometabolic pattern which differs from sibling controls and is indicative of 
SHE. Relationships between cognitive ability and neurometabolites were also 
investigated to determine if intellectual deficits associated with liver disease are 
reflected in reduced concentrations of NAA, or disturbances in other 1H-MRS-detectable 
cerebral metabolites. 
 
7.2.5 Hypotheses 
 
1. If present, the characteristic combination of biomarkers of SHE, namely reduced 
choline and mI and increased Glx, would correlate with greater cognitive 
dysfunction and decreased FSIQ. 
2. Post-transplant patients would show a pattern of metabolite values closer to that 
for sibling controls. 
3. As a potential marker of neuronal viability and health, NAA would negatively 
correlate with measures of general cognitive ability. 
 
7.3 Method 
 
7.3.1 Participants 
 
A total of 40 participants (15 females, 25 males; (mean age 13.1, SD: 5.0)) from the 
principal cohort described in Chapter 3 underwent the MR procedure. Twenty-nine 
participants from this cohort were patients with liver disease and 11 were healthy 
sibling controls.  
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34 participants (23 females, 11 males,) from a total of 40 participants were included in 
the final analyses. Descriptive data for the sibling control and patient groups are 
provided in Table 7-1, page 152. Three patients did not tolerate the scan procedure. 
Data from a further three participants was excluded due to poor quality spectra in both 
frontal and occipitoparietal voxels, as a result of artefact induced by motion or non-
neural tissues. 
 
7.3.2 Neuroimaging 
 
The standardised neuroimaging protocol is described in Chapter 3 (section 3.5.3, page 
67). 
 
The 1H-MRS data was obtained with a Siemens 3T Trio scanner (Siemens Medical 
Solutions, Berkshire, UK) using standard acquisition software and a quadrature head 
coil. Single-voxel 1H-MRS (2 cm3) was performed following localisation of the volume of 
interest (VOI) using a 5-plane localiser (TR: 20 msec, TE: 5 msec, 10 slices at 5 mm 
thickness). Manual voxel positioning maximised the white matter contribution and 
minimised the intrusion of grey matter, and ensured that the voxel did not 
encroach upon non-neural sources. Automated shimming was followed by a stimulated 
echo acquisition mode (STEAM) pulse sequence (TR: 2,000 msec, TE: 30 msec, 96 
averages), including water suppression, for voxels in both frontal (Fro) and 
occipitoparietal (OP) cortex. To validate data quality, assess reliability and quantify 
error variance introduced by scanner-related factors such as that caused by field 
inhomogenieties, data from two successive scans of the same voxel were obtained and 
averaged for each participant. 
 
7.3.3 Psychometric assessments 
 
The standardised protocol for administration of psychometric assessments is described 
in Chapter 3, page 51. 
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An age-appropriate battery of the Wechsler Preschool and Primary Scale of Intelligence-
III, Wechsler Intelligence Scale for Children-IV or Wechsler Adult Intelligence Scale-III 
was administered for each child to derive scores for Verbal, Performance, Working 
Memory and FSIQ and IPS. 
 
7.3.4 Data analysis 
 
Psychometric test scores were converted to scaled scores to standardise the data across 
age groups according to the standard Wechsler administration instructions. 
 
The metabolite values were estimated post-hoc using LCModel (Provencher, 2001). This 
software provides spectral quantification and metabolite detection optimised for short 
echo time spectroscopy. All analyses reported here adopt the standard convention of 
expressing NAA as a ratio to creatine (NAA/Cr). 
 
7.4 Results 
 
7.4.1 Summary spectroscopy data and data screening 
 
Ross, Jacobson et al. (1994) suggested quantitative criteria that enable prediction of 
SHE with MR spectroscopic data, whereby SHE is considered present when the mI/Cr 
and Cho/Cr ratios are less than 2SD below normal, with or without a Glx/Cr ratio more 
than 1SD above normal, where ‘normal’ was defined as metabolite values obtained in a 
sample of 12 sibling controls. Therefore, to adequately detect potential group 
differences in neurometabolite values, the stringent screening criteria applied to 
spectroscopic data in Chapter 6 (exclusion of data ±2SD) was not applied here. 
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Table 7-1 Descriptive data for the sibling control and liver disease groups with available psychometric and spectroscopy data
Group 
Total 
n 
Mean 
age 
(years) 
SD age 
(years) 
M:F n Diagnoses 
Sibling controls 11 12.2 5.08 5:6 
 
  
Early-onset liver 
disease, pre-
transplant 
13 13.1 5.0 8:5 
8 Extra-hepatic biliary atresia 
4 Progressive familial intrahepatic cholestasis 
    
1 Neonatal haemochromatosis 
Early-onset liver 
disease, post-
transplant 
5 16.2 3.0 3:2 
2 Progressive familial intrahepatic cholestasis 
2 Extra-hepatic biliary atresia 
1 Acute liver failure 
Acute liver 
failure, post-
transplant 
5 14.0 4.1 4:1 
1 Autoimmune hepatitis  
1 Fulminant hepatitis A infection 
3 Sero-negative hepatitis  
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Summary spectroscopy data for the sibling control group and the three individual 
patient groups (early-onset liver disease (EOLD) pre-transplant, EOLD post-transplant 
and acute liver failure (ALF) post-transplant) is shown in Table 7-2. 
 
 Table 7-2 Summary of spectroscopy data for paediatric liver disease patients vs sibling controls 
  
Sibling 
controls 
EOLD pre-
Tx 
EOLD 
post-Tx 
ALF 
post-Tx 
Mean age 12.7 13.8 16.2 14.0 
Mean age SD 4.90 4.97 2.95 4.01 
Occipitoparietal voxel 
N 11 13 5 5 
Mean Cho/Cr (SD) .23 (.05) .22 (.04) .25 (.02) .23 (.04) 
Mean NAA/Cr (SD) 1.61 (.84) 1.34 (.58) 1.60 (.33) 1.67 (.15) 
Mean mI/Cr (SD) .71 (.60) .69 (.21) .52 (.23) .70 (.07) 
Mean Glx/Cr (SD) 1.85 (.23) 2.35 (1.33) 2.05 (.24) 1.69 (.14) 
Frontal voxel 
N 10 11 5 5 
Mean Cho/Cr (SD) .25 (.07) .25 (.08) .18 (.13) .28 (.03) 
Mean NAA/Cr (SD) 1.58 (.13) 1.68 (.14) 1.02 (.71) 1.54 (.12) 
Mean mI/Cr (SD) .72 (.10) .71 (.38) 2.18 (3.36) .71 (.06) 
Mean Glx/Cr (SD) 1.95 (.21) 2.00 (.39) 9.99 (18.28) 1.90 (.21) 
Mean and standard deviations of metabolite values as ratios to creatine are shown for both frontal 
and occipitoparietal voxels. 
Frontal cortex data for one sibling control and two EOLD pre-Tx participants were excluded from 
analyses due to poor quality as a result of artefact induced by motion or non-neural tissues 
 
Mean metabolite ratios are largely consistent with those reported previously in adults 
and children (Danielsen and Ross, 1999; Ozturk, Degaonkar et al., 2009). Distributional 
normality of spectroscopy data cannot be assumed. As data from Chapter 6 showed, the 
procedures used for data screening and the suitability of statistical analysis strategy 
may critically underpin the validity of the findings obtained from a given study, a point 
particularly important here as outlier data were deliberately retained in the analyses. 
As with data from Chapter 6, the unscreened data did not 
consistently satisfy distributional assumptions of normality (evaluated with the 
Shapiro-Wilk statistic at an α level of .05), and as a consequence were analysed using 
non-parametric statistical techniques. 
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7.4.2 1H-MRS metabolite differences between patients and controls 
 
An Independent-samples Kruskall Wallis test showed no main effect of disease category 
on metabolite values. The significance values for each metabolite in both frontal and 
occipitoparietal cortex are shown in Table 7-3. 
 
Table 7-3 Differences in neurometabolite values between sibling 
controls and liver disease groups 
Metabolite 
Kruskall 
Wallis p 
value (3 df) 
Chi-square 
Frontal voxel 
Cho/Cr .563 2.05 
NAA/Cr .225 6.68 
mI/Cr .083 4.36 
Glx/Cr .838 .86 
Occipitoparietal voxel 
Cho/Cr .421 2.82 
NAA/Cr .094 2.12 
mI/Cr .549 6.39 
Glx/Cr .096 6.36 
Non-parametric Kruskall-Walllis test was used to assess differences 
in neurometabolites in both frontal and occipitoparietal cortex as the 
unscreened data did not conform to a normal distribution. 
 
Based on the mean values obtained in the sibling control cohort, none of the patients 
exceeded the diagnostic cut-offs established by Ross et al. (1994) in frontal cortex 
voxels (mI/Cr< .52 and Cho/Cr< .11, Glx> 2.16). The same is true of occipitoparietal, 
although frontal volumes were focused on due to their greater functional link to 
cognitive ability. Therefore, none of the patients in the present cohort could be 
diagnosed as having SHE using 1H-MRS data alone. 
 
Data illustrating the differences in neurometabolites according to disease category is 
shown for the frontal volume only (Figure 7-2 to Figure 7-5, pages 155 and 156) as this 
region is functionally related to the cognitive outcome measures of interest to a greater 
degree than the occipitoparietal cortex, a region which was used as a control. 
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Figure 7-2 Comparison of mean frontal cortex NAA/Cr values between control and liver disease 
groups 
Error bars represent ±1 standard error mean. EOLD post-Tx patients had lower NAA/Cr compared to the 
other three groups but this difference was not statistically significant. 
 
 
Figure 7-3 Comparison of mean frontal cortex Cho/Cr values between control and liver disease 
groups 
Error bars represent ±1 standard error mean. EOLD post-Tx patients had lower Cho/Cr compared to the 
other three groups but this difference was not statistically significant. 
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Figure 7-4 Comparison of mean frontal cortex mI/Cr values between control and liver disease 
groups 
 Error bars represent ±1 standard error mean. EOLD post-Tx patients had higher mI/Cr than the other 
three groups. The difference was not however statistically significant, an effect that can be attributed to 
the much greater variance in metabolite values in this patient group.  
 
 
Figure 7-5 Comparison of mean frontal cortex Glx/Cr values between control and liver disease 
groups 
Error bars represent ±1 standard error mean. EOLD post-transplant patients had higher Glx/Cr than the 
other three groups. The difference was not however statistically significant, an effect that can be 
attributed to the much greater variance in metabolite values in this patient group. 
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7.4.3 Inter-regional and gender differences in metabolite values 
 
A Related-samples Wilcoxon Signed-rank test was used to assess inter-regional 
differences in metabolite values across all groups. No significant differences in median 
NAA/Cr, mI/Cr or Glx/Cr were observed between frontal and occipitoparietal voxels 
(p= .83 .37 .05 respectively). Cho/Cr was significantly higher in frontal cortex than 
occipital cortex (p= .02). An Independent-samples Kruskall Wallis test showed no main 
effect of gender on metabolite values (p> .05). 
 
7.4.4 Relationships between 1H-MRS-detectable metabolites and 
cognitive ability 
 
The data from Chapter 4 showed that there were no significant differences between 
diagnostic groups for FSIQ. To supplement the findings in Chapter 6 for correlations (or 
lack of) between neurometabolites and cognitive variables in adults, the relationships 
between neurometabolites and cognitive ability were also assessed here. Analysis of the 
continuous relationships between MRS metabolites and cognitive variables across the 
entire cohort of 34 paediatric participants was justified as no statistically significant 
differences for metabolite values were observed between groups. 
 
Non-parametric correlation coefficients for the unscreened data (n= 34) showed 
that the relationships between IPS or FSIQ and Cho/Cr, NAA/Cr, mI/Cr and Glx/Cr were 
neither strong nor statistically significant at a Bonferroni-corrected α value of .003 
(.05/16 correlations).  
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Table 7-4 Correlations between neurometabolites in frontal cortex and IQ variables 
    Correlation with cognitive ability; r (p value) 
 
n FSIQ IPS PIQ VIQ 
Cho/Cr 29 .33 (.84) -.03 (.89) .39* (.04) .30 (.12) 
NAA/Cr 29 .10 (.61) -.06 (.77) .03 (.86) .14 (.46) 
mI/Cr 29 -.03 (.87) .19 (.34) .01 (.96) -.84 (.67) 
Glx/Cr 29 -.04 (.85) -.13 (.51) -.02 (.92) .12 (.54) 
Non-parametric Spearman’s Rho test was used to assess the relationship between 
neurometabolites and psychometric scores as the unscreened neurometabolite data did not 
conform to a normal distribution. 
*p< .05, but not statistically significant at Bonferroni-corrected α level of .003 
 
Screening of metabolite values to remove all univariate outliers (±2SD) results in the 
exclusion of data from six participants. Concentrations of the four metabolites of 
interest in the remaining sample of 28 were normally distributed when evaluated with 
the Shapiro-Wilk statistic at an α level of .05. However, no significant relationships 
between neurometabolite values and cognitive variables are observed when parametric 
(Pearson’s r) statistics are applied (p> .05). 
 
7.5 Discussion 
 
7.5.1 1H-MRS-detectable metabolites as biomarkers in paediatric 
liver disease 
 
1H-MRS is a valuable addition to existing neuroimaging methods for the study of brain 
development in humans and is able to provide in vivo biochemical information with 
potential diagnostic value. 1H-MRS was used in a cross-sectional study of a paediatric 
population to investigate whether children with liver disease have a neurometabolic 
pattern which differs from sibling controls in pattern association with subclinical 
hepatic encephalopathy. The most important finding of the present study was that there 
are no significant differences in metabolite concentrations, neither among the three 
groups of children with different stages of liver disease, nor between patients and age-
matched sibling control children. 
 
The findings of the present study are in contrast with previous studies of SHE in which 
two characteristic changes in 1H-MRS spectra are described: (1) an elevation of 
glutamine (Glx) peak, and (2) the reduction of the mI and choline peaks. The area under 
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each peak in the 1H-MRS spectra represents the relative concentration of nuclei 
detected for that particular molecule (see Chapter 3 for a detailed discussion), and is 
therefore reflective of the concentration of that metabolite in the tissue being assessed. 
The potential neuropathological changes associated with deviations in these particular 
metabolites in relation to liver disease has been almost exclusively observed in adults, 
and the mechanisms of action on cognitive outcomes in SHE are still largely unclear. 
 
7.5.1.1 Glx in liver disease 
 
The spectral peaks of glutamine and glutamate are often grouped together as Glx, 
because their spectral overlap makes it hard to resolve them adequately. Glutamine is 
easily detectable with 1H-MRS, whilst glutamate is the most abundant amino acid in the 
brain and is released by approximately 90% of excitatory neurons (Magistretti, Pellerin 
et al., 1999). The role of Glx in liver disease is open to speculation (Zwingmann and 
Butterworth, 2005), but the increase in Glx peaks seen on MR spectroscopy may be a 
result of excess ammonia taken up by the astrocytes, which then convert glutamate to 
glutamine. 
 
Ammonia metabolism is compromised by liver dysfunction and ammonia has 
consistently been shown to be important in the pathogenesis of HE (Lemberg and 
Fernández, 2009). Excessive ammonia is toxic to the CNS and can, for example, inhibit 
excitatory post-synaptic potentials, thereby producing a general depression of CNS 
function. In a small group of children with clinically suspected SHE, Foerster, Conklin et 
al. (2009) observed a positive significant correlation between grey matter Glx and 
ammonia levels (r= .66). Astrocytes are the site of ammonia detoxification in the brain 
and they eliminate ammonia by the synthesis of glutamine through amidation of 
glutamate. Accumulation of glutamine in astrocytes induced by hyperammonemia 
produces osmotic stress and astrocyte swelling (Häussinger, Kircheis et al., 2000). In 
the present study, however, elevated levels of Glx were not seen in the patient cohort 
compared to sibling controls, nor were 1H-MRS values representative of these 
metabolites correlated with cognitive function. 
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7.5.1.2 mI in liver disease 
 
A decrease in the concentration of brain organic osmolytes such as mI indicates the 
activation of the process of regulatory volume decrease of astrocytes. In response to 
elevated intracellular levels of glutamine resulting from excess ammonia, the astrocyte 
swelling hypothesis predicts that homeostatic mechanisms occur to limit the osmotic 
load in astrocytes, leading to the extracellular release of mI (Häussinger, Kircheis et al., 
2000). MR studies in SHE have provided important in vivo data, which have contributed 
to the current theories on astrocyte swelling (Häussinger, Kircheis et al., 2000). Ross, 
Jacobson et al. (1994) report that decrease in mI levels may be the central derangement 
in chronic HE, with grey and white matter mI levels proving the best predictors of mild 
HE, but no significant difference between patients and controls were observed in the 
present study. 
 
7.5.1.3 Choline in liver disease 
 
The choline resonance contains contributions from phosphocholine and 
glycerophosphorylcholine, both of which are cell membrane precursor and degradation 
products (Vereb, Szollosi et al., 2003). The characteristic reduction of choline in SHE, 
which was not observed in this present study, is likely to reflect choline’s importance in 
brain metabolism (Zeisel, 2000; Zeisel, 2004), specifically through alterations in 
phospholipid metabolism, membrane fluidity, or secondary changes in water content 
due to the osmolytic effects of choline. 
 
7.5.1.4 NAA in liver disease 
 
NAA provides a surrogate marker for the health and viability of neural tissue (Barker, 
2001; Moffett et al., 2007). NAA concentrations in white matter reflect the metabolic 
function of axons as well as the extent and efficiency of their myelination (Bjartmar et 
al., 2002). In comparison to the 1H-MRS detectable neurometabolites, it appears that 
neuronal loss and degeneration, as indexed by NAA, is largely unaffected in SHE, at least 
in adults (Binesh, Huda et al., 2005; Huda, Guze et al., 1998; Thomas, Huda et al., 1998). 
In a single, small study in children, Tkac, Hamernick et al. (2004) observed a reduction 
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of NAA/Cr in pre-transplant patients compared to sibling controls. However, to a large 
extent NAA has been overlooked as SHE does not seem to be associated with a loss of 
neurons or the reduced integrity of myelin. 
 
In the present study, although no significant inter-group differences were observed, 
there was an interesting pattern of results for the early-onset post transplant group. 
Frontal cortex NAA/Cr and Cho/Cr showed a trend toward reduced values compared to 
sibling controls (see Table 7-2, page 153), (d)= 1.33 (see Figure 7-2, page 155) and 1.55 
(see Figure 7-3, page 155, respectively. In addition, greater degree of variability in mI 
and Glx was observed in this group compared to the others (see Table 7-2 and, Figure 
7-4 and Figure 7-5 for illustration). The range in metabolite values, particularly of Glx 
(see Figure 7-4, page 156), are important, because variation in metabolite values must 
be significantly higher than the precision of the MRS measurement (approximately 9%, 
see Chapter 3) before metabolite values can be confidently interpreted as a true 
reflection of biological variation in SHE.  
 
In four paediatric post-transplant patients, Tkac, Hamernick et al. (2004) observed a 
regularisation in SHE markers that were previously abnormal. They noted, however, 
that the post-transplant concentration of glutamine specifically remained significantly 
higher compared to the normal adult brain, therefore indicating a slower than expected 
reversal of the effects of liver hypo-function on cerebral metabolic function, as 
detectable by 1H-MRS. However, given the small sample size of both the patient and 
sibling control group and the lack of plausible explanation for reduced NAA/Cr in the 
context of liver disease, these findings must be interpreted with caution as the 
generality of the effects of liver disease are unknown. 
 
7.5.2 The potential for age-related changes to mask disease-related 
effects 
 
Foerster, Conklin et al. (2009) suggest that children with clinically suspected mild HE 
have changes in metabolic profiles of mI and Glx which are similar to adults. However, 
they make this claim without reference to age-matched control data for their cohort of 
12 children, which they did not collect given ethical concerns about MR on small 
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children. The lack of a large database of normative age-matched data makes it extremely 
difficult to assess the true strength of disease-associated metabolite changes in 
childhood and is an important limitation for assessing the contribution 1H-MRS as a 
diagnostic tool. 
 
Two years of age marks a major landmark in brain development. The appearance of 
brain structures is similar to that of adults; the brain close to 80% of its adult weight, 
and all the major fibre tracts are identifiable by age three (Matsuzawa, Matsui et al., 
2001). Levels of 1H-MRS-detectable metabolites that may index various aspects of 
neurological development vary by anatomic region and have been shown to change 
nonlinearly with age. Metabolite changes, particularly for choline, mI and NAA, continue 
rapidly through the first year or so (Huppi, Fusch et al., 1995; Kimura, Fujii et al., 1995; 
Kreis, Ernst et al., 1993; Kreis, Hofmann et al., 2002; Pouwels, Brockmann et al., 1999; 
van der Knaap, van der Grond et al., 1990; Vigneron, Barkovich et al., 2001). 
Maturational changes of Glx are underreported in the literature due to their multiplet 
visibility and overlapping resonances of the two individual metabolites. 
 
An age-dependent increase of the total concentration of NAA in cerebral grey and white 
matter with normal brain development has been found predominantly during the first 
three years of life (Huppi, Fusch et al., 1995; Huppi, Posse et al., 1991; Pouwels, 
Brockmann et al., 1999). Since there is no major increase in the number of neurons after 
birth, this increase in NAA concentration must be related to other processes of 
neurological maturation, such as the proliferation of dendritic arborisations, synaptic 
connectivity and axonal myelination (Kato, Nishina et al., 1997). 
 
Several of the studies investigating newborns (Cady, Penrice et al., 1996; Huppi, Posse 
et al., 1991; Kreis, Ernst et al., 1993) have demonstrated decreases in choline with age, 
particularly in the first year. During later childhood and adolescence, choline remains at 
a constant adult level and therefore exhibits the same regional distribution as described 
for adults (Pouwels and Frahm, 1998). mI has been observed as the dominant peak in 
the 1H-MRS spectra at birth (Kreis, Ernst et al., 1993). 
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A few of the limited number of studies measuring maturational changes in mI have 
described subsequent decreases of mI during the first year of life and a continuing 
marked reduction of the metabolite up to the age of two (Huppi, Fusch et al., 1995; 
Kreis, Ernst et al., 1993). Whilst the majority of metabolite changes are apparent in 
neonates and infancy, they continue, but to a lesser degree, through adolescence 
(Horska, Kaufmann et al., 2002). Whilst explanations of the observed changes in 1H-
MRS-detectable neurometabolites are still largely a matter of debate, it is clear that they 
are related to maturational processes in the brain. 
 
A Spearman’s Rho tests for the relationship between non-normally distributed 
spectroscopy data and age in the healthy cohort of 11 showed no significant 
correlations for NAA, Cho or Glx in either frontal or occipitoparietal regions. 
Occipitoparietal mI was, however, strongly negatively correlated with age (r= -.68, p= 
.02). Pouwels et al. found that mI concentrations across the thalamus, basal ganglia and 
grey matter regions remain largely constant with age, but that mI in the cerebellum 
decreases from its highest value during early development by approximately 30% 
toward adolescence and adulthood (Pouwels, Brockmann et al., 1999). 
 
However, as other work has found no age-dependant change of mI in the cerebellum or 
any other region (Huppi, Posse et al., 1991), the interpretation of the non-parametric 
correlation between age and occipitoparietal mI/Cr values in this small healthy cohort 
requires cautious interpretation. This caution is further justified by further analysis, 
which showed that the non-parametric correlation between occipitoparietal mI and age 
became non-significant when assessed across the entire cohort of 34 (which is 
theoretically justified as no group differences were observed); r= -.31, p= .84. All other 
correlations between metabolites and age also remained non-significant (p> .05). It is 
also important to recognise simple linear regression analyses may mask non-linear 
relationships between age and neurometabolite values, but much greater numbers of 
participants are required in order to adequately investigate these potentially subtle 
associations.  
 
A deeper understanding of the changes in normal brain development is crucial prior to 
the application of 1H-MRS to the study of pathological conditions. Given the immaturity 
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of the brain at birth and its rapid postnatal development to approximate adult 
structures, such normative data needs to be age-matched and referenced. More studies 
of large populations, in well-defined clinical settings, are required in order to confirm 
and extend current findings from existing longitudinal and cross-sectional studies and 
determine if in vivo 1H-MRS can provide independent diagnostic and prognostic indices 
of liver disease. 
 
7.5.3 1H-MRS-detectable metabolites and cognitive ability in 
paediatric liver disease 
 
Non-parametric correlation coefficients for the unscreened data (n=34) showed that the 
relationships between IPS or FSIQ and Cho/Cr, NAA/Cr, mI/Cr and Glx/Cr were neither 
strong, nor statistically significant at a Bonferroni-corrected α level of .003 (see Table 
7-4, page 1588). Analysis of the FSIQ sub-scores shows a moderate statistically 
significant correlation between frontal Cho/Cr and Performance IQ scores at an 
uncorrected α level of .05 (r= . 39, p= .037; see Table 7-4)). Taken as a whole however, 
and when using strictly appropriate statistical analyses, the results of the present study 
indicate that there is no correlation between the concentrations of brain metabolites 
and the developmental achievement of the child. 
 
Others have observed relationships between SHE markers and cognitive performance. 
In a group of 17 patients diagnosed with SHE, Thomas, Huda et al. (1998) observed that 
performance on the Frontal Index (measured by performance on the assessments 
including the Colour Trails task, Rey-Osterreith and Digit Symbol subtests) was strongly 
correlated to baseline mI/Cr levels; patients with the lowest levels of mI/Cr were the 
most seriously impaired (r= .67, n= 17, p< 01). mI also correlated with Motor and 
Memory Indexes (r= .24), but the results were not statistically significant in their 
relatively small sample. This correlation with Frontal Index has also been observed by 
Huda, Guze et al. (1998), with Binesh, Huda et al. (2005) also finding a positive 
correlation between mI and motor speed and dexterity (r= .54). 
 
The role of ammonia in cognitive deficits associated with SHE also appears to be 
important. Both Thomas, Huda et al. (1998) and Huda, Guze et al. (1998) found that 
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baseline blood ammonia levels are associated with lower performance on cognitive 
measures. However, both studies also found that neither Glx, nor Cho/Cr, were 
correlated with cognitive measures. In a group of 30 post-liver transplant children, 
Gilmour, Adkins et al. (2009) observed a strong correlations between PIQ measures and 
pre-transplant growth retardation and elevated serum ammonia (r= .45). 
 
In support of ammonia as the potential link between cognitive ability and brain 
metabolism in SHE, Foerster, Conklin et al. (2009) found that that changes in choline 
and Glx within their patient group were proportional to biochemical markers of HE, 
including plasma ammonia level and the ratio of branched-chain to aromatic amino 
acids. However, as discussed earlier, no sibling controls were studied for comparison. 
Foerster et al.’s recent study is one of the few, along with Tkac, Hamernick et al. (2004), 
that employed 1H-MRS in children with liver disease, an indication of the relative 
paucity of 1H-MRS applications. 
 
The results of the present study also show that the putative neuronal viability marker, 
NAA, commonly overlooked in studies of SHE, does not provide a biomarker of 
intellectual performance per se. In the evaluation of a child with liver disease, one might 
encounter normal, low or even elevated concentrations of NAA in the brain. 
 
Pre and post-transplant data from children (Tkac, Hamernick et al., 2004) and adults 
(Thomas, Huda et al., 1998) and the limited studies investigating cognitive ability 
(Binesh, Huda et al., 2005; Huda, Guze et al., 1998; Thomas, Huda et al., 1998), suggest 
that the metabolite changes are not insignificant correlates of SHE and may reflect 
metabolism related to cerebral dysfunction. The relative reductions of NAA and choline, 
and greater variation in mI and Glx in the early-onset post transplant patients in the 
present study (see Figures 7-2 to 7-5), in parallel with specific deficits in IPS in this 
group (Chapter 3), is worthy of note and certainly motivates further investigations of 
MRS is paediatric liver disease patients. 
 
However, the concerns raised by Moss, Tarter et al. (1992), in relation to cognitive 
function and SHE assessed with serum liver function tests, apply just as well to 
spectroscopic studies: the heterogeneity of the subjects studied with respect to age, 
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gender, socioeconomic status, hepatic diagnosis and disease severity, as well as other 
intra- or extra-hepatic pathologic mechanisms (e.g. fatty acid deprivation, alterations in 
membrane fluidity or aberrant amino acid metabolism), are likely to have contributed 
to the substantial variability in the relationships between metabolites and cognitive 
ability observed by others, or lack of relationships in the case of the present cohort. In 
terms of MRS specifically, many of the issues that trouble the work in sibling controls, 
which are discussed in Chapter 6, apply here. Issues of data analysis, metabolite 
quantification, voxel placement and the like, are compounded further in clinical studies, 
where studies are necessarily fewer and with smaller cohorts. 
 
7.6 Conclusion 
 
The consistency of the metabolites observed between the patient and sibling control  
suggests that neurodevelopment, as assessed by selective 1H-MRS-detectable 
neurometabolite biomarkers, is ostensibly normal in this clinical cohort.  
 
Early detection of alterations in brain metabolites may be helpful in mitigating the 
neurocognitive declines seen in some children with liver disease. Whilst the present 
findings do not confirm the specific pattern of metabolite changes typically seen in 
healthy adults in other studies of this kind, they add to the small, but important and 
growing, body of studies neuroimaging neurometabolism with MRS children. 
 
MRS holds promise as a screening tool for biomarkers in liver disease because of the 
increased precision gained through using continuous measures rather than ordinal or 
categorical ones. It has the potential to become an alternative to neuropsychological test 
batteries for the assessment of the clinical manifestations of liver disease, and 
potentially allow tracking of the patient’s response to clinical interventions designed to 
minimise the progression of their disease. However, the use of 1H-MRS is still largely 
exploratory and what is currently missing is careful quantification, age-specific, 
reproducible, studies in newborns, infants, children and adolescents to provide context 
for the clinical data. 
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8 Discussion and conclusions 
 
8.1 Introduction 
 
Using a multi-modal approach, the present set of studies aimed to develop and refine 
analytic tools for biochemical assays, for use with both adult and paediatric populations. 
The main aim was to investigate some of the potential biochemical underpinnings of 
cognition, relating neural, systemic and behavioural levels of analysis. 
 
Chapter 1 introduced the approaches employed to studying the biological bases of 
individual variation in cognitive ability and the utility of the converging methods 
approach to clarify biological mechanisms which account for differences in 
psychometric test performance. Chapter 2 described the nature of EFA metabolites and 
their importance and function in neural tissue, highlighting that the effects of fatty acids 
are multifactorial and are specific to individual classes of fatty acid. EFAs and their 
PUFA metabolites have important roles not only at the membrane level, primarily 
through their influence in phospholipid cell membrane fluidity, but also through their 
involvement in inflammatory processes. Both of these roles may be important in 
understanding the modulatory role of fatty acids on cognition in health and in disease. 
 
Animal dietary deprivation models have demonstrated that chronic deficiency in EFAs, 
particularly in early neurodevelopment, is associated with significant cognitive 
impairment including deficits in memory and learning. Observational studies of 
breastfeeding versus formula feeding and randomised controlled trials comparing 
children fed formulas either supplemented or unsupplemented with EFAs and/or 
PUFAs are the common methods for investigating the cognitive effects of EFAs in human 
children. Whilst the data is not unequivocal, infants who receive formula milk, as 
opposed to breast milk which is naturally high in EFAs, suffer cognitive impairments 
including slower processing speed and lower general IQ. Supplementation with high 
levels of EFAs has been found to ameliorate some of these cognitive deficits, which are 
commonly assessed using the Mental and Psychomotor Development Indices of the 
Bayley Scales of Infant Development. 
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Disease models provide a useful paradigm for studying the cognitive deficits associated 
with suboptimal EFA levels in children. Intervention studies where EFA deficiency is 
induced are precluded by ethical considerations, such as the potential effects of long-
term dietary restriction. In the present study, a paediatric liver disease model was used 
to answer questions of whether: 
 
1. Sub-optimal concentrations of EFAs, as a result of fat malabsorption or 
dependence on inadequate dietary sources, is associated with deficits in 
cognitive ability. 
2. 1H-MRS-detectable metabolites can provide surrogate markers of sub-clinical 
changes in neuronal viability. 
 
This investigation entailed four main bodies of work, three with the paediatric liver 
disease clinical population and one with a set of healthy adult controls. The specific 
convergent methods employed were described in Chapter 3. 
 
 Chapter 4 investigated cognitive outcomes in a group of paediatric patients with 
early-onset liver disease or acute liver failure compared to sibling controls using 
psychometric tests to assess the neuropsychological impact of the disease. 
 Chapter 5 assessed the range of EFA concentrations and deficiency biomarkers in 
erythrocytes in the patient and control groups and examined the relationship 
between current EFA status and cognitive outcomes. 
 Chapter 6 investigated the relationships between natural variations in 
neurometabolites assayed by 1H-MRS and cognitive ability in a healthy adult 
population. 
 Chapter 7 evaluated the potential of 1H-MRS to add information to the study of 
children with liver disease by revealing abnormalities in cerebral metabolism. 
 
The conclusions that can be drawn from the studies described in this thesis fall into two 
categories; those relating to the empirical results and their implications for the 
understanding of EFAs and 1H-MRS-detectable metabolites in cognition in general and 
paediatric liver disease in particular, and those concerned with the experimental 
techniques employed and the theoretical framework in which they are currently used. 
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The following discusses the issues and limitations of 1H-MRS and GC-MS methods, 
followed by examples of directions of research motivated the present studies and 
concluding remarks. 
 
8.2 Key findings of the present studies 
 
In the following discussion, mutually informative studies have been grouped together. 
Cognitive outcomes (Chapter 4) will be discussed in the context of EFA status (Chapter 
5), followed by discussion of the 1H-MRS studies in sibling controls and the paediatric 
liver disease patients (Chapters 6 and 7). 
 
8.2.1 Studies 1 and 2: Cognitive outcomes and EFA status in 
paediatric liver disease 
 
In the first set of analyses the effects of chronic liver disease on cognitive outcomes as 
assessed with age-appropriate, standardised assessments of verbal and nonverbal 
cognitive skills were investigated. Liver disease appears to have significant negative 
effects on specific aspects of cognitive development, with age at the onset of disease an 
important moderator of these effects. Whilst no significant deficit was observed in FSIQ 
between disease groups, significant differences were observed between the early onset, 
post-transplant group and age-matched sibling controls on a measure of IPS, with 31% 
of the variance in IPS explained by the effects of onset of liver disease coupled with 
transplantation. 
 
The dissociation in results the between pre and post-transplant early-onset patients 
may be explained by the fact that the transplanted patients were those that were 
suffering the most severe effect of liver disease, which would therefore precipitate the 
most significant disturbances to normal development. This finding is in accordance with 
the literature, which has shown that earlier onset of liver disease is associated with a 
greater degree of cognitive deficits (Stewart, Campbell et al., 1992; Stewart, Uauy et al., 
1988; Stewart, Uauy et al., 1989), and is in keeping with the hypothesis that potential 
disturbances in the early stages of neurodevelopment as a result of liver disease 
precipitate demonstrable deficits in cognitive ability later in life. 
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Disturbances in EFA status, due to dietary deficiency resulting from dependence on 
artificial nutritional feeds and/or malabsorption due to the specific deficits in liver 
function and lipid metabolism, was hypothesised to be one the mechanisms that 
contributed to cognitive deficits observed in patients with early-onset liver disease. 
Compared to sibling controls, no signs of fatty acid deficiency, indexed by EFA status 
biomarkers in erythrocyte membranes, were observed in any of the cohorts of patients 
with liver disease. If the acquired biomarkers are accurate, this suggests that: (1) these 
patients were not deficient in their dietary intake of the EFAs, LA and ALA at least in the 
three months prior to the participation in the study; and (2) these patients are able to 
sufficiently metabolise these precursor lipids to synthesise the LCPUFAs, DHA and EPA, 
to levels comparable to sibling controls.  
 
Whilst the biomarkers indicate that the patients were not deficient in their current 
dietary intake, measures of actual dietary intake would provide useful context for the 
biomarkers detected in red cell membranes actual and help clarify potential 
dissociations between intake and metabolism. Dietary intake data was available for a 
limited number of patients recruited into the study (Appendix A, Table A, page 2076), 
but analysis of this incomplete set of data may not have been particularly informative. 
 
The findings of these two studies have important implications in the treatment of 
patients with liver disease. With respect to clinical outcomes, there is increasing 
support for the use of omega-3 fatty acids in the treatment of liver disease, particularly 
parenteral nutrition associated liver disease (PNALD) (Diamond, Sterescu et al., 2008; 
Koletzko and Goulet, 2010). Fish-oil based PN feeds have, for example, been associated 
with the reversal of cholestasis and fatal liver disease compared to soya-based feeds, 
which lack appreciable levels of PUFAs (Gura, Lee et al., 2008). 
 
The results of the present study suggest that early-onset patients, particularly those 
who are most ill and therefore require transplant, are those that may benefit from PUFA 
supplementation in early infancy. Phenylketonuria (PKU) is an inborn error of amino 
acid metabolism that precludes natural protein in a diet that is also typically DHA 
deficient and provides an analogous model to the one adopted in the present study. 
Whilst severe neurological damage is completely prevented in PKU-affected individuals 
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by adequate dietary management, in patients aged from 1 to 11, Koletzko, Beblo et al., 
(2009) observed that PKU patients showed slower visual evoked potentials, a measure 
of processing speed, compared to controls. These effects were ameliorated with 3 
months of high-dose omega-3 supplementation. 
 
The results from studies of PKU and PNALD patients provides rationale and motivation 
for better dietary management and prospective supplementation interventions in early-
onset patients with the aim of normalising the deficits in processing speed potentiated 
by suboptimal EFA status in early development. The acute liver failure patients, whose 
liver disease developed after the critical perinatal stage, showed no signs of cognitive 
deficit as a result of EFA deficiency, and may not therefore require specific EFA 
supplementation to achieve normal developmental outcomes. 
 
However, support for the use of PUFA supplementation must be tempered by the fact 
that the data on EFAs and cognitive outcomes is still largely exploratory. Studies of the 
effects of EFA supplementation on cognitive outcomes in children older than two years 
of age are severely limited in number (Eilander, Hundscheid et al., 2007), and have not 
consistently found positive ameliorative effects of supplementation (Gadoth, 2008). 
McCann and Ames (2005) stressed that the effects of omega-3s such as DHA may be 
overstated, because even in randomised controlled trials formulas are typically 
supplemented with other LCPUFAs, particularly AA, in addition to DHA. This confers an 
inherent lack of specificity and means that these studies are not therefore able to 
attribute significant effects to the presence of omega-3 fatty acids only. 
 
In the present study the hypothesis that current levels of omega-3 fatty acids would 
correlate strongly with cognitive performance was not confirmed. The biomarker for 
omega-3 status (comprised of the sum of EPA and DHA, putatively the most important 
LCPUFAs), did not correlate significantly with FSIQ or IPS performance (r= .03 and .20; 
p> .05). The omega-6 index (comprised of the percentage total of LA and ALA) was 
significantly negatively correlated with FSIQ (r= -.62; p< .001; see Figure 5-2 , page 96) 
and showed a trend correlation with IPS (r= -.39; see Figure 5-3, page 96). 
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EFAs are known to modify several important physiological features of neurons such as: 
membrane fluidity; the action of membrane bound enzymes, receptors and ion 
channels; production and activity of neurotransmitters; and signal transduction, which 
controls the activity of neurotransmitters and neuronal growth factors. There are two 
mechanisms of these effects: (1) a long-term action on the composition and functioning 
of the membranes; and (2) a short-term action that would involve the metabolism of 
phospholipids (with subsequent modulation of signal transduction) and the action of 
EFA-derived metabolites such as eicosanoids.  
 
The biomarkers of EFA status assessed in this study reflect intake and metabolism of 
EFAs over the preceding 3 months. That such a relatively transient measure is highly 
correlated with FSIQ (see Figure 5-2, page 96), which is ostensibly extremely stable 
over time, is worthy of note and implicates to a long-term moderator of EFA status. One 
such mechanism could be the recently identified genetic component of fatty acid 
metabolism, which is discussed in further detail as a future direction of research in 
section 8.5.2. 
 
8.2.2 Studies 3 and 4: Cognitive spectroscopy and the utility of 1H-
MRS biomarkers of paediatric liver disease 
 
The use of 1H-MRS in cognitive research is still largely exploratory, so before applying 
these measures in a clinical paediatric cohort, a study was undertaken to establish the 
strength of relationships between neurometabolites and cognitive variables in a cohort 
of 38 healthy young adults. Whilst the correlations observed between 1H-MRS 
detectable neurometabolites and IQ in the present study were within the range 
reported in the literature, the magnitude of these effects were dependent upon the 
extent to which outlying values were accounted for in statistical analyses (Chapter 6). 
 
Coupled with the range of effect sizes reported in the literature, is substantial 
methodological variability between studies. Differences such as the age of participants, 
the cortical regions investigated, the 1H-MRS acquisition parameters used and the 
cognitive skills targeted, pose a significant challenge for drawing inferences about the 
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strength of the relationship between neurometabolites obtained with proton 
spectroscopy and IQ variables at the population level. 
 
The final study (Chapter 7) evaluated the extent to which 1H-MRS can add information 
to the study of children with liver disease by revealing abnormalities in cerebral 
metabolism. A specific pattern of neurometabolite changes, specifically a decrease in 
choline and mI and increase in Glx, has been previously observed in adult and paediatric 
samples (Atkison, Ross et al., 2002; Kreis, Ross et al., 1992; Taylor-Robinson, Sargentoni 
et al., 1994b; Tkac, Hamernick et al., 2004). However, in this study, neither significant 
differences were observed in metabolite concentrations among the three groups of 
children with liver disease (early onset, pre-transplant, early onset, post-transplant and 
acute liver failure, post transplant), nor between these patients and sibling control 
children matched for age. 
 
The consistency of the metabolite values observed in the patients and control groups 
(Table 6-2, page 130) suggests that neurodevelopment, assayed by surrogate 
neurometabolite markers, is normal in this cohort, and that: (1) deviant 
neurometabolism, indexed by the particular set of 1H-MRS metabolites studied, is not 
the mechanism which explains deficits in processing speed seen in early-onset patients; 
(2) relations between neurometabolites and cognitive outcomes may be masked by 
other effects. The heterogeneity of the subjects studied with respect to age, gender, 
socioeconomic status, hepatic diagnosis and disease severity, as well as other intra- or 
extra-hepatic pathologic mechanisms (e.g. fatty acid deprivation, alterations in 
membrane fluidity or aberrant amino acid metabolism), are likely to have contributed 
to the substantial variability in the relationships between metabolites and cognitive 
ability observed by others, or lack of relationships in the case of the present cohort; (3) 
the cohort studied were not sufficiently compromised with respect to hepatic function 
for the previously reported pattern of neurometabolite changes to be precipitated. 
Participation in the current study required approval from the patient’s consultant. For 
five patients hospitalised while awaiting transplantation it was judged that they would 
not to be able to tolerate an MRS scan, which means that the most severe cases of liver 
failure were not included in this study for ethical and practical reasons. 
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8.3 Recommendations for future studies  
 
Based on the findings from the present set of studies and examination of the current 
state of the literature, three sets of specific recommendations are suggested to move the 
field forward. 
 
8.3.1 Implementation and reporting of data screening 
 
The first set of recommendations pertains to the reporting of data screening procedures 
and appropriate use of statistical analysis, particularly in 1H-MRS studies where there is 
considerable variability between studies. Neurometabolite data obtained from normal 
populations cannot be assumed to be normally distributed and given that inappropriate 
use of parametric statistics on non-normal data can lead to errors in data interpretation, 
it is recommended that a concerted effort should be made to make explicit the extent of 
data screening employed in future studies. 
 
8.3.2 Hypothesis-driven enquiry 
 
The second set of recommendations concerns the framework in which studies are 
performed. To date, the substantial number of variables (EFA biomarkers or 1H-MRS-
detectable neurometabolites) under investigation, coupled with a lack of specifically 
identified a priori research hypotheses, renders the typical study susceptible 
to inflated Type 1 error resulting from the large number of statistical comparisons 
employed. The methodological approach to data analytic strategy in future studies 
should be directly informed by the a priori hypotheses adopted as this will govern the 
choice and range of psychometric, EFA and spectroscopy measures and how these are 
treated in the analyses, minimising over-extrapolation of the data. 
 
8.3.3 The need for normative data 
 
In placing the clinical findings of the present study in context, it was stressed in Chapter 
7 that the lack of a large database of normative age-matched data makes it difficult to 
assess the true strength of disease-associated metabolite changes in childhood and  
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is an important limitation for assessing the contribution 1H-MRS as a diagnostic tool.  
An understanding of the changes that take place in normal brain development is crucial 
prior to the application of 1H-MRS in the study of pathological conditions, particularly 
given the demonstration of regionally specific, non-linear changes in metabolite 
concentrations, particularly in the first two years of life (Kreis, Ernst et al., 1993; 
Pouwels, Brockmann et al., 1999).  
 
The diagnostic criteria for neurometabolite values in SHE, suggested by Ross, Jacobson 
et al. (1994), which were based on normative data derived from an ostensibly normal 
group of 12 adults, were used in the present study. Whilst these data provide useful 
guidelines, the value of the data is limited by the lack of sufficient sample sizes and at 
various ages, which would provide wider context for abnormal changes, particularly in 
paediatric populations. 
 
Within the MRS community, there needs to be a concerted effort to follow the precedent 
set by the National Institute of Mental Health’s Pediatric Brain Imaging Project (Lenroot 
and Giedd, 2007) to create a database of developmental MRS data across the lifespan, 
comparable to that created by the project for anatomical MRI data. 
 
8.4 Methodological considerations and limitations in the 
present study 
 
8.4.1 Fatty acid analytic methods 
 
The application of conventional GCMS procedures to analysis of biological samples is 
disadvantaged by the high risk of contamination and recovery losses in multi-step 
procedures. Furthermore, these methods are impractical for analysing large series of 
samples, especially when the quantities of biological samples are limited. To overcome 
these disadvantages and owing to the time-intensive nature of GC, other studies have 
used alternative techniques such as High Performance Liquid Chromatography (HPLC) 
or Liquid Chromatography-Mass Spectrometry (LC-MS) (Peterson and Cummings, 
2006). Additionally, Thin Layer Chromatography (TLC), described in detail by Christie 
(1982), allows for quantification of fatty acids in individual phospholipids, for example 
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phosphatidylcholine or phosphatidylinositol, providing not only a quantitative measure 
of total fatty acids, but also where in the lipid membrane these fatty acids are located, 
further helping clarify their functional roles. 
 
Methods that combine extraction and derivitisation in a single step have been 
developed to provide higher resolving power and enable less abundant fatty acids to be 
detected. These include fast gas chromatography (Bondia-Pons, Castellote et al., 2004; 
Mondello, Casilli et al., 2004) and the use of a direct thermal desorption interface to 
profile the fatty acid composition of human plasma and whole human blood (Akoto, 
Vreuls et al., 2008). New optimised methods have been also devised that can profile 
lipids small quantity (i.e. fingertip (50l) blood samples), with the ability to detect 100 
fatty acids and related compounds (Bicalho, David et al., 2008). These methods provide 
the opportunity to develop an efficient and readily achievable database for large fatty 
acid methyl esters database from small, easily obtainable samples. Application of the 
analytic methods described above were beyond the scope and remit of the present 
study, but are worth considering in the broader scheme of its aims, particularly in the 
context of being able to easily create a databank of normative erythrocyte EFA data. 
 
8.4.2 Paediatric 1H-MRS 
 
A persistent and inherent problem in paediatric MRI is the difficulty involved with 
determining the histological correlates of the various tissue classes that are assigned as 
cortical ‘grey,’ ‘unmyelinated white,’ ‘myelinated white’ and ‘cerebrospinal fluid’. The 
ability to discriminate and measure different brain tissues is provided by the image 
contrast: the degree of the ‘white’ appearance of myelinated tissue, compared with the 
‘grey’ of the adjacent cortical grey matter. Tissue contrast in infant MRI scans differs 
from scans obtained in later childhood, primarily because of the higher water content 
and lower myelin deposition in infant brains (Barkovich, Kjos et al., 1988; Paus, Collins 
et al., 2001). Accurate localisation of a voxel to a specific anatomic location without 
spectral contamination from adjacent tissues is especially difficult in infant populations 
as their small brain size makes it difficult to sample homogenous regions of cortical 
tissue. 
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The extent to which MRS samples grey or white matter can modulate the metabolite 
values obtained (Wiedermann, Schuff et al., 2001). In the present study, frontal and 
occipitoparietal white matter was assessed by positioning the voxel so as to maximise 
sampling of white matter and minimise grey matter content. Whilst tissue 
compartmentation can be performed post hoc, the MRS spectra is principally an average 
over all tissue types that occur within the volume at the time of sampling, which for 
neural tissues includes glial and neuronal cells, and with different extracellular spacing 
depending on the amount of white matter, grey matter or cerebrospinal fluid the 
volume of interest contains. 
 
Smaller voxel sizes may aid in reducing the inhomogeniety of the sampled tissue, but 
decreasing voxel size leads to a corresponding decrease in the SNR of the MR signal 
(Freeman, 2003). Issues of tissue inhomogeniety and SNR can, in part, be overcome by 
multi-voxel techniques like chemical shift imaging (CSI), which acquires multiple 
spectra simultaneously from slices or volumes of the brain to form metabolite-specific 
images from the resulting peak-intensities. 
 
Discussion of the applications of MRS and the need for more normative data must also 
consider the associated limitations and hazards of MR techniques in order to ensure the 
method is safe (McKinley, Bouffler et al., 2008; Shellock and Kanal, 1994), particularly 
when considering paediatric populations (Peterson and Ment, 2001). The practical 
difficulties of functional MRI have been discussed previously (Logan, 1999); many, if not 
all, of the same issues apply to MRS. The obvious limitations for the general use of MRS 
are that it is still, in relative terms, very expensive and reliant on specialised medical 
physics support, and is therefore not commonly available outside principally clinical 
settings. 
 
MR methods also require a considerable degree of participant cooperation. This can be 
difficult to achieve with paediatric populations, where the unfamiliar environment of 
the scanner may induce anxiety. Immobility is also essential in order to minimise 
motion artefact and therefore sedation may be necessary for younger children. General 
anaesthesia undoubtedly allows MRI to be carried out in anxious or uncooperative 
children, but its use continues to be controversial and fraught with practical and ethical 
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complications (Lawson, 2000), and it may not be appropriate outside exclusively 
clinical settings. 
 
Foerster, Conklin et al. (2009) did not collect data from healthy controls in their study of 
paediatric HE over concerns of the ethics and practicalities of MR on small children. 1H-
MRS is entirely safe if strict standard operating procedures are followed (Kanal, 2004; 
Shellock and Kanal, 1994). Whilst MR of young populations is undoubtedly difficult, in 
the present work, MRS data was collected in 34 of 40 children (including 11 sibling 
controls, one as young as 2 years old). Only three patients were unable to tolerate the 
scanner procedure (with claustrophobia once in scanner bore cited as the principal 
factor). Data from a further three participants were removed because of poor quality 
spectra as a result of motion artefact or encroachment in the voxel of non-neural tissue.  
 
Successful scanning of young children in research settings is attributable to preparation 
with the child and guardian beforehand, and flexibility and patience with regards to 
scan sequences. As a part of the present study, an introductory video was developed 
that was aimed directly at the children and their guardians. The video provided a child-
centred guide to the MR process and environment in order to familiarise participants 
with the research prior to consent and participation in the study.  
 
In addition to issues of patient compliance, demands on scanner availability may 
preclude prolonged scan sessions. However, advances in MR technology are leading to 
progressively shortened scan times and allow acquisition of multiple spectra in a single 
occasion without the need for sedation. Compared with 1.5T, the improved SNR of 3T 
field strength adopted in the present studies shorted the total data acquisition time by a 
factor of 4 while maintaining a comparable SNR (Lin, An et al., 2003). 
 
Applications of MR technologies still tend to be technology-led and improvements in 
technical methodologies are central to further developments in achieving better control 
of artefacts, greater spatial resolution and allowing 1H-MRS to become progressively 
more quantitative within time-frames feasible for paediatric populations. With a large 
body of information on software, equipment, techniques, and activation results being 
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rapidly accumulated, cognitive-MRS studies should be easier to perform and the 
interpretation of the results more instructive in the future. 
 
8.5 Future directions 
 
A number of refinements to the methods and procedures employed and potential 
avenues of research motivated by the findings of the present work proposed. 
 
8.5.1 A neurophysiological measure of processing speed  
 
An alternative to behavioural paper-pencil or even computerised measures of 
processing speed is magnetoencephalography (MEG), a non-invasive neuroimaging tool 
that can tap processing speed at a neurophysiological level. By localising and 
characterising activity of the central nervous system through the measurement of the 
associated magnetic fields emanating from the brain, MEG is able to measure neural 
activity with millisecond precision. 
 
The temporal resolution of the auditory system is exquisite, with neural systems 
capable of sub-millisecond resolution in decoding features in the acoustic signal 
(Eggermont, 2001). Psychophysical measures of gap detection, where a silent gap is 
inserted in a tone or noise burst and the minimum detectable gap is measured, are in 
wide use as an objective method with which to evaluate auditory temporal acuity in 
both healthy and clinical populations (Eggermont, 2000; Eggermont, 2001) and may 
provide a useful endophenotype for developmental delay. 
 
As an adjunct to the present study, a small pilot investigation was conducted, with two 
sibling controls and two patients from the early onset, pre-transplant liver disease 
cohort, for the assessment of auditory-evoked field (AEF) responses in a gap detection 
task, in order to provide an efficient and objective index of auditory information 
processing in the human brain, with a view to use with young clinical populations. 
 
The findings from the pilot study were presented at the 2010 BIOMAG meeting (see 
Appendix B, page 215). Whilst a full discussion of the MEG data is beyond the scope of 
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this thesis, the findings of this pilot work is promising, as it is suggests a deficit in 
auditory temporal processing in patients compared to controls. Event-related fields 
(ERFs) afford the opportunity to acquire neural measures of auditory processing speed 
within a passive experimental paradigm in which children are not required to attend or 
respond to stimuli. The absence of confounds related to task compliance makes it 
possible to asses perceptual-level processing and makes this paradigm a particularly 
promising approach in the study of neurocognitive development and deficits in young, 
clinical populations. This paradigm offers a potential functional measure of processing 
speed at the neural level to complement biochemical data from 1H-MRS and the 
behavioural measures of psychometric tasks. 
 
8.5.2 The influence of genetic variation in fatty acid metabolism 
 
The Δ-5 and Δ-6 desaturase are the most important enzymes in the elongation and 
desaturation of EFA precursors (LA and ALA) to their long-chain PUFA metabolites 
(discussed in section 2.2, page 26; see Figure 2-4 and Figure 2-5, pages 29 and 30). 
Recent work suggests that there may be a strong genetic component to the fatty acid 
metabolism, with evidence of associations between single nucleotide polymorphisms 
(SNPs) in the two desaturase encoding genes (FADS1 and FADS2) and the concentration 
of omega-6 and omega-3 fatty acids (Lattka, Illig et al., 2010; Simopoulos, 2010). 
 
The action of the FADS gene variants influence the levels of both serum (Tanaka, Shen et 
al., 2009) and RBC membrane phospholipid levels (Rzehak, Heinrich et al., 2008) of 
EFAs. Variants in the FADS1 and FADS2 have a frequency of 26% and the minor alleles 
associated with lower AA and higher LA account for 28% of the variation in serum 
phospholipid AA and up to 12% of its precursor fatty acids (Simopoulos, 2010). 
 
The evidence gathered to date indicates that fats are systemically metabolised in 
different ways as a result of FADS gene variants, with a limited number of studies 
finding that this is associated with tangible changes in cognitive outcomes (Latta, Illig et 
al., 2010). Of particular relevance to the current study, Caspi, Williams et al. (2007) 
observed that IQ performance was higher in breastfed children compared with non-
breastfed children, and that there was an interaction between a specific SNP in the 
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FADS2 gene (rs 174575), breastfeeding and cognitive performance. The suggestion is 
that those children carrying one particular genotype benefit more from breast milk than 
children with a different genotype who neither gained an advantage from breastfeeding 
nor suffered a disadvantage from not being breastfed.  
 
Investigations into the influence of gene variants on EFA metabolism is an emerging 
field of research. Although this work is exploratory, if groups of fatty acids are 
differentially metabolised due to genetic variations, it is plausible that difference in EFA 
metabolism may lead to systemic changes in membrane EFA composition throughout 
the lifespan. Differences in EFA metabolism as a result of differences in FADS genes may, 
for example, explain the lack of association between breastfeeding and cognition 
observed by (Bakker, Ghys et al., 2003; Ghys, Bakker et al., 2002) in studies of early EFA 
status and cognitive outcomes. 
 
It may also explain the findings from the present study of negative associations between 
omega-6 fatty acids and FSIQ and IPS, as current fatty acid levels may be representative 
of long-term metabolism and utilisation. A speculative explanation for this finding may 
be that the long-term preferential metabolism and accumulation of omega-6 fatty acids 
by particular FADS gene variants may lead to displacement of important long-chain 
omega-3 PUFAs such as DHA and EPA in phospholipid membranes, leading to saturated, 
less fluid membranes, and other functional alterations as discussed in section 2.3. 
 
The incidence of allele variants of FADS1 and FADS2 and their impact on blood fatty 
acid levels and EFA utilisation may emerge as a productive area of research in 
contextualising the relationships between EFA status and cognitive outcomes. In terms 
of the wider study investigating the importance and potential deficiencies of EFAs in 
liver disease, identifying alleles associated with suboptimal EFA metabolism may be 
important, as these gene variants may exacerbate the potentially higher than normal 
requirements for these nutrients in patients with liver disease. 
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8.5.3 31Phosphorous spectroscopy 
 
Protons are in most cases the default nuclei for cognitive spectroscopy studies as 1H-
MRS uses the same hardware, such as head coils, as standard MRI. Observing nuclei 
other than protons requires the development of radio-frequency coils and other 
specialised hardware tuned to their specific frequencies and this has limited 
investigations in spectroscopy studies to only those neurometabolites with a high 
proportion of proton constituents. 
 
Phosphorous is an alternative nucleus that has particular relevance with the present 
study as 1H-MRS may not be the ideal tool for investigating choline-related metabolic 
developments in neuronal maturation.  
The normal phosphorous-MR spectrum of brain has seven major resonances (see Table 
8-1, page 183) Five of these; one from each of the three phosphates of ATP, one from 
phosphocreatine (a high energy buffer compound); and one from inorganic phosphate 
(a product of ATP breakdown), can be used as a measure intracellular inorganic 
phosphate (pHi), a surrogate marker of bioenergetics and metabolism (Erecinska, 
Stubbs et al., 1977). The two remaining major peaks, phosphodiester (PDE) and 
monoesters (PME), are in a complex way related to the 1H-MRS-detectable choline peak 
(Boulanger, Labelle et al., 2000). With proton nuclei, the biochemical interpretation of 
alterations in the MR-observed in vivo choline peak is complicated by the uncertainty in 
the metabolites contributing to the signal (see section 6.2.2, page 119). In neural tissue, 
choline is found primarily as membrane-bound phosphatidylcholine and also as a 
mixture of choline, phosphocholine and glycerophosphocholine in solution. 
 
PME and PDE reveal important information about neuronal cell membranes. 
Specifically, the PME resonance in 31P-MRS reflects membrane phospholipid anabolism 
as it includes the freely mobile precursors of membrane phospholipids such as 
phosphocholine and phosphoethanolamine. The PDE peak reflects membrane 
phospholipid catabolism as it contains contributions from breakdown products such as 
glycerophosphocholine and glycerophosphoethanolamine. It also contains 
contributions from less mobile phosphodiester-containing molecules, such as molecules 
involved in membrane structure (both cell membranes and intracellular organelle 
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membranes). As cell membranes are continually generated and broken down, 
expressing the PME and PDE levels as a ratio provides a measure of turnover 
equilibrium of membrane phospholipids. 
 
Table 8-1 Metabolites detectable by 31P MRS 
Metabolites Structure/function 
Phosphomonoester (PME) 
Phosphocholine, phosphoethanolamine and l-
phosphoserine contribute to the PME peak 
Phosphodiester (PDE) 
Glycerophosphocholine and glycerophospho-
ethanolamine contribute to the PDE peak 
Adenosine triphosphate 
moieties 
High energy phosphates and nucleotide and 
nucleoside phosphates 
Phosphocreatine (PCr) Energy storing moiety 
Inorganic phosphate (pHi) Intermediate in energy metabolism 
Macromolecular signals (broad 
components) 
Membrane phospholipids; phosphorylated proteins 
 
The PME peak is known to be elevated in areas of rapidly growing tissue and in cases of 
rapid membrane synthesis, such as in growing brain. It is probable that the elevation is 
caused by the increased presence of compounds meant for the production of membrane 
phospholipids (Boulanger, Labelle et al., 2000). If the choline peak mainly reflects 
structural components of cell membranes, especially myelin sheaths, a change in the 
Cho/Cre ratio may be closely related to the process of myelination. Depending on the 
region studied, decreases in choline values generally appear to be most prominent only 
after the first 2 years of life, which corresponds with the completion of the majority 
myelination (Kreis, Ernst et al., 1993). Investigation with 31P-MRS may aid in tapping 
more directly into the potentially disturbed processes of myelination in the early-onset 
patients with liver disease which may be precipitating deficits in IPS later in childhood. 
 
31P-MRS in cognitive research has largely focused on schizophrenia and schizo-affective 
disorders as a means of evaluating the role of the cell membrane in the aetiology of 
these disorders, specifically the membrane phospholipid theory of schizophrenia 
(Horrobin, 1998). These studies have yielded largely inconsistent results that none-the-
less point to decreased PMEs and increased PDE (indicating decreased membrane 
stability) in patients with schizophrenia (Puri, 2006; Puri, Counsell et al., 2008; Reddy, 
Keshavan et al., 2004; Rzanny, Klemm et al., 2003). 
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In terms of applications to liver disease, reductions in the PME/βATP and PDE/βATP 
ratios, have been consistently observed in adult patients with chronic liver disease, and 
these correlate with the reduction in choline concentrations observed using 1H-MRS 
(Patel, Forton et al., 2000; Taylor-Robinson, Sargentoni et al., 1994a). 31P-MRS is, 
however, yet to be used with younger populations in this context.  
 
There is also support for an association between peripheral and central measurements 
of membrane physiology. Richardson et al (2001) compared in vivo 31P-MRS 
measurements averaged over 10 large voxels within the brain and erythrocyte PUFA 
composition in normal adult subjects, and demonstrated an negative correlation 
between DHA and EPA acid content and PDE levels (Richardson, Allen et al., 2001). 
 
A correlation between RBC PUFAs and brain phospholipid metabolites does not indicate 
a direct causal relationship. If confirmed, however, such a correlation would provide a 
unique opportunity to simultaneously investigate convergent central and peripheral 
biochemistry with relation to EFA status and clinical and cognitive measures, in ways 
that are not possible with 1H-MRS measures of neurometabolic status. 
 
8.6 Conclusion 
 
This is the first study to have employed parallel measures of brain and blood 
biochemistry in a paediatric liver disease population with the aim of investigating some 
of the potential biochemical underpinnings of cognition. 
 
Multiple cellular functions and responses are affected as a consequence of 
neurometabolite and membrane lipid variations. Cognitive spectroscopy and studies of 
EFA and cognition in children are still largely exploratory, with a lack of consensus 
around the strength and significance of relationships between these biochemical 
markers and cognitive abilities. Inconsistencies and gaps in knowledge remain, making 
it difficult to draw general conclusions regarding the cognitive and functional changes in 
response to natural or induced variations in these neurometabolite and EFA substrates. 
The subtlety of these relationships motivates the development of an explanatory 
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framework that discriminates between statistical significance and statistical relevance, 
particularly in the studies of rare and difficult populations. 
 
The evidence presented here suggests that the numerous activities of the liver that are 
disturbed as a consequence of liver disease may each contribute in some small degree to 
the observed deficits in cognitive functioning, specifically information processing speed, 
and particularly in patients whose early neurodevelopment was impacted.  
 
Further cross-sectional longitudinal studies using 1H-MRS and GC-MS, or their variant 
techniques, in larger subject populations, will be instrumental in confirming and 
extending current findings. Quantitative studies that seek correlation with subsequent 
behaviour and cognition are likely to provide valuable insight into the organisation of 
neural systems that underlie cognitive development in children, the differential 
contribution of neurometabolites and EFAs to cognitive functioning across the life span, 
and the mechanisms that are impacted in abnormal states like liver disease. Studies may 
need to be multicentre in order to achieve reliably large numbers of subjects, or if 
performed in a single centre, conducted in such a way as to be comparable with data 
from other sites in future analyses. 
 
Converging methodologies offer a challenging, but promising and novel approach to 
explore brain-behaviour relationships from micro- to macro-scopic levels of analysis. 
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Appendix A: Catalogue of measures 
 
Below is a comprehensive list of the data and measures obtained in the present study. 
Inclusion and analysis of some portions of data collected was considered beyond the 
scope of this thesis, but will be informative in interpreting the data in future analyses. 
 
Demographic data 
 
 Date of birth 
 Age 
 Gender 
 Postcode (for calculation of Deprivation Index and estimate of SES) 
 Ethnicity. 
 
Clinical measures 
 
 Disease diagnosis 
 Disease category (early onset, pre-transplant; early onset, post-transplant; acute 
liver failure , pre-transplant) 
 Age of liver disease onset 
 Date of liver transplant 
 Length of hospitalisation 
 Bilirubin level at time of study. 
 
Anthropometry 
 
 Height (cm) + height z-score 
 Weight (kg) + weight z-score 
 Mid-arm circumference (cm) 
 Triceps skinfold (cm) 
 Head circumference (cm). 
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Dietary data 
 
 Estimate of frequency of current fish intake (per month) 
 Total dietary intake (g/day) 
 Percentage intake of average requirement 
 Dietary fatty acid intake (oleic, linoleic, α-linolenic, arachidonic, DHA; see Table 
A). 
 
Breastfeeding data 
 
 Duration of breastfeeding (weeks) 
 Estimate of frequency of maternal fish intake during pregnancy (per month). 
 
Psychometric assessment 
 
Wechsler Preschool and Primary Scale of Intelligence for Children ─ 3rd Edition (WPPSI-
III) (Wechsler, 2002) 
Wechsler Intelligence Scale for Children – 4th Edition, (WISC-IV) (Wechsler, 2003) 
Wechsler Adult Intelligence Scale – 3rd Edition (WAIS-III) (Wechsler, 1997b) 
Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 1997a) 
 
 Full-scale IQ 
 Verbal IQ 
 Information Processing Speed Index 
 Working Memory. 
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Table A Examples of fatty acid dietary intake data for patients enrolled in the current study 
Disease category Subject 
Total 
dietary 
fat 
(g/day) 
% average 
requirement† 
Oleic 
(18:1) 
(g) 
Linolenic 
(18:2) 
(g) 
Alpha-
linoleic 
(18:3) 
(mg) 
Arachidonic 
(20:4) (mg) 
DHA 
(22:6) 
(mg)‡ 
Metabolic disease 
(Tyrosinaemia)  
1 34.93 73 8.7 1.7 110 0 0 
2 33.95 133 14.4 1.7 260 20 0 
3 38.75 93 12.6 2.3 160 0 0 
4 84.5 183 13.9 36.85 230 0 0 
Early-onset liver 
disease (EOLD), no 
transplant  
5 71.9 80 24.1 7.44 320 0 0 
6 43.8 54 13.2 3.5 70 30 30 
Early-post liver 
disease + transplant 
7 43.27 51 17.8 4.61 50 0 20 
Acute liver failure 
(ALF) + transplant 
8 28.7 50 10 1.09 120 30 30 
9 81.8 104 2.11 1.18 60 280 70 
Healthy sibling 10 44.03 66 10.3 1.32 220 50 10 
† average of fat generally below recommended intake 
‡ Recommended DHA intake is 120mg (see Table 2-2, page 34 ) 
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Gas chromatography-mass spectrometry 
 
Table B Summary of fatty acids detected in 
erythrocyte membranes with standard GC-MS 
Common name 
Carbon 
number 
Saturated fats  
myristic 14:0 
palmitic  16:0 
stearic  18:0 
Monounsaturated fats  
oleic  18:1 
Omega-9  
 mead 20:3 
 Omega-6  
linoleic 18:2 
dihomo-γ-linolenic 20:3 
arachidonic 20:4 
adrenic 22:4 
osbond 22:5 
Omega-3  
alpha-linolenic 18:3 
eicosapentaenoic 20:5 
docosahexaenoic 22:6 
 
Table C Summary of erythrocyte biomarkers of essential fatty acid status 
Index Fatty acids 
SFA stearic + palmitic + myristic  
MUFA oleic 
Omega-3 index  DHA + EPA  
Omega-6 index arachidonic + linoleic  
Omega-3:Omega-6  Omega-3 index/Omega-6 index 
EFA shortage marker mead acid 
Functional DHA shortage marker DHA/osbond acid 
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Proton Magnetic Resonance Spectroscopy 
 
 N acetyl aspartate/creatine 
 Choline/creatine 
 Myo-Inositol/creatine 
 Glutamate-Glutamine(Glx)/Creatine. 
 
Metabolite values were obtained in two principal regions: frontal and occipitoparietal 
cortex. Additional temporal cortex data was also collected in 11 participants. 
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Appendix B: Conference abstracts 
 
The following is a list of abstracts of work from the present study presented at 
conferences. In addition to the investigations described in the main body of this thesis, 
some of the work presented included disease control patients with intestinal failure and 
metabolic disease who were recruited into the study and a number of clinical case 
studies. 
 
Aston University Postgraduate Research Day (July 2009) 
Birmingham, UK 
 
Biochemical correlates of cognitive function 
Abstract: Poster presentation 
 
Patel T, Talcott JB 
School of Life & Health Sciences, Aston University, Birmingham, UK  
 
Developments in psychological assessment and neuroimaging techniques are enabling 
the study of the neurophysiological basis of individual variation in cognitive ability with 
increasing refinement. Localized Proton Magnetic Resonance Spectroscopy (1H-MRS) 
allows non-invasive, in vivo quantification of neurometabolites such as N-acetyl-
aspartate (NAA), choline and myo-Inositol, which have been related to cognitive 
functions including information processing speed (IPS) (Ross and Sachdev. Brain Res 
Rev. 44, 83-102, 2004). This cross-sectional investigation of 35 healthy volunteers 
combined neuroimaging and biochemistry with cognitive testing (Wechsler Adult 
Intelligence Scales III), with the aim of linking brain-biochemistry to variability in 
behaviour. It was hypothesized that there would be a positive correlation between NAA 
levels, a marker of neuronal health, and cognitive performance, particularly IPS. 
Conversely, levels of choline and myo-Inositol, associated with membrane turnover and 
gliosis, would be expected to be negatively correlated with cognitive performance. A 
significant correlation was observed between frontal region NAA/creatine 
concentration and Matrix Reasoning score (r = 0.386, p = 0.043), with NAA/Creatine 
accounting for 14% of the variance in scores. No relationship was found between 
metabolite concentrations and IPS. No significant correlations were observed between 
cognition and metabolites in occipitoparietal region. 1H-MRS is potentially a sensitive 
tool for assessing the biochemical correlates underlying cognitive function. Possible 
mechanisms underlying the association of neurometabolites with cognition are 
discussed and future directions of work, including the addition of a more extensive test 
battery and assessing and improving the reliability of 1H-MRS measures, helping refine 
the use of MRS in behavioural neurosciences, are presented. 
  
 212 
 
XIth International Symposium on Small Bowel 
Transplantation (September 2009) 
Bologna, Italy 
 
Tracking paediatric cognitive outcomes following small bowel transplantation: a 
case study 
Abstract: Poster presentation 
 
Patel T1, Blyth J2, Mears J2, Sira J2, Clarke S2, Kelly DA2, Gupte G2, Griffiths G1, Beath SV, 
Talcott JB1 
1Depts of Life & Health Sciences and Chemical Engineering, Aston University, 
Birmingham, UK 
2Birmimgham Children’s Hospital, Birmingham, UK 
 
Introduction: Infants with intestinal failure (IFx) now survive and grow satisfactorily 
with parenteral nutrition (PN), but IQ may be affected. A potential reason for this may 
be dependency on a single source of lipid based on soya oil (Intralipid), which lacks 
essential polyunsaturated fatty-acids (PUFAs) normally found in breast milk and diet. 
 
Methods: Psychometric data collected over ten years were used to assess 
developmental outcomes of an 11 year old boy who received SBTx at age 9 months 
because of liver failure secondary to PN and IFx caused by Hirchsprung’s disease. 
Current PUFA status was measured and neurochemistry non-invasively assessed with 
Proton-Magnetic Resonance Spectroscopy (1H-MRS).  
 
Results: Pre-Tx, the patient demonstrated mild cognitive delay and normal motor 
development. Six months post-Tx the patient displayed significant motor and mental 
delay. Between three and five years post-Tx, IQ plateaued in the borderline/low average 
range (72 and 79 respectively). By ten years post-Tx, IQ had risen to 97, well within 
average range. His PUFA intake was negligible until commencing Nutrtini orally (662 
mg/L PUFA), 6 months post-SBTx. He is now on a normal diet (300mg PUFA/day). 
Neurometabolite values, such as N-acteyl aspartate, which provide markers of neuronal 
health, showed a normal profile for a healthy 11 year old child. 
 
Conclusion: In contrast to a cohort of children maintained on PN for 5 years or more 
(Hill et al Arch Dis Child. 2005;90:A16), this boy, who commenced normal diet from 1 
year, has a normal IQ and distribution of neurometabolites, demonstrating that early 
SBTx is consistent with good long-term cognitive outcome. 
  
 213 
 
British Society of Paediatric Gastroenterology, Hepatology 
and Nutrition (BSPGHAN) (January 2010) 
Liverpool, UK 
 
Tracking paediatric cognitive outcomes following combined liver small bowel 
transplantation: a case study 
Abstract: Oral presentation 
 
1T Patel, 2J Blyth, 2SV Beath, 2J Sira, 2J Mears, 2S Clarke, 2G Gupte, 1G Griffiths, 1JB Talcott, 
2DA Kelly. 
1Depts of Life & Health Sciences and Chemical Engineering, Aston University, 
Birmingham, UK 
2Birmimgham Children’s Hospital, Birmingham, UK 
 
Introduction: Infants with intestinal failure (IFx) now survive and grow satisfactorily 
with parenteral nutrition (PN), but IQ may be affected. A potential reason for this may 
be dependency on a single source of lipid based on soya oil (Intralipid), which lacks 
essential polyunsaturated fatty-acids (PUFAs) normally found in breast milk and diet. 
 
Aim: Our aim was to assess the long-term cognitive and developmental effects of 
combined liver and small bowel transplantation and the potential detrimental effects of 
PN-induced PUFA deficiency. 
 
Methods: Psychometric data collected over ten years were used to assess 
developmental outcomes of an 11 year old boy who received SBTx at age 9 months 
because of liver failure secondary to PN and IFx caused by Hirchsprung’s disease. 
Current dietary intake was assessed with a comprehensive 5-day diet diary. PUFA 
status was assessed in red blood cell (RBC) membranes by conventional Gas 
chromatography-mass spectrometry. Neurochemistry was non-invasively assessed with 
proton magnetic resonance spectroscopy (1H-MRS) in occipitoparietal and frontal 
cortex regions. 
 
Results: Pre-Tx, the patient demonstrated mild cognitive delay and normal motor 
development. Six months post-Tx the patient displayed significant motor and mental 
delay. Between three and five years post-Tx, IQ plateaued in the borderline/low average 
range (72 and 79 respectively). By ten years post-SBTx, IQ had risen to 97, well within 
average range. His PUFA intake was negligible until commencing Nutrini orally (662 
mg/L PUFA), 6 months post-SBTx. The patient is now on a normal diet (300mg 
PUFA/day). Neurometabolite values recorded by MRS, such as N-acteyl aspartate and 
choline, which provide markers of neuronal health, showed a normal profile for a 
healthy 11 year old child. At 10 years post-SBTx, the patient’s essential PUFA levels, 
specifically docosahexaenoic acid and eicosapentaenoic acid, were no different to 
healthy age-matched controls (4% vs 4.23% of total fatty acid content), which 
consistent with his MRS and cognitive assessments. 
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Conclusion: In contrast to a cohort of children maintained on PN for 5 years or more (S. 
Hill et al Arch Dis Child. 2005;90:A16), this boy, who commenced normal diet from 1 
year, has a normal IQ and distribution of neurometabolites and essential blood lipids, 
demonstrating that early SBTx is consistent with good long-term cognitive outcome. 
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17th International Conference on Biomagnetism (BIOMAG) 
(March 2010) 
Dubrovnik, Croatia 
 
Sensitivity to gaps in noise: Using MEG to assess auditory temporal resolution in 
paediatric populations  
Abstract: Poster presentation*  
1Patel T, 1Witton C, 1Thai JN, 2Beath SV, 2Kelly DA, 1Seri, S, 1Griffiths, G, 1Talcott JB 
1Depts of Life & Health Sciences and Chemical Engineering, Aston University, 
Birmingham, UK 
2Birmimgham Children’s Hospital, Birmingham, UK 
 
*Poster presented on my behalf by JB Talcott 
 
Impaired neural timing has been demonstrated across a range of developmental 
disorders (e.g. dyslexia) and clinical conditions (e.g. hepatic encephalopathy). Neural 
timing can be operationally defined in different ways, but one core feature that 
underlies performance on many cognitive and behavioural tasks is the encoding of 
stimulus changes that occur within a millisecond timescale. Auditory gap detection 
provides a measure of temporal resolution on this scale, where psychophysical 
thresholds indicate the shortest silent gap in noise which can be detected. Although gap 
detection has been measured previously with MEG, this study focused on developing an 
optimised paradigm for use with young children and patient populations where full 
compliance and vigilance for a neuroimaging task may not be assured. MEG data was 
collected using a 252 channel CTF scanner, while participants were presented with a 
420 second continuous diotic Gaussian noise stimulus. The noise was interrupted at 
jittered intervals around 500ms with pseudo-randomised gap durations of either 3, 6, 
10 or 30ms. Subsequent to the removal of baseline trend, the data was subdivided into 
500ms epochs centred around the gap and averaged for each gap length. Mean 
amplitudes of the evoked response for each gap duration was calculated for the sensor 
with the peak response and normalised to the response for the 30-ms gap. The gradient 
of the linear relationship between response amplitude and gap length therefore 
provided a metric of physiological sensitivity to gap duration. Data from both adult 
listeners and children with probable hepatic encephalopathy indicate that this MEG gap 
detection paradigm yields a reliable and valid index of auditory temporal resolution 
with potential clinical utility. MEG paradigms which minimise the length of the 
recording epochs are particularly beneficial for obtaining data with younger and other 
variably compliant populations.  
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Aston Postgraduate Research Day (June 2010) 
Birmingham, UK 
 
Investigating biochemical correlates of cognitive function with Proton Magnetic 
Resonance Spectroscopy: refining the methodological framework 
Abstract: Poster presentation 
 
Patel T, Talcott JB 
School of Life & Health Sciences, Aston University, Birmingham, UK 
 
Proton Magnetic Resonance Spectroscopy (1H-MRS) is a non-invasive imaging technique 
that enables quantification of neurochemicals in vivo and thereby facilitates 
investigation of the biochemical underpinnings of human cognition. Studies have 
typically focused on relationships between measures of N-acetyl aspartate (NAA), a 
surrogate marker of neuronal health and function, and broad measures of cognitive 
performance, such as Full-scale IQ. In this cross-sectional study of 34 healthy 
individuals, we assessed NAA levels in occipitoparietal and frontal cortical white matter 
in parallel with IQ measures. We hypothesized a positive correlation between NAA and 
Full-scale IQ, and with Information Processing Speed in particular. In contrast to several 
previous studies, we found neither strong, nor significant, predictive relationships 
between NAA and cognitive ability. The range of relationships and effect sizes in the 
literature reveals the exploratory nature of current cognitive spectroscopy. Sources of 
variability between studies include methodological differences in spectroscopic 
protocols, the neuroanatomical location of voxels, the neuropsychological assessments 
employed and heterogeneity in population samples. Of particular concern is the 
multiple comparisons problem inherent to studies that have measured several 
neurometabolites over multiple brain regions and employed a battery of intelligence 
measures without detailing specific research hypotheses a priori, as these are 
particularly susceptible to inflated Type 1 error rates. Although 1H-MRS offers a 
sensitive tool for assessing neurochemistry, the relationships between brain 
metabolites and broad aspects of human behaviour are subtle, and highlight the need to 
develop an explanatory framework that discriminates between statistical relevance and 
statistical significance in investigations of this kind. 
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American Association for the Study of Liver Disease (AASLD) 
Annual Meeting (November 2010) 
Boston, USA 
 
Polyunsaturated fatty acid status and cognitive outcomes in paediatric liver 
disease 
Abstract: Poster presentation* 
 
1T. Patel, 2S.V. Beath, 2J.Ackrill, 2S. Clarke, 2A.Daly, J. Blyth, 2J. Mears, 2J. Sira, 2G. Gupte, 
2P.McKiernan, 2I.van Mourik, 1G. Griffiths, 1J.B. Talcott, 2D.A. Kelly. 
1Aston University, Birmingham, UK 
2 Birmingham Children’s Hospital, Birmingham, UK 
 
*Poster presented on my behalf by DA Kelly 
 
Introduction: Essential Polyunsaturated Fatty Acids (PUFAs), omega-6 (n-6) and the 
omega-3 (n-3) are complex lipids found in high concentrations in the central nervous 
system, where they serve a multitude of structural and functional roles, which may 
modulate cognitive function. Fat malabsorption in liver disease, or abnormal fat intake 
caused by dependency on EFA-deficient intravenous nutrition, may lead to suboptimal 
concentrations of PUFAs in red blood cells, which may manifest as changes in cognitive 
ability. Our aim was to measure the range of PUFA concentrations in children with liver 
disease compared to sibling controls and assess the relationship between PUFA status 
and cognitive ability. 
 
Method: PUFA status was assessed in red blood cell (RBC) membranes by conventional 
Gas Chromatography-Mass Spectrometry. Percentage total of EPA and DHA were taken 
as markers of omega-3 status and Linoleic and Arachidonic acid of omega-6. Full-scale 
IQ was assessed with an age-appropriate Weschler’s psychometric test battery 
(Wechsler FSIQ). 
 
Results: We observed no significant difference in IQ between the groups, but a 
significant negative correlation was found between pro-inflammatory omega-6 fatty 
acids and FSIQ across the cohort (r = -0.525, p = 0.025). The omega-3:omega-6 ratio was 
also found to be significantly lower the chronic liver disease group compared to the 
sibling control and post-transplant group (F(2,15) = 4.88, p= 0.023, effect size (d) = 1.66 
and 1.23, respectively). 
 
Group n Mean age Mean n-3 
(% total) 
Mean n-6 
(% total) 
n-3:n6 FSIQ 
Sibling control 5 15.4 15.0 16.2 0.92 105 
Chronic liver 
disease (no Tx) 
3 14 13.9 18.1 0.77 85 
Post-Tx 10 14.1 15 16.8 0.90 95 
 
Conclusion: Our findings suggest no significant deficiency of omega-3 fatty acids in 
liver disease patients, but the relationship between pro-inflammatory fatty acids and IQ 
requires further investigation. Liver transplantation in early childhood is consistent 
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with recovery of good long-term cognitive outcome. Longitudinal studies of transplant 
patients assessing dietary intake and PUFA and cognitive status will help clarify the role 
of EFAs in cognitive development in paediatric liver disease. 
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American Association for the Study of Liver Disease (AASLD) 
Annual Meeting (November 2010) 
Boston, USA 
 
Essential fatty acids (EFAs) and polyunsaturated fatty acids (PUFAs) in patients 
with intestinal failure and after small bowel transplantation (SBTx): relationship 
to cognitive outcomes 
Abstract: Poster presentation* 
 
1Patel T, 2Beath SV, 2Clarke S, 2Sira J, 2Blyth J, 2Mears J, 1Griffiths G, 1Talcott J, 2Gupte G, 
2Kelly DA 
1Aston University, Birmingham, UK 
2Birmingham Children’s Hospital, Birmingham, UK 
 
*Poster presented on my behalf by DA Kelly 
 
Aim: To measure the status of EFAs and PUFAs in patients before and after SBTx, 
because the exposure to these fatty acids in parenteral nutrition and after 
transplantation is known to be widely different from healthy children. 
 
Methods: 4 children aged 11–15yrs and one infant aged 2 years were recruited: two 
had undergone SBTx 5 and 10 years previously and three were on the transplant list for 
small bowel transplantation. None of the children had been breast fed and all had 
received Intralipid, which lacks polyunsaturated fatty-acids (PUFAs), from birth. The 3 
children awaiting SBTx had been converted to a new source of lipid containing fish oils 
1–12 months prior to blood sampling (SMOFlipid Fresenius Kabi). We compared their 
exposure to EFAs and PUFAs at the same time as measuring their body PUFA stores in 
erythrocyte (RBC) membranes using Gas Chromatography Mass Spectrometry (GC-MS), 
and related these measures to their Full-scale IQ (Wechsler FSIQ). 
 
Results: All the children on SMOFlipid had satisfactory levels of DHA, but they had high 
levels of the pro-inflammatory PUFA arachidonic acid. Subjects 3 and 4 were carrying 
mead acid in RBC membranes, suggesting that they had had insufficient EFAs in the 
weeks preceding the blood sampling. The diet of subjects who had been successfully 
transplanted were associated with the EFA deficiency marker mead acid (subject 1) and 
subject 2 had relatively low amounts of DHA, neither subject showed a pro-
inflammatory bias. 
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Subject 
Total cals and 
type of lipid 
 
Fatty acid 
intake (mg/kg 
per day) 
18:1, 18:2, 18:3, 
20:4; 22:6 
RBC 
20:3 
% 
 
RBC 
20:4 
% 
 
RBC 
22:5 
% 
RBC 
22:6 
% 
FSIQ 
1 MK Oral diet  Pending (10mg/ 
kg PUFA/day) 
9.19 8.96 0.0 8.13 97 
2 RS Oral diet  Pending 7.52 7.83 6.34 6.56 90 
3 DS 48cals/kg/d2g/kg 
SMOF/day 
556, 374; 50; 
10; 44; 
10.76 11.40 0.0 10.72 100 
4 JB 76cals/kg/d2g/kg 
SMOF/day 
556; 374; 50; 
10; 44  
7.68 9.63 0.31 10.35 94 
5 AF 80cals/kg/d2.5g/
kg SMOF/day 
687; 460; 60; 
12; 54 
0.0 12.28 0.0 10.58  
Controls   8.1-
8.6 
8.1-
9.2 
6.7-
7.6 
7.1-
8.3 
100 
18:1 oleic acid; 18:2 linoleic acid, 18:3 linolenic acid, 20:3 mead, 20:4 arachidonic acid, 
 22:5 osbond, 22:6 docosahexaenoic acid (DHA) 
 
Conclusion: Children may require EFA supplements after SBTx. SMOFlipid is associated 
with above average DHA concentrations, but this is associated with a pro-inflammatory 
bias in patients awaiting SBTx. 
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British Association for Parenteral and Enteral Nutrition 
(BAPEN) (November 2010)  
 
Sequential changes in polyunsaturated fatty acid composition of red cell 
membranes before and after small bowel transplant; a case report 
Abstract: Poster presentation* 
 
S.V. Beath1, T. Patel2, S Clarke1, J Sira1, G. Gupte1, S.Protheroe1, DA Kelly1, G. Griffiths2, J 
Talcott2 
 
1Birmimgham Children’s Hospital, Birmingham, UK 
2Depts of Life & Health Sciences and Chemical Engineering Aston University, 
Birmingham, UK 
 
*Poster presented on my behalf by SV Beath 
 
Children with intestinal failure are dependent on intravenous lipid solutions to survive 
and historically the lipid source has been soya oil, which is rich in essential fatty acids. 
Recently there have been concerns that reliance on a single source of lipid, which 
contains a high proportion of so-called pro-inflammatory omega-6 fatty acids, may be a 
factor in the development of liver disease (Koletzko and Goulet. Curr Opin Clin Nutr 
Metab Care. 2010;13:321-6). The use of a multi-source lipid (SMOFresnius) consisting of 
soya oil, medium chain fatty acids, olive oil and fish oil became available in the UK in 
2007 and is being increasingly used, although the long-term effects on the liver function 
and other tissues have not yet been determined. The aim of this study was to evaluate 
the polyunsaturated fatty acid status in an 11 year old boy prior to small bowel 
transplant, when he was receiving SMOF as part of his parenteral nutrition, and 
periodically until 12 months after transplant, when he was established on the enteral 
feed Peptamen. PUFA levels were measured in red blood cell (RBC) membranes by Gas 
chromatography-mass spectrometry. The dietary intake of fatty acids was calculated 
from the PN prescription and dietetic records. 
 
The markers of both omega-6 (20:4) and omega-3 (22:6) PUFAs decreased significantly 
and came down to just above the range for healthy volunteers by 5 months post-
transplant. This change in PUFAs was associated with reduced intake of long chain fatty 
acids when PN was stopped and Peptamen Junior commenced. We conclude that the PN 
fat source may have been over-providing essential fatty acids and DHA, and despite a 
reduction in EFA intake and lack of DHA in Peptamen Junior, this child was able 
synthesise DHA satisfactorily from his enteral food source. 
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Pre-
transplant 
2 months 
after Tx 
5 
months 
after Tx 
8 
months 
after Tx 
12 
months 
after Tx 
Intravenous FA 
intake (mg/kg/ day) 
 
    18:1, 18:2;  556; 374;  
0 0 0 0 18:3n3, 20:4, 22:6 50;10; 44 
n3: n6 ratio -0.24 
Enteral FA* intake 
(mg/kg/ day) 
     
18:1, 18:2, 
0 
132: 320; 132: 
320; 
155; 374; 155; 374; 
18:3n3, 20:4, 22:6 70; 0; 0 70; 0; 0 82; 0 82; 0 
n3: n6 ratio -0.22 -0.22 -0.22 -0.22 
RBC PUFA (%)      
18:1; 18:2; 18:3 20; 10; 9;  10; 10; 11; 8; 10: 10; 10; 8; 11; 10;11;11; 
20:4; 22:6 11.3; 12.1 11.9; 8.4; 10; 9.4 10; 9.9;  11.4; 9.9 
n3:n6 ratio -0.71 -0.79 -1.05 -0.92 -0.88 
18:1: oleic acid; 18:2: linoleic acid; 18:3: α-linolenic acid; 20:4: arachidonic acid; 22:6: 
docosahexanaenoeic acid (DHA)  
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Society for Neurosciences Annual Meeting (November 2010) 
 
Biochemical correlates of cognition: exploring the relationships between blood, 
brain and behaviour 
Abstract: Poster presentation 
 
Patel T1, Blyth J2, Beath S2, Witton C1, Kelly D2, Griffiths D1, Talcott JB1 
1Depts of Life & Health Sciences and Chemical Engineering, Aston University, 
Birmingham, UK 
2Birmimgham Children’s Hospital, Birmingham, UK 
 
This multi-modal investigation utilises convergent biochemical assay techniques to 
explore the relationships between brain and blood biochemistry and cognitive ability. It 
is well-established that essential fatty acids (EFAs) are crucial for normal brain 
development and function, but their specific behavioural effects are yet to be elucidated. 
We employed conventional Gas chromatography-mass spectrometry of erythrocyte 
membranes in conjunction with standard batteries of psychometric assessment, such as 
the Wechsler’s Adult Intelligence Scale, to assess the relationship between EFAs and 
their long-chain polyunsaturated metabolites, such as arachidonic acid and 
docosahexaenoic acid, and specific cognitive abilities. In our cohort of healthy 
individuals, significant negative correlations were observed between levels of pro-
inflammatory omega-6 fatty acids in erythrocyte membranes and Full-scale IQ (r = -
0.401, p = 0.035). Alongside the blood measures, we employed single-voxel Proton-
Magnetic Resonance Spectroscopy (1H-MRS) in frontal and occipitoparietal cortex to 
assess biochemistry at the neural level. In contrast with previous cognitive 
spectroscopy studies, we observed no significant correlations between measures of 
cognitive ability and surrogate markers of neuronal viability such as N-acetyl aspartate 
and choline.  
 
Our results suggest that the relationships between brain and blood metabolites and 
broad aspects of human behaviour are subtle and complex, and highlight the need for 
both hypothesis-driven enquiry and for distinguishing between statistical relevance and 
statistical significance in studies of this kind. Multi-modal investigations offer a 
promising, novel approach to exploring brain-behaviour relationships from micro- to 
macroscopic levels of analysis, but the conceptual framework within which these 
techniques are employed requires refinement. 
 
